IN THIS ISSUE

TOP 5 CAUSES OF NONBLANCHING SKIN LESIONS

Top 5 Keys to Otitis Externa Management
Central Diabetes Insipidus Case
Corneal Ulceration Algorithm: Diagnosis & Management
Mesenchymal Stem Cell Therapy for Orthopedic Conditions
Differentials of Increased & Decreased Creatinine
Experience the many layers of Advantage Multi®
(imidaclorpid + moxidectin)

Every dog and cat deserves comprehensive, broad-spectrum protection. That's why Advantage Multi® delivers layers of protection from heartworms, fleas and intestinal parasites.

Provide the multi-layered protection of Advantage Multi® to the pets in your care.

Visit LayersofMulti.com or contact your Bayer Sales Representative.

*Treats and controls roundworms, hookworms and whipworms in dogs and roundworms and hookworms in cats.

CAUTION: Advantage Multi® is only available from a licensed veterinarian. Dogs: WARNING: DO NOT ADMINISTER THIS PRODUCT ORALLY. For the first 30 minutes after application, ensure that dogs cannot lick the product from application sites on themselves or other treated animals. Children should not come in contact with the application sites for two (2) hours after application. (See Contraindications, Warnings, Human Warnings and Adverse Reactions for more information.) Cats: Do not use on sick, debilitated, or underweight cats. Avoid oral ingestion.

© 2019 Bayer, Shawnee Mission, KS 66201. Bayer, the Bayer Cross and Advantage Multi are registered trademarks of Bayer. AM19567

See page 4 for product information summary.
Providing small animal practitioners and their teams with practical, relevant information on the latest topics in veterinary medicine
Significantly different joint mobility scores versus placebo

- In a double-blinded, placebo-controlled clinical study, client-observed joint mobility scores were significantly different on Day 84 in the MOVOFLEX® Soft Chews group versus the placebo group¹

Easy to administer

- In a survey of 500+ pet owners, 97% of owners ranked MOVOFLEX Soft Chews as easy to administer²

Contains a proprietary blend of 5 ingredients

- These ingredients work together to protect against free radicals and to support healthy bones, flexibility, joints, and connective tissues

ZANTHIN®
Natural astaxanthin

Boswellia serrata

BIOVAFLEX®
Egg shell membrane

Proprietary hyaluronic acid

Vitamin D₃

Important Safety Information for MOVOFLEX® Soft Chews: Warnings: For animal use only. Keep out of the reach of children and animals. In case of accidental overdose, contact a health professional immediately. Cautions: Safe use in pregnant animals or animals intended for breeding has not been proven. If animal’s condition worsens or does not improve, stop product administration and consult your veterinarian.

What is your favorite veterinary-related expression?

“All bleeding stops eventually.”—Susan R

“Age is not a disease.”—Kayla D

“Never let the sun set on a pyometra.”—Sandi H

“When in doubt, cut it out.”—Amy C

“When you hear hoofbeats, think horses before zebra.”—Beth M

Fill in the blanks: I have been practicing for ___ years, and I still misspell ______.

“10, pruritus. Pruritis? I don’t know.”—Anna G

“2, dehiscence. I am not even sure that is spelled right.”—Sarah M

“15, intussusception. I always struggle with it.”—April S

“7, ventilation. I always want it to have a double l.”—Andrea C

“40, abscess. Abcess, absess? Lol.”—Diane F

“11, ophthalmologist! I always miss that first h.”—Taylor O

Do you use a continuous suture pattern in the abdominal wall?

70% Yes

30% No

FOLLOW US

facebook.com/cliniciansbrief
@CliniciansBrief
clinicians.brief
**Advantage Multi**® for Dogs

**INDICATIONS:** For the treatment and control of the following intestinal parasites species: Hookworms (*Ancylostoma caninum*), *Ancylostoma tubaeforme*; *Toxocara canis*; Whiptails (*Dirofilaria immitis*).

**CONTRAINDICATIONS:** Do not administer this product orally.

**WARNINGS:**
- Do not allow cats to lick treated dogs.
- Dogs treated with Advantage Multi must be kept separated from other treated animals and other pets to reduce the risk of ingestion.
- Do not use this product in dogs with skin disorders. (See Contraindications, Warnings, and Adverse Reactions for more information.)
- Do not use this product on cats.
- Do not use in dogs with a history of Seizures.
- Do not use in dogs with atopic dermatitis or equine hypersensitivity disorders.
- Do not use in dogs that have a prior history of adverse reactions to this product.
- Do not use on cats that are less than 3 lbs. in body weight.

**DOGS:**
- The safety of Advantage Multi for Dogs has not been evaluated in heartworm-positive dogs or for cats with systemic disorders.
- The safety of Advantage Multi for Dogs has not been established in breeding, pregnant, or lactating bitches.
- The safety of Advantage Multi for Dogs has not been established in breeding, pregnant, or lactating cats.
- The safety of Advantage Multi for Dogs has not been established in heartworm-positive dogs with a history of systemic disorders.
- The safety of Advantage Multi for Dogs has not been established in breeding, pregnant, or lactating cats.

**CATS:**
- The safety of Advantage Multi for Cats has not been established in breeding, pregnant, or lactating bitches.
- The safety of Advantage Multi for Cats has not been established in breeding, pregnant, or lactating cats.
- The safety of Advantage Multi for Cats has not been established in heartworm-positive dogs.

**PRECAUTIONS:**
- Do not use this product where there is the possibility of other dogs coming in contact with the application sites. If contact with other dogs occurs, wash hands thoroughly with soap and water after handling the application site.
- Do not use this product on cats with a history of systemic disorders.
- Do not use this product on cats that have a prior history of adverse reactions to this product.
- Do not use this product on cats that are less than 3 lbs. in body weight.
- Do not use this product on dogs with a history of Seizures.
- Do not use this product on cats with atopic dermatitis or equine hypersensitivity disorders.
- Do not use this product on dogs that have a prior history of adverse reactions to this product.

**ADVERSE REACTIONS:**
- Nausea and vomiting in treated animals.
- Numbness and tingling in the ears, face, or neck.
- Hypersensitivity reactions, including pruritus, scratching, and licking.
- Seizures.
- Erythematous rash.
- Anaphylaxis.

**PRECAUTIONS:**
- Do not use this product in cats with a history of systemic disorders.
- Do not use this product in cats that have a prior history of adverse reactions to this product.
- Do not use this product in cats that are less than 3 lbs. in body weight.
- Do not use this product in dogs with a history of Seizures.
- Do not use this product in dogs that have a prior history of adverse reactions to this product.

**CONTRAINDICATIONS:** Do not administer this product orally.

**WARNINGS:**
- Do not administer this product orally.
- Do not use in dogs with a history of Seizures.
- Do not use in dogs with atopic dermatitis or equine hypersensitivity disorders.
- Do not use in dogs that have a prior history of adverse reactions to this product.
- Do not use in dogs with a history of systemic disorders.

**DOGS:**
- The safety of Advantage Multi for Dogs has not been evaluated in heartworm-positive dogs or for cats with systemic disorders.
- The safety of Advantage Multi for Dogs has not been established in breeding, pregnant, or lactating bitches.
- The safety of Advantage Multi for Dogs has not been established in breeding, pregnant, or lactating cats.
- The safety of Advantage Multi for Dogs has not been established in heartworm-positive dogs with a history of systemic disorders.
- The safety of Advantage Multi for Dogs has not been established in breeding, pregnant, or lactating cats.

**CATS:**
- The safety of Advantage Multi for Cats has not been established in breeding, pregnant, or lactating bitches.
- The safety of Advantage Multi for Cats has not been established in breeding, pregnant, or lactating cats.
- The safety of Advantage Multi for Cats has not been established in heartworm-positive dogs.

**PRECAUTIONS:**
- Do not use this product in cats with a history of systemic disorders.
- Do not use this product in cats that have a prior history of adverse reactions to this product.
- Do not use this product in cats that are less than 3 lbs. in body weight.
- Do not use this product in dogs with a history of Seizures.
- Do not use this product in dogs that have a prior history of adverse reactions to this product.

**ADVERSE REACTIONS:**
- Nausea and vomiting in treated animals.
- Numbness and tingling in the ears, face, or neck.
- Hypersensitivity reactions, including pruritus, scratching, and licking.
- Seizures.
- Erythematous rash.
- Anaphylaxis.

**PRECAUTIONS:**
- Do not use this product in cats with a history of systemic disorders.
- Do not use this product in cats that have a prior history of adverse reactions to this product.
- Do not use this product in cats that are less than 3 lbs. in body weight.
- Do not use this product in dogs with a history of Seizures.
- Do not use this product in dogs that have a prior history of adverse reactions to this product.

**CONTRAINDICATIONS:** Do not administer this product orally.

**WARNINGS:**
- Do not administer this product orally.
- Do not use in dogs with a history of Seizures.
- Do not use in dogs with atopic dermatitis or equine hypersensitivity disorders.
- Do not use in dogs that have a prior history of adverse reactions to this product.
- Do not use in dogs with a history of systemic disorders.

**DOGS:**
- The safety of Advantage Multi for Dogs has not been evaluated in heartworm-positive dogs or for cats with systemic disorders.
- The safety of Advantage Multi for Dogs has not been established in breeding, pregnant, or lactating bitches.
- The safety of Advantage Multi for Dogs has not been established in breeding, pregnant, or lactating cats.
- The safety of Advantage Multi for Dogs has not been established in heartworm-positive dogs with a history of systemic disorders.
- The safety of Advantage Multi for Dogs has not been established in breeding, pregnant, or lactating cats.

**CATS:**
- The safety of Advantage Multi for Cats has not been established in breeding, pregnant, or lactating bitches.
- The safety of Advantage Multi for Cats has not been established in breeding, pregnant, or lactating cats.
- The safety of Advantage Multi for Cats has not been established in heartworm-positive dogs.

**PRECAUTIONS:**
- Do not use this product in cats with a history of systemic disorders.
- Do not use this product in cats that have a prior history of adverse reactions to this product.
- Do not use this product in cats that are less than 3 lbs. in body weight.
- Do not use this product in dogs with a history of Seizures.
- Do not use this product in dogs that have a prior history of adverse reactions to this product.

**ADVERSE REACTIONS:**
- Nausea and vomiting in treated animals.
- Numbness and tingling in the ears, face, or neck.
- Hypersensitivity reactions, including pruritus, scratching, and licking.
- Seizures.
- Erythematous rash.
- Anaphylaxis.
BRIEF SUMMARY: Before using Coraxis™, please consult the product insert, a summary of which follows:

**WARNINGS:***
- Do not administer this product orally.
- For the first 30 minutes after application, ensure that dogs cannot lick the product from application sites on themselves or other treated animals, and separate treated dogs from one another and from other pets to reduce the risk of accidental ingestion. Ingestion of this product by dogs may cause severe respiratory tract irritation, poisoning, Waterloo, and generalized anesthetic signs. In acute ingestions, dogs may vomit, and may have more severe signs and may include coma and death. The signs may be more severe in young animals.
- Some dogs are more sensitive to avermectins due to a mutation in the NAT1 gene (formerly AB1 gene). Dogs with this mutation may require fewer avermectin boluses to induce an aversion behavior. If they lapsed the product, the usual common foals associated with this condition include Cushing's and idiopathic cases.
- Although there is no specific antidote for avermectin toxicity, severely affected dogs have completely recovered from apparent fatality with intensive supportive care.

**HUMAN WARNINGS:**
- For human use, stop up the mouth of children.
- Children should not come in contact with applications sites for at least 2 hours after application. Please wash hands thoroughly with soap and warm water after handling. Children dressed in clothing that comes into contact with the product should be washed and changed.

**CONSULT THE EXPERTS PAGE 13**

**RENEE CARTER,** DVM, DACVO, is an associate professor of ophthalmology at Louisiana State University, where she also earned her DVM and completed a rotating internship. Dr. Carter completed a residency in comparative ophthalmology at University of Wisconsin–Madison. Her primary research interests are in corneal wound healing, equine recurrent uveitis, and nanoparticle drug delivery of ocular uveitis medications.

**MARY ANNA LABATO,** DVM, DACVM (SAIM), is a clinical professor and the section head of small animal medicine at Cummings School of Veterinary Medicine at Tufts University. She has a special interest in renal disease and interventional therapies.

**ELIZABETH R. MAY,** DVM, DACVD, is an associate professor of small animal dermatology at University of Tennessee. She earned her DVM from Texas A&M University and completed a dermatology residency at University of Tennessee. Dr. May’s main area of concentration is treatment of otitis in companion animals.

**JANET PERALTA,** DVM, is an internal medicine resident at Veterinary Specialty & Emergency Center in Levittown, Pennsylvania. She completed a rotating internship at Cummings School of Veterinary Medicine at Tufts University. Her interests are endocrinology and renal and respiratory disease.

**CORAXIS (moxidectin)**

Topical Solution for Dogs

**INDICATIONS:**
- Is also indicated for the treatment and control of the following intestinal parasites:
  - Toxocara canis
  - Toxascaris leonina
  - Ancylostoma spp.
  - Necator americanus
  - Trichuris vulpis
  - whipworm

**WARNING:**
- Do not administer this product orally.
- For the first 30 minutes after application ensure that dogs cannot lick the product from application sites on themselves or other treated animals, and separate treated dogs from one another and from other pets to reduce the risk of accidental ingestion. Ingestion of this product by dogs may cause severe respiratory tract irritation, poisoning, Waterloo, and generalized anesthetic signs. In acute ingestions, dogs may vomit, and may have more severe signs and may include coma and death. The signs may be more severe in young animals.
- Some dogs are more sensitive to avermectins due to a mutation in the NAT1 gene (formerly AB1 gene). Dogs with this mutation may require fewer avermectin boluses to induce an aversion behavior. If they lapsed the product, the usual common foals associated with this condition include Cushing's and idiopathic cases.
- Although there is no specific antidote for avermectin toxicity, severely affected dogs have completely recovered from apparent fatality with intensive supportive care.

**HUMAN WARNINGS:**
- For human use, stop up the mouth of children.
- Children should not come in contact with applications sites for at least 2 hours after application. Please wash hands thoroughly with soap and warm water after handling. Children dressed in clothing that comes into contact with the product should be washed and changed.

**CONSULT THE EXPERTS PAGE 13**
See the transdermal difference.

**Coraxis™ (moxidectin) Topical Solution for Dogs** leverages its transdermal formulation for the delivery of **2,500 μg/kg** of moxidectin to:

- Kill established heartworm larvae from the previous 30 days
- Kill incoming heartworm larvae for the next 30 days
- Treat and control hookworms, roundworms and whipworms with monthly application

**1 dose.**

**6 parasites.**

**30 days.**

That’s **Coraxis™**

---

Coraxis™ is not approved for the treatment of adult *D. immitis.*

CAUTION: Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.

WARNING: **DO NOT ADMINISTER THIS PRODUCT ORALLY.** For the first 30 minutes after application ensure that dogs cannot lick the product from application sites on themselves or other treated animals. Children should not come in contact with the application sites for two (2) hours after application. (See Contraindications, Warnings, Human Warnings, and Adverse Reactions, for more information.) CONTRAINDICATIONS: Do not use this product on cats.

©2019 Bayer, Shawnee Mission, Kansas 66201

Bayer (reg'd), the Bayer Cross (reg'd) and Coraxis™ are trademarks of Bayer. CX191412

See page 5 for product information summary.
TOP 5
Top 5 Causes of Nonblanching Skin Lesions
Darren Berger, DVM, DACVD

NOTICE OF CORRECTION
In the Research Note “Infrared Thermography & Aortic Thromboembolism in Cats” in the March 2019 issue of Clinician’s Brief, an incorrect temperature was listed. The Fahrenheit temperature difference of 36.3°F (2.4°C) between ipsilateral nonaffected and affected limbs should have been listed as 4.2°F (2.4°C). Clinician’s Brief regrets the error.

CONSULT THE EXPERTS
Central Diabetes Insipidus
Janet Peralta, DVM
Mary Anna Labato, DVM, DACVIM (SAIM)

DIAGNOSTIC/MANAGEMENT TREE
Corneal Ulceration
Renee Carter, DVM, DACVO

DIFFERENTIAL DIAGNOSIS
Increased & Decreased Creatinine
Julie Allen, BVMS, MS, MRCVS, DACVIM (SAIM), DACVP

TOP 5
Top 5 Keys to Successful Management of Otitis Externa
Erin E. Aufox, DVM
Elizabeth R. May, DVM, DACVD

CUTTING EDGE
Mesenchymal Stem Cell Therapy
Nicole S. Amato, DVM, DACVS (Small Animal)
The chew dogs love.

THE SCIENCE YOU CAN TRUST.

Fight plaque, calculus and halitosis with OraVet® Dental Hygiene Chews – the only chew with the power of delmopinol!

- Unique dual-action mechanism
- Highly palatable
- Designed to provide an extended chew duration
- Proven technology

Delmopinol creates a protective barrier against the bacteria that cause bad breath and are the basis for plaque.

The scrubbing action of the chew works in parallel with the delmopinol to effectively remove plaque and calculus.
WSAVA DENTAL SERIES
Tooth Resorption
Brook A. Niemiec, DVM, DAVDC, DEVDC, FAVD
Gottfried Morgenegg, DVM
Cedric Tutt, BVSc (Hons), MMedVet, DEVDC
brief.vet/tooth-resorption

QUIZ
Canine Uterine Disorders
Autumn P. Davidson, DVM, MS, DACVIM
brief.vet/uterine-disorders
Modern Veterinary Therapeutics Announces Medetomidine Hydrochloride
Modern Veterinary Therapeutics (modernveterinarytherapeutics.com) has announced the US launch of Medetomidine Hydrochloride (ANADA 200-610), the first FDA-approved generic medetomidine hydrochloride injection (1 mg/mL) for sedation and analgesia in dogs. This follows the earlier launch of Revertidine (ANADA 200-624), a reversal agent for medetomidine and dexmedetomidine and the first FDA-approved generic atipamezole hydrochloride injection (5 mg/mL). Call 407-852-8039 for more information.
—Press Release 5/2019

Zoetis Becomes First Human–Animal Bond Certified Company
Following creation of their joint Human–Animal Bond Certification program, the NAVC (navc.com) and the Human Animal Bond Research Institute (habri.org) have announced Zoetis (zoetis.com) as the first Human–Animal Bond Certified company. Several Zoetis employees completed the certification program and received training on the science behind the human–animal bond and how this science supports the practice of veterinary medicine. Zoetis’ support of the bond includes its K-9 Courage and Pet Effect programs.

More than 500 professionals have signed up for this certification, which offers 22 hours of RACE-approved CE credit. To learn more about the Human–Animal Bond Certification, visit navc.com/hab.
—Press Release 5/2019

Fifth Edition of FlexVet Released
Smith Veterinary Consulting & Publishing (smithvet.com) has launched the 5th edition of FlexVet: How to Be One, How to Hire One. The Comprehensive Practice Guide for Relief & Part-Time Veterinarians. The book features a wide range of resources to help practices, part-time clinicians, and relief (locum) clinicians navigate the business intricacies of flexible work. The new 2019 edition includes updates on taxes and insurance, sample contracts and letters, and current links to information online. Other topics include business plans, budgeting, marketing, and social media.

The book can be purchased online at amazon.com/dp/B07QX931BT.—Press Release 4/2019

 Companion Animal Health INSight Diagnostic Platform
Companion Animal Health (companionanimalhealth.com) has announced the INSight System, a fully integrated needle arthroscopy platform with an advanced image capture system for patient-side intra-articular diagnostic procedures. The INSight system allows for visualization of the interior of joints with small, tablet-based technology. The integrated needle scope has a retractable needle, auto-focusing fiber optic camera, and light source, which enable clinicians to visually confirm diagnosis, inject regenerative medicine products, and perform follow-ups after intra-articular procedures. To learn more about the new Companion INSight System, visit companionanimalhealth.com/page/insight-system.—Press Release 4/2019

SEND INFORMATION FOR PRACTICE HOTLINE TO editor@cliniciansbrief.com
Food hypersensitivity in the dog and cat can cause a myriad of effects on several different systems of the body, with the integument and digestive system being most commonly affected.

Non-seasonal pruritus is one of the more common manifestations of food allergy. The pattern of pruritus can be a clue, with food allergy commonly associated with otitis and perineal pruritus (ears and rears). Because no reliable test yet exists for diagnosing food allergy, feeding trials from six to eight weeks remain the only method of diagnosing food allergy in the dog or cat.

It is well known that chicken and beef are some of the more common allergens for food-allergic patients (Jeffers). With the increased knowledge of cross-reactions between many intact proteins (such as chicken with other poultry, beef with other ruminants or dairy), the utilization of hydrolyzed protein diets continues to grow. Because of lower price, veterinarians (and certainly clients) are tempted to use one of the plethora of OTC “novel” protein diets as a test diet. However many studies continue to show they are often contaminated with other common proteins (Raditic 2011), and even if they were pure, the concern with cross-reactivity remains. Clinical experience shows us no one single diet is always effective in a food-allergic patient. Failures with hydrolyzed protein diets occur when some of the protein remains intact, so verifying that 100% of the protein is hydrolyzed to a small enough size is essential (Olivry 2010).

For a food trial to be effective, concurrent treats and chewable medications or nutraceuticals must also be eliminated. I remind clients some people react adversely to peanut dust on an airline flight! Nearly one in three of this author’s patients with food allergy will exhibit concurrent gastrointestinal manifestations, ranging from frequent vomiting and diarrhea to more subtle signs such as flatulence or frequent (more than two) bowel movements per day. The classic or hallmark clinical sign for food allergy in the cat is pruritus, especially of the head. Others will manifest as “self-induced alopecia”, or any of the variable eosinophilic granuloma complex.

Double-Blind Clinical Trial

When one compares efficacy between hydrolyzed diets, certain diets prove superior in efficacy, or with fewer adverse events. In a 16-week, double-blinded, cross-over clinical trial in 57 dogs, a hydrolyzed salmon-based diet (Blue Buffalo NVD HF) proved as efficacious as a well-known hydrolyzed poultry-feather diet (Royal Canin Ultamino) at diagnosing food allergy in dogs, with statistically fewer adverse events (Lewis 2019).

References

Jeffers JC et al. Responses of dogs with food allergies to single-ingredient dietary provocation. *JAVMA* 1996

Olivry T, Bizikova P. A systematic review of the evidence of reduced allergenicity and clinical benefit of food hydrolysates in dogs with cutaneous adverse food reactions. *Veterinary Dermatology* 2010, 21,32-41


Successfully Treat Adverse Food Reactions with BLUE Natural Veterinary Diet® HF Hydrolyzed for Food Intolerance

- Featuring highly digestible salmon hydrolysate – a novel protein with a mean molecular weight of 2,000 daltons
- Enriched with omega-3 fatty acids, which have been shown to reduce inflammation in skin cells
- Complete and balanced nutrition so clients can use for long-term feeding

Read about Tinsley's successful outcome and learn why BLUE Natural Veterinary Diet® HF Hydrolyzed for Food Intolerance may be right for your patients.

Visit bluebuffalo.com/tinsley to learn more.

---

(888) 323-BLUE
Central Diabetes Insipidus

Janet Peralta, DVM
Veterinary Specialty & Emergency Center
Levittown, Pennsylvania

Mary Anna Labato, DVM, DACVIM (SAIM)
Cummings School of Veterinary Medicine at Tufts University

History
A 10.5-year-old, 59.5-lb (27-kg), spayed Australian shepherd crossbreed was presented for examination for a 6-month history of persistent polyuria (PU) and polydipsia (PD) without stranguria or pollakiuria. The owner noted that large amounts of urine would leak approximately once to twice per week while the dog was asleep. Vomiting and/or diarrhea were not reported, and the patient had a normal appetite and energy level. Pollakiuria occurred once 5 months prior to presentation and was responsive to a 10-day course of amoxicillin (22 mg/kg PO q12h); urinalysis was not performed. A seasonal flea and tick preventive was the only other medication given.

Physical Examination
The dog was bright, alert, and responsive, and vital signs were within normal parameters. Dehydration was not present. Her abdomen was tense on palpation. The remainder of the physical examination was unremarkable. BCS was ideal at 5/9, and weight loss was not reported.

Diagnosis
PU/PD are nonspecific clinical signs. The potential causes for PU/PD are central diabetes insipidus (CDI), primary or secondary nephrogenic diabetes insipidus (NDI; eg, hyperadrenocorticism, hypoadrenocorticism, hyperthyroidism, liver disease, hypercalcemia, pyelonephritis), osmotic diuresis (eg, diabetes mellitus, chronic kidney disease, Fanconi syndrome, postobstructive diuresis), low renal medullary tonicity, and psychogenic polydipsia (PP).1

Based on the patient’s history of PU/PD and the results of laboratory diagnostics and imaging (Table, next page), many of the most common causes of PU/PD could be ruled out, leaving complete or partial CDI,
exoosmotic polyuria/polydipsia (PU/PD), the most probable causes are primary (rare) or secondary (more common) NDI, and PP.

Clinical Signs
PU/PD is confirmed if water consumption is >100 mL/kg/day, urine production is >50 mL/kg/day, and random urine specific gravity (USG) is ≤1.012. Urine from the patient’s first urination of the morning (3 AM) had a USG of 1.001. In general, a USG between 1.012 and 1.018 may indicate partial CDI. Additional testing (eg, preprandial and postprandial serum bile acid concentration) may be necessary to further exclude liver disease.

A modified water deprivation test is designed to determine whether endogenous adenosine vasopressin (AVP) is released in response to dehydration and whether the kidneys respond to this stimulus, but it can be time-consuming and is associated with risks (eg, severe dehydration, hypernatremia, death). Also, although useful in differentiating primary NDI from CDI, a modified water deprivation test may not differentiate partial CDI from PP with complete certainty. Dogs and cats with partial or complete CDI or primary NDI have an impaired ability to pass concentrated urine when dehydrated.

A desmopressin acetate trial could help determine the cause of PU/PD in this patient. Desmopressin tablets or conjunctival drops of 0.01% desmopressin human intranasal spray should be administered every 12 hours for 7 days, and the desmopressin effect should be evaluated after 5 to 7 days of treatment (required to overcome medullary washout). CDI is likely if an observable or measurable decrease in water consumption is noted and USG increases by at least 50% or exceeds 1.018.

Clinical Background
CDI, which can be congenital or secondary due to trauma or neoplasia, is caused by any condition that damages the neurohypophyseal system (eg, infection, neoplasm, trauma, vascular disease, autoimmune hypothalamitis, cysts), destruction of the antidiuretic hormone (ADH) production site in the hypothalamus, loss of major axons that carry ADH to storage sites in the posterior pituitary, or disruption of the ability to release stores of ADH. A prolonged hypoxic event (eg, cardiac arrest) can lead to development of CDI.

### TABLE

#### LABORATORY DIAGNOSTICS & IMAGING

<table>
<thead>
<tr>
<th>Diagnostic Test</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood pressure*</td>
<td>126/63</td>
</tr>
<tr>
<td>Mean arterial pressure*</td>
<td>67</td>
</tr>
<tr>
<td>CBC</td>
<td>Normal</td>
</tr>
<tr>
<td>Serum chemistry profile†</td>
<td></td>
</tr>
<tr>
<td>Phosphorus</td>
<td>2.4 mg/dL (range, 2.6-7.2 mg/dL)</td>
</tr>
<tr>
<td>Albumin</td>
<td>4.2 g/dL (range, 2.8-4.8 g/dL)</td>
</tr>
<tr>
<td>Alanine aminotransferase</td>
<td>56 U/L (range, 14-86 U/L)</td>
</tr>
<tr>
<td>Cholesterol</td>
<td>379 mg/dL (range, 82-354 mg/dL)</td>
</tr>
<tr>
<td>Symmetric dimethylarginine</td>
<td>11 µg/dL (range, 0-14 µg/dL)</td>
</tr>
<tr>
<td>ACTH stimulation</td>
<td></td>
</tr>
<tr>
<td>Basal cortisol</td>
<td>1.8 µg/dL (range, 1.7-7.9 µg/dL)</td>
</tr>
<tr>
<td>Post-ACTH stimulation</td>
<td>10 µg/dL (range, 6.19 µg/dL)</td>
</tr>
<tr>
<td>Bile acids (pre-/post-)</td>
<td>Normal</td>
</tr>
<tr>
<td>Urinalysis (cystocentesis)†</td>
<td></td>
</tr>
<tr>
<td>USG</td>
<td>1.006</td>
</tr>
<tr>
<td>pH</td>
<td>6.5</td>
</tr>
<tr>
<td>Squamous epithelial cells</td>
<td>≤0.1/hpf (range, 0-3/hpf)</td>
</tr>
<tr>
<td>USG samples</td>
<td></td>
</tr>
<tr>
<td>1.001 (3 AM)</td>
<td></td>
</tr>
<tr>
<td>1.006 (6 PM)</td>
<td></td>
</tr>
<tr>
<td>1.004 (10 AM)</td>
<td></td>
</tr>
<tr>
<td>Urine cortisol:creatinine ratio†</td>
<td>12§</td>
</tr>
<tr>
<td>Urine culture</td>
<td>No growth</td>
</tr>
<tr>
<td>Abdominal ultrasonography‖</td>
<td></td>
</tr>
<tr>
<td>Right kidney smaller than left kidney; borderline normal in size</td>
<td></td>
</tr>
<tr>
<td>Bladder contained a large volume of urine; patient urinated 45 minutes prior to examination</td>
<td></td>
</tr>
<tr>
<td>Bladder wall thickness was normal*</td>
<td></td>
</tr>
<tr>
<td>No masses or calculi</td>
<td></td>
</tr>
</tbody>
</table>

*Measured using Doppler. Normal systolic blood pressure is <140 mm Hg.
†All other results were normal.
‡Taken from an at-home sample
§Cushing’s disease is highly unlikely in dogs with urine cortisol:creatinine ratio ≤13.
¶All other structures in the abdomen were within normal limits.

A desmopressin acetate trial could help determine the cause of PU/PD in this patient. Desmopressin tablets or conjunctival drops of 0.01% desmopressin human intranasal spray should be administered every 12 hours for 7 days, and the desmopressin effect should be evaluated after 5 to 7 days of treatment (required to overcome medullary washout). CDI is likely if an observable or measurable decrease in water consumption is noted and USG increases by at least 50% or exceeds 1.018.

Clinical Background
CDI, which can be congenital or secondary due to trauma or neoplasia, is caused by any condition that damages the neurohypophyseal system (eg, infection, neoplasm, trauma, vascular disease, autoimmune hypothalamitis, cysts), destruction of the antidiuretic hormone (ADH) production site in the hypothalamus, loss of major axons that carry ADH to storage sites in the posterior pituitary, or disruption of the ability to release stores of ADH. A prolonged hypoxic event (eg, cardiac arrest) can lead to development of CDI.
CDI must be suspected if there is any history of trauma. MRI or CT is recommended if neurologic signs are present and if there is suspicion of intracranial neoplasia.

NDI can be familial, which is rare, or acquired (ie, secondary to several diseases) and can lead to decreased action of AVP in the kidney. Desmopressin supplementation cannot effectively manage NDI due to lack of response of AVP receptors in the kidney or lack of AVP receptor numbers. The prognosis of primary NDI is guarded-to-poor because of limited therapeutic options.

**Treatment**

Treatment may not be necessary if the patient has unlimited access to water and PU/PD is not distressing to the owner.²

Desmopressin, a synthetic AVP analogue, can be given for partial or complete CDI; prognosis depends on the underlying cause of CDI. Desmopressin is a potent V₂-receptor agonist and has minimal effects in V₁ receptors if no hypertension is observed. The 0.01% human intranasal solution (dogs, 1-4 drops [≈1.5-5 μg/drop] q8-24h; cats, 1 drop q12h) should be administered in the conjunctival sac or nose. The injectable formulation of desmopressin (administered intravenously over 15-30 minutes and repeated as needed) in dogs and cats has a short-term effect and is best used in cases of diabetes insipidus as a diagnostic tool. Tablets can also be given (dogs, 100 μg PO q12-24h; cats, 25-50 μg PO q8-12h). Therapeutic response is variable.

Dose and frequency should be titrated to effect for each patient. Response to treatment is rapid, and PU returns quickly if treatment is discontinued.⁸ Desmopressin is generally safe, and complications are uncommon.¹ The most common complications are hyponatremia and failure to decrease water intake. If the patient develops hyponatremia, desmopressin should be discontinued, then only given as needed. Close monitoring of electrolytes and USG is needed at the beginning of treatment until the appropriate individual dose is achieved.

In this patient, phenylpropanolamine (1 mg/kg PO q12h) was tried without success to manage the urinary incontinence episodes. The patient was then started on an initial trial therapy of desmopressin tablets (0.2 mg PO q12h). The tablet dosage was later increased (0.3 mg PO q12h), after which USG was concentrated at 1.022 and clinical signs resolved.

The patient did not return for a follow-up examination within the next year. At an eventual return visit, she had a USG of 1.003, but the owner chose not to resume treatment.

**Conclusion**

Diabetes insipidus is an important differential for PU/PD, and, although not a very common condition, it must be considered when managing a dog or cat presented with PU/PD. Other causes of PU/PD should be excluded before diagnosis of diabetes insipidus is pursued.

**References**


Intestinal Nematode and Cestode Treatment and Control: Dogs may be exposed to and can become infected with roundworms, whipworms, hookworms, and tapeworms, but are not infested with these worms or parasites. Clients should be advised of appropriate measures to prevent reinfestation of their dog with intestinal parasites. Because the prepatent period for E. multilocularis may be as short as 26 days, dogs treated at the labeled monthly intervals may become reinfected and shed eggs between treatments.

Contraindications: There are no known contraindications to the use of SENTINEL SPECTRUM Chews.

Warnings: Do not use for in humans. Keep this and all drugs out of the reach of children.

Precautions: Treatment with fewer than 6 monthly doses after the last exposure to mites may not provide complete heartworm prevention (see EFFECTIVENESS).

To report suspected adverse drug events, contact Virbac at 1-800-338-3659 or the FDA at 1-888-FDA-VETS.

Technical assistance, call Virbac at 1-800-338-3659

Dosage and Administration: SENTINEL SPECTRUM Chews should be administered monthly, with the minimum dose being 2.0 mg/lb (0.9 mg/kg) milbemycin oxime, 0.25 mg/lb (0.11 mg/kg) lufenuron, and 2.1 mg/lb (0.9 mg/kg) praziquantel. For heartworm prevention, given orally to dogs 6 months of age or older after mosquitoes are present (see EFFECTIVENESS).

To ensure adequate absorption, always administer SENTINEL SPECTRUM Chews to dogs immediately after or in conjunction with a normal meal.

SEN TinEL SPECTRUM Chews may be offered to the dog by hand or added to a small amount of dog food. The chewables should be administered in a manner that encourages the dog to chew, rather than to swallow without chewing. Chewables may be broken into pieces and fed to dogs that normally swallow treats whole. Care should be taken that the dog consumes the complete dose, and treated animals should be observed a few minutes after administration to ensure that no part of the dose is lost or rejected. If it is suspected that any of the dose has been lost, redosing is recommended.

Heartworm Prevention: SENTINEL SPECTRUM Chews should be administered at monthly intervals beginning within one month of the dog’s first seasonal exposure to mosquitoes and continuing until at least 6 months after the dog’s last seasonal exposure (see EFFECTIVENESS). SENTINEL SPECTRUM Chews may be administered year-round without interruption. When switching from another heartworm preventative product to SENTINEL SPECTRUM Chews, the first dose of SENTINEL SPECTRUM Chews should be given within a month of the last dose of the former product.

Flea Treatment and Prevention: Treatment with SENTINEL SPECTRUM Chews provides effective control of flea infestations for the remainder of the year, preferably starting one month before fleas become active and continuing monthly through the end of flea season. In areas where fleas are common year-round, monthly treatment with SENTINEL SPECTRUM Chews should continue the entire year without interruption.

To minimize the likelihood of flea reinfestation, it is important to treat all animals within a household with an approved flea protection product, as necessary.
IVERHART MAX® Soft Chew
(ivermectin/pyrantel pamoate/praziquantel)

For oral use in dogs only.

Caution: Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.

Description: IVERHART MAX® Soft Chew is a combination of three anthelmintics (ivermectin/ pyrantel pamoate/praziquantel). The soft chews are available in four sizes in color-coded packages for oral administration to dogs according to their weight (see Dosage and Administration).

Indications: For use in dogs to prevent canine heartworm disease by eliminating the tissue stage of heartworm larvae (Dirofilaria immitis) for a month (30 days) after infection and the treatment and control of roundworms (Toxocara canis, Toxascaris leonina), hookworms (Ancylostoma caninum, Uncinaria stenocephala, Ancylostoma braziliense), and tapeworms (Dipylidium caninum, Taenia planiformis) infections in dogs were demonstrated in well-controlled laboratory studies.

Dosage and Administration: IVERHART MAX Soft Chew should be administered orally at monthly intervals and the recommended minimum dose level of 6 mcg of ivermectin per kilogram (2.72 mcg/lb), 5 mg of pyrantel (as pamoate salt) per kg (2.27 mg/lb), and 5 mg of praziquantel per kg (2.27 mg/lb) of body weight, as follows:

<table>
<thead>
<tr>
<th>Dog Weight Pounds</th>
<th>Soft Chew per Month</th>
<th>Soft Chew Size</th>
<th>Ivermectin Content</th>
<th>Pyrantel Pamoate Content</th>
<th>Praziquantel Content</th>
</tr>
</thead>
<tbody>
<tr>
<td>6.0 to 12</td>
<td>1</td>
<td>Toy</td>
<td>34 mcg</td>
<td>28.5 mg</td>
<td>28.5 mg</td>
</tr>
<tr>
<td>12.1 to 25</td>
<td>1</td>
<td>Small</td>
<td>68 mcg</td>
<td>57 mg</td>
<td>57 mg</td>
</tr>
<tr>
<td>25.1 to 50</td>
<td>1</td>
<td>Medium</td>
<td>136 mcg</td>
<td>114 mg</td>
<td>114 mg</td>
</tr>
<tr>
<td>50.1 to 100</td>
<td>1</td>
<td>Large</td>
<td>272 mcg</td>
<td>228 mg</td>
<td>228 mg</td>
</tr>
</tbody>
</table>

IVERHART MAX Soft Chew is recommended for dogs 5 weeks of age or older. For dogs over 100 lbs, use the appropriate combination of these soft chews.

Remove only one dose at a time from the packaging. Return the remaining soft chew(s) to the box to protect from light. The soft chew can be offered to the dog by hand or added, intact, to a small amount of dog food. Care should be taken to ensure that the dog consumes the complete dose. The treated dog should be observed for a few minutes after administration to confirm that none of the dose has been lost or rejected. If it is suspected that any of the dose has been lost, redosing is recommended.

IVERHART MAX Soft Chew should be given at monthly intervals during the period of the year when mosquitoes (vectors), potentially carrying infective heartworm larvae, are active. The initial dose must be given within a month (30 days) after the dog’s first exposure to mosquitoes. The final dose must be given within a month (30 days) after the dog’s last exposure to mosquitoes.

When replacing another heartbeat preventative product in a heartworm disease prevention program, the first dose of IVERHART MAX Soft Chew must be given within a month (30 days) of the last dose of the former medication. A heartworm test should be performed prior to switching heartbeat preventative products.

If the interval between doses exceeds a month (30 days), the effectiveness of ivermectin can be reduced. Therefore, for optimal performance, the soft chew must be given once a month on or about the same day of the month. If treatment is delayed, whether by a few days or many, immediate treatment with IVERHART MAX Soft Chew and the recommended dosing regimen will minimize the opportunity for the development of adult heartworms.

Warnings: For use in dogs only. Keep this and all drugs out of reach of children and pets. In safety studies with ivermectin/pyrantel pamoate/praziquantel tablets, testicular hypoplasia was observed in some dogs receiving 3 and 5 times the maximum recommended dose monthly for 6 months (see Animal Safety).

In case of ingestion by humans, clients should be advised to contact a physician immediately. Physicians may contact a Poison Control Center for advice concerning cases of ingestion by humans.

Precautions: Use with caution in sick, debilitated, or underweight animals and dogs weighing less than 10 lbs (see Animal Safety). The safe use of this drug has not been evaluated in pregnant or lactating bitches.

All dogs should be tested for existing heartworm infection before starting treatment with IVERHART MAX Soft Chew, which is not effective against adult Dirofilaria immitis. Infected dogs should be treated to remove adult heartworms and microfilariae before initiating a heartworm prevention program.

While some microfilariae may be killed by the ivermectin in IVERHART MAX Soft Chew at the recommended dose level, IVERHART MAX Soft Chew is not effective for microfilaria clearance. A mild hypersensitivity-type reaction, presumably due to dead or dying microfilariae and particularly involving a transient diarrhea, has been observed in clinical trials with ivermectin alone after treatment of some dogs that have circulating microfilariae.

Adverse Reactions: In a field study with IVERHART MAX Soft Chew, self-limiting adverse reactions, including vomiting, diarrhea, lethargy, difficulty swallowing, excessive salivation, increased water consumption, and coughing were reported. Self-limiting adverse reactions, including lethargy, limps, salivation, shaking, diarrhea, decreased appetite, licking lips, and belching were reported between 20 minutes and 72 hours following treatment in a field study with ivermectin/pyrantel pamoate/praziquantel tablets.

In field studies with ivermectin/pyrantel pamoate tablets, vomiting or diarrhea within 24 hours of dosing was rarely observed (1.1% of administered doses). The following adverse reactions have been reported in dogs following the use of ivermectin products: depression/lethargy, vomiting, anorexia, diarrhea, mydriasis, ataxia, staggering, convulsions, and hypersalivation. To report suspected adverse events, for technical assistance, or to obtain a copy of the Safety Data Sheet (SDS), contact Virbac, Inc., 1-800-339-3859 or log onto the additional information about adverse drug experience reporting for animal drugs, contact the FDA at 1-888-FDA-VETS or online at http://www.fda.gov/AnimalVeterinary/SafetyHealth.

Effectiveness: Prevention of the tissue larval stage of heartworm (Dirofilaria immitis) and the elimination of the adult stage of hookworm (Ancylostoma caninum, Uncinaria stenocephala, Ancylostoma braziliense), roundworm (Toxocara canis, Toxascaris leonina), and tapeworm (Dipylidium caninum, Taenia planiformis) infections in dogs was demonstrated in well-controlled laboratory studies.

Palatability: In a field study of 132 dogs, IVERHART MAX Soft Chew was offered once monthly for 3 months. The dogs voluntarily consumed 86.3% of the doses from the owner’s hand or from a bowl within 5 minutes, 13.0% accepted the dose when it was offered in food or administered by placing onto the back of the dog’s tongue (pilling), and 0.7% of the doses were unable to be administered.

Animal Safety: Studies with ivermectin indicate that certain dogs of the Collie breed are more sensitive to the effects of ivermectin administered at elevated dose levels (more than 16 times the target dose level of 6 mcg/kg) than dogs of other breeds. At elevated doses, sensitive dogs showed more adverse reactions, which included mydriasis, depression, ataxia, tremors, drooling, paralysis, excitability, stupor, coma, and death. No signs of toxicity were seen at 10 times the recommended dose (27.2 mcg/lb) in sensitive Collies. Data from these studies support the safety of ivermectin products in dogs, including Collies, when used at the label recommended dose.

Because ivermectin and praziquantel are approximately 30% more bioavailable in the IVERHART MAX Soft Chew than in the ivermectin/pyrantel pamoate/praziquantel tablets used in the following target animal safety studies, the margin of safety is narrower than reported in these studies. The potential for adverse reactions may be greater in individual dogs administered IVERHART MAX Soft Chew than ivermectin/pyrantel pamoate/praziquantel tablets.

In a target animal safety study using ivermectin/pyrantel pamoate/praziquantel tablets, doses were administered to 8-week-old Beagle puppies at one, three, and five times the maximum recommended dose of 12.5 mcg/kg ivermectin, 10.47 mg/kg pyrantel, and 10.47 mg/kg praziquantel. The dogs were treated every 30 days for 6 months. Vomiting within 6 hours of dosing and soft or watery feces within 24 hours of dosing were observed. Other observations during the study were: ano-genital swelling, lethargy, head movements, shallow, audible or difficult breathing, and salivation. One dog in the 5X group had tremors and decreased activity. Treatment-related vomiting and soft feces were reported during this study.

In a study of the effectiveness of ivermectin/pyrantel pamoate/praziquantel tablets for the treatment of Toxocara canis, one 8.1 lb, 72-day-old puppy died 6 days after administration of the label dose. This puppy and many other puppies in the study had high worm burdens and was reported to have diarrhea, sometimes bloody, frequently before and after treatment. Dehydration and signs of anemia (pale mucous membranes) were the only abnormal gross necropsy finding observed. No definitive cause was determined. In a 90-day field study using ivermectin/pyrantel pamoate/praziquantel tablets, the most serious adverse reactions (lethargy, limps, and salivation) were seen in dogs weighing less than 10 lbs (see Precautions).

Storage Information: Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (59°F to 86°F).

How Supplied: IVERHART MAX Soft Chew is available in four dosage strengths (see Dosage and Administration) for dogs of different weights. Each strength comes in a package of 6 soft chews.

NADA 141-441. Approved by FDA.

Manufactured by: Virbac, Inc., Fort Worth, TX 76137 USA
Phone: 1-800-339-3859
© 2017 Virbac Corporation. IVERHART MAX is a registered trademark of Virbac Corporation. 302143-03
9/17.
Heartworm infection is on the rise¹ and many dogs are going unprotected.

To order both tasty options for your clinic, contact your Virbac representative at 1-844-4-VIRBAC (1-844-484-7222).

Important Safety Information for SENTINEL® SPECTRUM® Chews (milbemycin oxime/lufenuron/praziquantel): Dogs should be tested for heartworm infection prior to use. Mild hypersensitivity reactions have been noted in some dogs carrying a high number of circulating microfilariae. Treatment with fewer than 6 monthly doses after the last exposure to mosquitoes may not provide complete heartworm prevention. For complete product information, refer to the product insert. To obtain a product insert, contact Veterinary Technical Product Support at 1-800-338-3659, or visit us.virbac.com.

Important Safety Information for IVERHART MAX® Soft Chew (ivermectin/pyrantel pamoate/praziquantel): All dogs should be tested for existing heartworm infection before starting treatment with IVERHART MAX Soft Chew. Use with caution in sick, debilitated, or underweight dogs weighing less than 10 lb. Gastrointestinal and neurological signs, such as convulsions, have been reported following the use of ivermectin products. For complete product information, refer to the product insert. To obtain a product insert, contact Veterinary Technical Product Support at 1-800-338-3659, or visit us.virbac.com.

For complete product information, please see pages 16 and 17.


© 2019 Virbac Corporation. All Rights Reserved. SENTINEL, SPECTRUM, and IVERHART MAX are registered trademarks of Virbac Corporation. 6/19 36897
**CORNEAL ULCERATION**

Renee Carter, DVM, DACVO

*Louisiana State University*

---

**CORNEAL ULCERATION OBSERVED**

- **Yes:**
  - Corneal stromal loss, infiltrate, or malacia present?
    - **No:**
      - Lipping epithelial edges and chronicity present?
        - **No:**
          - Repeat cotton tip debridement
        - **Yes:**
          - Go to Complex Ulcer, next page
    - **Yes:**
      - Dogs
      - Cats
  - Indolent ulcer (SCCED)
    - Confirm patient age (older age [eg, 7-9 years] associated with SCCED) and absence of contributing ocular disorders (eg, entropion, lid mass, KCS)
    - Evaluate for underlying cause of ulceration
  - **DIAGNOSIS**
    - Simple ulcer
      - Typically acute
      - Distinct edges and/or margins
    - **DIAGNOSIS**
      - Indolent ulcer (SCCED)
    - **DIAGNOSIS**
      - Feline herpes
    - Mechanical lesion (eg, entropion, distichia)
    - Evaluate for underlying cause of ulceration
  - **DIFFERENTIALS**
    - Topical broad-spectrum antibiotic (eg, fluoroquinolone, erythromycin, oxytetracycline)
    - Debridement of ulcer
    - Grid keratotomy should be avoided due to increased risk for corneal sequestrum formation
    - ± swab for FHV-1 PCR
    - ± topical or systemic antiviral agent

- **No:**
  - Fluorescein negative and patient comfortable?
    - **No:**
      - Repeat cotton tip debridement
      - ± grid keratotomy, anterior stromal puncture, or diamond burr keratotomy
    - **Yes:**
      - Discontinue therapy

**TREATMENT**

- Elizabethan collar
- Topical broad-spectrum antibiotic 3-4 times daily
- ± topical atropine as needed for pain/reflex uveitis*
- ± oral NSAID
- Cotton tip debridement of loose epithelial edges
- Elizabethan collar
- Topical broad-spectrum antibiotic (eg, triple antibiotic ointment or solution [eg, neomycin–polymyxin–bacitracin], fluoroquinolone)
- Topical atropine as needed for pain
- ± bandage contact lens
- ± oral NSAID
- ± topical or oral tetracycline to speed wound healing
- Additional recommended treatment (eg, grid keratotomy, anterior stromal puncture, diamond burr keratotomy) to speed healing
- Recheck in 10-14 days

---

*Atropine should be used with caution in patients with KCS and glaucoma; less atropine is needed when uveitis or complex ulcer is not present.
†Oral tetracyclines are not indicated unless the patient has an upper respiratory infection caused by *Mycoplasma spp* or *Chlamydophila felis*.

---

**Footnotes:**

- FHV-1 = feline herpesvirus type 1
- KCS = keratoconjunctivitis sicca
- SCCED = spontaneous chronic corneal epithelial defects

---

**June 2019 cliniciansbrief.com**
**DIAGNOSIS**

**COMPLEX ULCER**

Evaluate for underlying cause of ulceration

- Collect samples from lesion edges
  - Corneal cytology
  - Corneal aerobic culture and susceptibility (± fungal or anaerobic) testing

**TREATMENT**

- Based on cytology results (pending culture):
  - Rods: Consider aminoglycoside or fluoroquinolone as first-line topical medications
  - Cocci: Consider triple antibiotic as first-line medication
  - Ulcer with infiltrate: Infection should be assumed, even if no bacteria or fungal organisms noted on cytology
  - Evaluate previous and/or current medications when choosing topical therapy
  - Change drug class if conditions worsen on current medical therapy
  - Frequency (eg, 4-12 times daily) of topical medications depends on severity
  - Topical serum or plasma drops recommended to treat melting corneal ulcers (eg, corneal malacia) until edges of ulcer become sharply defined
  - Elizabethan collar
  - Atropine (1-2 times daily), if not contraindicated
  - ± oral NSAIDs, if not contraindicated
  - Recheck frequently (eg, every 1-3 days)

**DIFFERENTIALS**

- KCS
- Trauma

**DIAGNOSIS**

Lagophthalmos

- Brachycephalic conformation (bilateral)
- Facial nerve paralysis (often unilateral)
- Exophthalmos (eg, abscess, cellulitis, neoplasia, mucocele, cyst, myositis, salivary gland inflammation) secondary to orbital disease (unilateral)
- Buphthalmos secondary to chronic primary or secondary glaucoma (unilateral or bilateral)

**DIFFERENTIALS**

- Nasal ulceration

**DIAGNOSTIC/MANAGEMENT TREE**

- OP HTHALMOLOGY
- PEER REVIEWED

---

KCS = keratoconjunctivitis sicca
STT = Schirmer tear test
**DIFFERENTIALS**

- Nasal fold trichiasis secondary to conformation
- Medial canthal entropion secondary to conformation
- Foreign body behind third eyelid
- Eyelid mass

**DIFFERENTIALS**

- Ectopic cilia
- Distichia
- Entropion
- Eyelid mass

**TREATMENT**

- Surgical correction of eyelid and/or conformational abnormality
- Removal of foreign body or mass, if indicated
- Lubricating broad-spectrum topical antibiotic
- Elizabethan collar
- Recheck after 1 week

Nasal ulceration

Dorsal, ventral, or lateral ulceration

---

**Redefining Surgery Recovery**

*Fiberglass kennels and cages from Mason Company are quieter, softer, warmer, attractive and more durable than cold metal.*

Quiet Cottages™ and Heated Recovery Cages are the stacked caged system of the future.

- Molded, solid-surface fiberglass cage bodies have contemporary look and feel.
- Available with individual built-in drains to ensure sanitary conditions.
- Warmer, quieter and less reflective than stainless steel to reduce fear, anxiety and stress in animals.

The UltraBase™ Above Floor system is available only from Mason Company.

- One piece fiberglass floor with 6” sides eliminates leaks.
- Individual drains to prevent cross contamination.
- Stainless steel side panels for durability and ease of cleaning.

(800) 543-5567
www.MasonCo.com/surgery
info@MasonCo.com

Visit our website to download this helpful guide!
Pericardial Disease in the Dog

Pericardial effusion can impair cardiac function by limiting normal cardiac filling and compressing the heart, resulting in cardiac tamponade. Acquired pericardial effusion is common in dogs and is most often idiopathic or caused by cardiovascular-related neoplasia. Transudates rarely cause clinical signs, with the exception of heart base tumors, which can obstruct lymphatic drainage, resulting in large, compressive effusion. Exudates are caused by infective or noninfective (eg, penetrating foreign body) pericarditis and are not common. Hemorrhagic effusion is most common and often occurs in older dogs with heart or heart base tumors and/or pericardial neoplasia. Idiopathic pericardial hemorrhage is the most prominent cause of pericardial hemorrhage in dogs younger than 6 years.

In cardiac tamponade, intrapericardial fluid pressure results in cardiac compression with subsequent low cardiac output and congestive heart failure. The development of cardiac tamponade depends on the rate—not simply the volume—of pericardial fluid accumulation. Acute and severe hypotension in cardiac tamponade can result in syncope and sudden death. Chronic cardiac tamponade, in which compensatory mechanisms lead to elevated venous pressure behind the heart, can result in congestive heart failure (primarily right-sided). Acute clinical signs include low blood pressure and jugular distension, with variable physical findings. Signs of chronic effusion include elevated jugular venous pressure, muffled heart sounds, ascites, and pulsus paradoxus. ECG may reveal decreased amplitude QRS complexes, electrical alternans, and/or ST segment elevation. Radiography typically demonstrates a globular-shaped heart. Echocardiography is highly sensitive for detection of pericardial effusion.

Pericardiocentesis is the treatment of choice for initial stabilization, as intrapericardial pressure typically drops dramatically once half the fluid volume has been drained. Drainage may be curative for idiopathic pericardial hemorrhage, but patients must be monitored for development of constrictive pericardial disease. Recurrent effusion or cases related to neoplasia require repeat drainage or surgery (eg, subtotal pericardiectomy). Prognosis is typically favorable for patients with idiopathic pericardial hemorrhage but is guarded in those with infective pericarditis and generally unfavorable in those with heart or heart base tumors.—Bonagura JD
READY. AIM. CLARO.

Fight canine otitis externa with one big dose of love. Claro® (florfenicol, terbinafine, mometasone furoate) Otic Solution is the only FDA-approved, single-dose treatment administered by you with guaranteed compliance and no at-home treatments.

Claro® is indicated for the treatment of otitis externa in dogs associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (Staphylococcus pseudintermedius).

CAUTION: Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian. CONTRAINDICATIONS: Do not use in dogs with known tympanic membrane perforation. CLARO® is contraindicated in dogs with known or suspected hypersensitivity to florfenicol, terbinafine hydrochloride, or mometasone furoate.

©2019 Bayer, Shawnee Mission, Kansas 66201
Bayer, the Bayer Cross and Claro are registered trademarks of Bayer. CL19207

See page 25 for product information summary.
**“Hands-Off” Neurology**

Two parts of the neurologic examination—posture and gait analysis—do not require touching the patient. Initial distant posture assessment involves evaluating whether patients are standing, sitting, or lying down and whether they are able to right themselves and stand. Sitting sternally with both rear legs tucked under or extended straight forward is often noted in patients experiencing severe weakness or paralysis of the rear limbs, whereas a patient affected in all 4 limbs may require help to sit sternally. Head tilt may indicate unilateral vestibular disease, whereas a head turned to one side may indicate a forebrain lesion. Posture also provides information regarding pain (eg, an animal with cervical pain holding the head close to the ground with the back arched). Some postural presentations for certain regional spinal abnormalities are pathognomonic. For example, Schiff-Sherrington posture is seen in patients with sudden onset of a severe lesion of the thoracolumbar spinal cord.

Gait analysis is key to distinguishing neurologic from orthopedic conditions, as neurologic problems typically cause weakness and ataxia, whereas orthopedic problems cause lameness. There are 3 subtypes of ataxia:

- Proprioceptive ataxia is caused by lesions of the proprioceptive pathways of the brainstem or spinal cord and manifests as incoordination and inconsistent stride lengths.
- Cerebellar ataxia is characterized by hypermetria of the limbs, trunca sway, wide-based stance, and head tremors.
- Vestibular ataxia is caused by central or unilateral peripheral vestibular system disturbances and is recognized as falling, drifting, or rolling to one side.

—Moore S

---

**Antimicrobial Use in the Emergency Patient**

Emergency patients with infectious disease may be stable and treated as outpatients, have sepsis and require hospitalization, or be critically ill with severe sepsis or septic shock. The presence or absence of critical illness affects the choice and route of antimicrobial administration. If the patient requires antimicrobials, considerations must be made regarding the patient, microorganism, and antimicrobials. Potential adverse effects on the host may preclude an antimicrobial choice. The suspected organism and its intrinsic resistance to antimicrobials, whether the selected antimicrobials are bacteriostatic or bactericidal, and the ability of the antimicrobials to penetrate the affected tissue should all be considered.

In septic patients, culture and susceptibility testing are warranted; however, in patients with severe sepsis or septic shock, antimicrobial therapy should be initiated as soon as possible if obtaining a culture is expected to be delayed more than 45 minutes. Longer delays in initiating therapy in patients with severe sepsis or septic shock have been associated with increased rates of acute kidney injury, organ dysfunction, and length of hospital stay. Escalation therapy (ie, choosing a narrow-spectrum antibiotic and potentially switching when culture and susceptibility testing results are received) is standard when treating outpatients or hospitalized stable septic patients. De-escalation therapy (ie, choosing a broad-spectrum antibiotic then modifying based on culture and susceptibility results) may be considered for patients with severe sepsis or septic shock and has not been shown to promote multidrug resistance. There is little evidence regarding the appropriate duration of antimicrobial treatment; sepsis guidelines in humans have suggested a typical course of 7 to 10 days’ duration.—Epstein S

---

**Potential adverse effects on the host may preclude an antimicrobial choice.**
Otitis externa (OE), defined as inflammation of the external ear canal, is a common disease in dogs. Patients may exhibit a range of clinical signs, including head shaking, scratching, pain, and otic exudate. The PSPP (primary, secondary, perpetuating, and predisposing factors) system classifies OE as either primary or secondary. Primary causes create disease in the normal ear without any other cause or factor. In primary OE, the environment of the ear is changed, allowing secondary infection to occur. Secondary OE occurs when secondary causes create disease in an abnormal ear; these causes are generally easy to eliminate. Predisposing and perpetuating factors change the structure or function of the ear canal, thereby contributing or promoting OE.

Recent research has added to the understanding of these common pathogens and may aid in the management of canine OE patients.

Expanding Knowledge of Canine Otic Microbiota & Mycobiota

The canine microbiome is composed of commensal bacteria (ie, microbiota) and fungal organisms (ie, mycobiota). Numerous studies relating to the human microbiome have been published and have observed several associating changes in the microbiome with a number of skin diseases. Although few such studies exist in dogs, a recent paper evaluating the canine skin microbiome found that dogs with allergic skin disease had a lower microbiome species richness as compared with healthy dogs. Further studies have investigated the microbiota and mycobiota of canine ears with and without OE.

Established methods for microorganism identification include culture and cytology. However, more advanced techniques are making further characterization of microbiomes possible.

Microbiota in Dogs With vs Without Otitis Externa

A recent study of canine OE used metagenomic techniques to evaluate the microbiota of canine ear canals in healthy versus atopic dogs without clinical signs of OE. Results confirmed those of an earlier study that found a more diverse population of bacteria present in the canine ear canal than had been previously noted with bacterial culture techniques. In addition, significant differences between healthy and allergic dogs were noted in the taxonomic distribution of bacterial groups found in ear canals.

In total, 15 bacterial groups were differentially represented between the 2 sets of dogs. Of these, 13 were overrepresented.
in the atopic dogs and included bacterial groups from the genera Staphylococcus and Ralstonia (previously classified in the genus Pseudomonas). In healthy dogs, 2 groups were overrepresented, including from the genus Escherichia. The authors proposed that this shift in bacterial population may play a role in the increased propensity for atopic dogs to develop OE.

Mycobiota in Dogs With vs Without Otitis Externa

Studies evaluating the mycobiota of dogs with and without allergic disease and/or OE have paralleled microbiota studies. In one study, metagenomic techniques were used to compare the cutaneous mycobiota of healthy dogs and dogs with allergic skin disease and no clinical signs. As with microbiota, the skin of allergic dogs was found to have decreased fungal richness; decreased fungal diversity was also noted in the ears of these dogs.

Earlier culture-based studies have documented the presence of these dogs. Recent studies have revealed the microbiome of the canine external ear canal to be far more diverse than previously thought. Advanced identification techniques have allowed for more detailed characterization of the microbiota and mycobiota identified a significantly higher abundance of Malassezia pachydermatis in affected ears.

Conclusion

Ongoing studies have revealed the microbiome of the canine external ear canal to be far more diverse than previously thought. Advanced identification techniques have allowed for more detailed characterization of the microbiota and mycobiota present in healthy dogs as compared with allergic dogs with and without OE. Further research may help determine the significance of these changes, how they relate to development of clinical disease, and whether changes in management of these patients might modify outcomes.

**PSPP Classification System**

<table>
<thead>
<tr>
<th>Primary Causes</th>
<th>Secondary Causes</th>
<th>Perpetuating Factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Allergy</td>
<td>• Bacterial and/or fungal infection (particularly Staphylococcus intermedius, Streptococcus spp, Pseudomonas aeruginosa, Escherichia coli, and Proteus mirabilis bacteria and the yeast Malassezia pachydermatis)</td>
<td>• Ear epithelium changes (eg, epithelial cell migration failure)</td>
</tr>
<tr>
<td>• Autoimmune disorders (eg, pemphigus)</td>
<td>• Medication reaction</td>
<td>• Changes to ear canal (eg, edema, stenosis, proliferation)</td>
</tr>
<tr>
<td>• Endocrine disorders</td>
<td>• Systemic disease</td>
<td>• Typanic membrane changes (eg, dilation, rupture)</td>
</tr>
<tr>
<td>• Epithelialization disorders</td>
<td>• Glandular disorders</td>
<td>• Glandular (eg, sebaceous hyperplasia)</td>
</tr>
<tr>
<td>• Foreign bodies</td>
<td>• Yeast overgrowth</td>
<td>• Periarticular fusibis</td>
</tr>
<tr>
<td>• Glandular disorders</td>
<td></td>
<td>• Middle ear disorders (eg, otitis media)</td>
</tr>
</tbody>
</table>

**References**

Intralipid Use for Intoxication

Intravenous lipid emulsions (ILEs) are part of the standard of care for intoxication in human medicine and have become common for treating specific intoxications in small animal medicine. The mechanism by which they improve clinical signs of toxicity remains unknown. One theory is that lipids increase cardiac performance, possibly by acting as an energy source for myocardial mitochondria or by increasing intracellular calcium in cardiac myocytes. A second theory is that ILEs act as a “lipid sink” that draws lipidsoluble intoxicants into the bloodstream, where they are sequestered and ultimately cleared; this is likely the mechanism by which ILEs work for lipophilic drug intoxication (eg, amloidipine, carprofen, diazepam, digoxin, itraconazole, ivermectin, lidocaine, ketoprofen, naproxen, trazadone, vinblastine).

There is no clinical evidence on the short-term safety of ILE boluses. Although potential adverse effects include decreased neutrophil function, pancreatitis, fat emboli, phlebitis, and hypersensitivity reactions, there have been no reports of negative outcomes related to ILE therapy for intoxication. Optimal dosing of ILE is unknown. Reports vary widely, but the most commonly cited dose is a 1.5-mL/kg bolus (typically over 1-2 minutes), followed by a 30- to 60-minute infusion (0.25 mL/kg/min). Human studies citing treatment with a 1.5-mL/kg bolus followed by 0.25-0.5 mL/kg/min may serve as a provisional dose regimen pending further studies in veterinary species.—Epstein S

Although potential adverse effects include decreased neutrophil function, pancreatitis, fat emboli, phlebitis, and hypersensitivity reactions, there have been no reports of negative outcome related to ILE therapy for intoxication.
Increased & Decreased Creatinine

Julie Allen, BVMS, MS, MRCVS, DACVIM (SAIM), DACVP
Cornell University

Following are differential diagnoses, listed in order of likelihood, for patients presented with increased or decreased creatinine.

**Increased Creatinine**

- Of note, any increase in creatinine should be interpreted in conjunction with urine specific gravity.
  - Renal disease
  - Dehydration
  - Postrenal obstruction or leakage
  - Breed predisposition
    - Sighthounds (eg, greyhounds [due to increased muscle mass])
    - Birman cats
    - Siberian and, to a lesser extent, Siamese and Somali cats

**Decreased Creatinine**

- Decreased muscle mass due to starvation or cachexia
- Increased glomerular filtration rate (eg, overhydration, portosystemic shunts, any cause of severe polyuria/polydipsia, pregnancy)

**References**


Hill’s® Prescription Diet® w/d® is now w/d® Multi-Benefit. It’s the same great-tasting nutrition trusted for multiple conditions — now with a new name that strikes the right chord.

The great tasting nutrition of w/d® Multi-Benefit is a four-hit wonder formulated:

1. To help minimize blood glucose fluctuation, which may reduce insulin dosage
2. To address fiber-responsive GI conditions such as colitis, diarrhea or constipation
3. Low in fat and calories to help lower lipid levels and avoid weight gain
4. With S+OXSHIELD™ to promote a urinary environment that reduces the risk of developing struvite and calcium oxalate crystals

RECOMMEND w/d® MULTI-BENEFIT A FOUR-HIT WONDER FOR FOUR CONDITIONS
Top 5 Causes of Nonblanching Skin Lesions

Darren Berger, DVM, DACVD
Iowa State University

Patchy, erythemic-to-violaceous skin lesions are commonly encountered in veterinary patients. Diascopy is a quick and efficient test that can help determine whether lesions are the result of vasodilation secondary to inflammation or associated with a more clinically concerning process.

In diascopy, a clear glass slide is placed over an erythemic lesion and pressure is applied while care is taken not to injure the patient or break the slide. A positive diascopy result occurs when the applied pressure results in blanching of the skin (Figure 1), as seen in cases of erythema secondary to simple vascular vasodilation. A negative diascopy result occurs when the applied pressure does not result in skin blanching.

Following are 5 of the author’s more common causes of skin lesions that will not blanch.

### 1. Cutaneous Adverse Drug Reactions

Cutaneous adverse drug reactions can result from administration of medications. Commonly implicated substances include antimicrobials (eg, β lactams, sulfonamides), NSAIDs (Figure 2), and antiparasitics. Drug reactions can appear as any dermatologic condition, with lesions being focal-to-generalized. Typical lesion patterns include urticarial angioedema, maculopapular eruptions, vesiculobullous reactions, nodules,

### TOP 5 CAUSES OF NONBLANCHING SKIN LESIONS

1. Cutaneous Adverse Drug Reactions
2. Petechiae & Ecchymoses from Coagulation Disturbances
3. Epitheliotropic T-Cell Lymphoma
4. Cutaneous Vasculitis
5. Erythema Multiforme

---

**FIGURE 1** Positive diascopy result indicated by the well-demarcated area of blanching (circle) in a patient with erythemic plaque secondary to calcinosis cutis
exfoliative erythroderma, purpuric lesions, pemphigus-like lesions, erythema multiforme, vasculitis, and toxic epidermal necrolysis. Clinical signs typically occur within 1 to 3 weeks of initiating administration of the offending drug but can also arise more quickly (eg, within days), after a single treatment, after years of use, or days after the medication has been stopped.

Because cutaneous adverse drug reactions can overlap with many dermatologic conditions, diagnosis is primarily based on suspicion from patient history, physical examination, and the elimination of other differentials. No particular clinical pathology or histopathology results can specifically indicate a cutaneous adverse drug reaction. Definitive diagnosis typically requires drug provocation testing (ie, readministration of the suspected offending agent), but this is considered unethical in many cases due to the severity and potentially fatal nature of disease.

Treatment consists of supportive care, immunomodulatory therapy (eg, glucocorticoids, cyclosporine), discontinuation of all possible offending drugs or nutraceuticals, and avoidance of chemically related drugs. In rare refractory cases, other immunomodulatory therapies such as intravenous immunoglobulin may be effective.

### Petechiae & Ecchymoses from Coagulation Disturbances

Petechiae and ecchymoses are erythemic-to-violaceous macular discolorations of the skin or mucosal surface. They occur secondary to blood vessel bleeding that may coalesce to affect a large surface area (Figure 3). These lesions are often seen with quantitative and/or qualitative hemostatic disorders, the most common of which is thrombocytopenia.

Diagnosis of these conditions involves a thorough patient history, CBC with blood smear review, coagulation profile, platelet function tests, bone marrow aspiration, infectious disease testing, and, if necessary, genetic testing.
Treatment is highly variable and depends on the underlying disorder and severity. Skin biopsy acquisition is contraindicated in cases of suspected petechiae and/or ecchymoses.

3 Epitheliotropic T-Cell Lymphoma
Epitheliotropic T-cell lymphoma is an uncommon disease of older animals in which neoplastic cells infiltrate the epidermal structures. The exact etiology is unknown, but an association with atopy has been proposed. Epitheliotropic T-cell lymphoma has various clinical presentations, including generalized exfoliative erythroderma (Figure 4), erosive-to-ulcerative plaque, cutaneous nodules, mucocutaneous lesions, and/or disease confined to the oral mucosa. Pruritus is common and, in the author’s experience, often leads to a misdiagnosis of allergic hypersensitivity. Patients with disease confined to the mucocutaneous junctions or oral mucosa are commonly misdiagnosed with autoimmune disease.

Diagnosis is confirmed via biopsy with histopathology, which demonstrates the characteristic epitheliotropism of the neoplastic cells and differentiates this condition from nonepitheliotropic cutaneous lymphoma. Prognosis is poor, with a reported median survival time of 6 months following diagnosis.

Several therapeutic protocols have been proposed in the treatment of epitheliotropic T-cell lymphoma in dogs, but oral administration of lomustine is most commonly used.

4 Cutaneous Vasculitis
Vasculitis is an uncommon disorder characterized by an aberrant immune response that results in blood vessel damage. It is considered to be a reaction pattern with numerous potential triggers. Possible inciting causes include medications, vaccinations, infectious disease, parasites, adverse reactions to food, familial disease, metabolic derangements, neoplasia, and idiopathic forms. Cutaneous lesions are usually well-demarcated and consist of edema,
purpura, alopecia, erosions, focal punctate ulcers, crusting, necrosis, and/or eschar formation (Figure 5). Although lesions may occur anywhere, the extremities, tips of the ears, oral mucosa, and tail are more commonly affected. Patients may also display systemic signs, which should correlate with disease severity.

Diagnosis is based on clinical suspicion and compatible skin biopsy results. Newer lesions show the best diagnostic yield of biopsy specimens, as chronic lesions may only reveal ischemic changes. Following a confirmed diagnosis, the patient should be evaluated for specific etiologies via blood work, urinalysis, tick-borne disease testing, imaging studies, coagulation profiles, and immunologic assays. In cases in which diagnostic testing fails to identify a probable cause, a diet elimination trial should be considered, as a retrospective study previously identified food allergy as the underlying etiology in a subset of cutaneous vasculitis cases.

Therapy should focus on removal or treatment of the underlying cause and immunomodulation. Prognosis is highly variable and dependent on the underlying cause, lesion extent, and degree of systemic involvement.

Erythema Multiforme

Erythema multiforme is an uncommon condition that, in veterinary medicine, is inappropriately synonymous with a drug reaction. Similar to vasculitis, numerous potential inciting causes (eg, medications, cutaneous adverse food reactions, bacterial infection, viral infection, vaccinations, neoplasia, idiopathic forms) have been associated with erythema multiforme. Disease varies from mild to severe based on systemic clinical signs. Common lesions include erythematous macules, papules, and plaque with central clearing that creates serpiginous-to-annular areas that eventually become necrotic, crusted, or hyperpigmented (Figure 6). Lesions commonly involve the ventrum, concave aspects of the ears, footpads, and/or mucocutaneous junctions. Diagnosis should be made via biopsy with histopathology, which should demonstrate indicative microscopic changes. After diagnosis is confirmed, blood work, urinalysis, infectious disease testing, and advanced imaging should be pursued to evaluate for underlying disease.

Initial treatment should consist of removing potential offending agents (eg, discontinuing medications, treating infections, avoiding suspect dietary antigens) and providing supportive care. Mild cases may resolve spontaneously, but immunosuppressive therapy is required in most cases and may be needed lifelong in chronic relapsing or idiopathic cases. Prognosis ranges from good to poor and is mostly dependent on the identification of the underlying cause and severity of systemic disease.

See page 67 for references.
NexGard® is a registered trademark, and  
FRONTLINE VET LABS is a trademark, of Merial. ©2018 Merial. All rights reserved.

NexGard® (afoxolaner) Chewables

Approval Experience (May 2018): The following adverse events are based on post-appraisal adverse drug experience reporting. Not all adverse events are reported to FDA/CVM. It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship to product exposure using these data. The following adverse events reported for dogs are listed in decreasing order of reporting frequency for NexGard:

Vomiting, pustules, lethargy, diarrhea (with and without blood), anorexia, hyperactivity/ restlessness, panting, erythema, ataxia, dermatitis (including rash, papules), allergic reactions (including hives, swelling), and tremors.

Contact Information:
For a copy of the Safety Data Sheet (SDS) or to report suspected adverse drug events, contact Merarial at 1-888-637-4251 or www.nexgardfordogs.com.

For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at http://www.fda.gov/AnimalVeterinary/SafetyHealth.

Mode of Action:
Afoxolaner is a member of the isoxazoline family, shown to bind at a binding site to inhibit insect and acarine ligand-gated chloride channels, in particular those gated by the neurotransmitter gamma-aminobutyric acid (GABA), thereby blocking pre- and post-synaptic transfer of chloride ions across cell membranes. Prolonged afoxolaner-induced hyperexcitation results in uncontrolled activity of the central nervous system and death of insects and acarines. The selective toxicities of afoxolaner between insects and acarines and mammals may be inferred by the differential sensitivity of the insects and acarines’ GABA receptors versus mammalian GABA receptors.

Effectiveness:
In a well-controlled laboratory study, NexGard began to kill fleas four hours after initial administration and demonstrated ≥93% effectiveness at eight hours. In a separate well-controlled laboratory study, NexGard demonstrated 100% effectiveness against adult fleas 24 hours post-infestation for 35 days, and was ≥93% effective at 12 hours post-infestation through Day 21, and on Day 35.

On Day 28, NexGard was 81.1% effective 12 hours post-infestation. Dogs in both the treated and control groups that were infested with fleas on Day 1 generated flea eggs at 12- and 24-hours post-treatment (0-11 eggs and 1-17 eggs in the NexGard-treated dogs, and 4-90 eggs and 0-118 eggs in the control dogs, at 12- and 24-hours, respectively). At subsequent evaluations post-infestation, fleas from dogs in the treated group were essentially unable to produce any eggs (0-1 eggs) while fleas from dogs in the control group continued to produce eggs (1-141 eggs).

In 90-day US field study conducted in households with existing flea infestations of varying severity, the effectiveness of NexGard against fleas on the Day 30, 60 and 90 visits compared with baseline was 98.0%, 99.7%, and 99.9%, respectively.

Collectively, the data from the three studies (two laboratory and one field) demonstrate that NexGard kills fleas before they can lay eggs, thus preventing subsequent flea infestations after the start of treatment of existing flea infestations.

In well-controlled laboratory studies, NexGard demonstrated ≥93% effectiveness against Dermacentor variabilis, >94% effectiveness against Ixodes scapularis, and >50% effectiveness against Rhipicephalus sanguineus, 48 hours post-infestation for 36 days. At 72 hours post-infestation, NexGard demonstrated >97% effectiveness against Amblyomma americanum for 30 days. In two separate, well-controlled laboratory studies, NexGard was effective at preventing Rhipicephalus sanguineus infestations after dogs were infested with Ixodes scapularis vector ticks 28 days post-treatment.

Animal Safety:
In a margin of safety study, NexGard was administered orally to 8 to 9-week-old Beagle puppies at 1, 3, and 5 times the maximum exposure dose (6.3 mg/kg) for three treatments every 28 days, followed by three treatments every 14 days, for a total of six treatments. Dogs in the control group were sham-dosed. There were no clinically-relevant effects related to treatment on physical examination, body weight, food consumption, clinical pathology (hematology, clinical chemistries, or coagulation tests), gross pathology, histopathology or organ weights. Vomiting occurred throughout the study, with a similar incidence in the treated and control groups, including one dog in the 5x group that vomited four hours after treatment.

In a well-controlled field study, NexGard was used concomitantly with other medications, such as vaccines, anthelmintics, antibiotics (including tetracyclines), steroids, NSAIDS, anesthetics, and antihistamines. No adverse reactions were observed from the concomitant use of NexGard with other medications.

Storage Information:
Store at or below 30°C (86°F) with excursions permitted up to 40°C (104°F).

Hov Supplies:
NexGard is available in four sizes of beef-flavored soft chewables: 1.13, 28.3, 88, or 136 mg afoxolaner. Each chewable size is available in color-coded packages of 1, 3 or 6 beef-flavored chewables.

NADA 141-406, Approved by FDA
Marketed by Frontline Vet LabsTM, a Division of Merial, Inc.
Duluth, GA 30096-4640 USA
Made in Brazil.
©2018 Merial. All rights reserved.
IMPORTANT SAFETY INFORMATION:
NexGard is for use in dogs only. The most frequently reported adverse reactions include vomiting, pruritus, lethargy, diarrhea and lack of appetite. The safe use of NexGard in pregnant, breeding, or lactating dogs has not been evaluated. Use with caution in dogs with a history of seizures or neurologic disorders. For more information, see the full prescribing information or visit www.NexGardClinic.com.

NexGard® is a registered trademark of the Boehringer Ingelheim Group. ©2019 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA 30096. All rights reserved. PET-1163-NEX03119.

See page 32 for product information summary.

Powerful protection can also be gentle:
✓ Safe for puppies as young as 8 weeks of age weighing 4 lbs or more
✓ Over 140 million doses of afoxolaner have been prescribed¹
✓ And it’s the only flea and tick control product indicated for the prevention of Borrelia burgdorferi infections as a direct result of killing Ixodes scapularis vector ticks

¹Data on file.
Making the Case for Heartworm Prevention in Cats
While they are harder to diagnose than dogs, cats get heartworm disease, too

Q. You’re a big believer in heartworm prevention in cats. What has driven that belief?
A. I saw my first feline heartworm case more than 25 years ago. The cat had died suddenly, so I performed a necropsy and found two adult heartworms in the heart. Back then, there were no preventives for cats, and veterinarians and owners were largely unaware of the problem. Today, awareness is higher and we have several products to choose from, which makes compliance easier. But we still have a long way to go.

Q. Heartworm screening is more challenging in cats than dogs. What is your approach?
A. Heartworm testing in cats has limitations, especially for routine screening. Some wellness panels only include antigen tests, which detect adult female worms; however, cats often have male-only and immature heartworms that can’t be detected on antigen tests. If a feline patient presents with unexplained cough or vomiting, we run both antibody and antigen tests. Antibody tests can detect current or recent infections of both male and female heartworms. The limitation is that it can’t determine if a cat is currently infected and the sensitivity of the test is nowhere near as accurate as an antigen test. Other diagnostic strategies include thoracic radiography, which is helpful in assessing the severity and progression of pulmonary disease, and ultrasonography, which can help confirm the presence of adult worms.

Q. How do you talk to cat owners about heartworm disease?
A. I stress that cats should not be treated as second-class citizens and emphasize that a lack of approved treatments makes prevention essential. We also educate owners about heartworm associated respiratory disease (HARD), which can be caused by infections from either immature or adult worms. Comparing HARD to asthma or COPD in people is an easy way to help owners understand how serious and long-lasting the condition can be. If owners are more motivated about issues like flea control than heartworm prevention, recommending a broad-spectrum product can be a good way to ensure patients are protected from internal as well as external parasites.

Q. How do you make the threat of heartworms feel real to cat owners—especially if they have indoor cats?
A. An indoor lifestyle protects cats from a number of threats, but it’s no guarantee against heartworms. I explain that mosquitoes readily enter houses through screens, open doors, attic soffits and bathroom exhaust vents, and may hover near doorways and garages, waiting to gain entry. I want owners to understand that while they can’t always prevent mosquitoes from biting their cats, they can readily prevent heartworms by administering preventives year-round.
FROM PAGE TO PATIENT

Designed to bridge the gap between research pages and daily practice protocol, the following pearls offer tips and techniques to grow the general practitioner’s clinical excellence.

36 Esophageal Perforation from Foreign Body
Jonathan Miller, DVM, MS, DACVS

38 Nutrient Deficiencies During Weight Loss in Dogs
Martha G. Cline, DVM, DACVN

41 Laryngeal & Intratesticular Lidocaine for Feline Anesthetic Techniques
Rebecca Johnson, DVM, PhD, DACVAA

46 Superficial Bacterial Folliculitis
William Oldenhoff, DVM, DACVD

48 Owner Perceptions of the Treatment of Feline Behavior Problems
Leslie Sinn, DVM, DACVB

52 Gallbladder Mucocoeles in Border Terriers
Faith I. Buckley, DVM, DACVIM (SAIM)

55 Effects of Noise in the Operating Room
Laura L. Nelson, DVM, MS, DACVS

58 Long-Term Outcome of Primary Immune-Mediated Thrombocytopenia
Lisa Singer, VMD, DACVIM

60 Salmonella Enteritidis Infection in Guinea Pigs
Radford Davis, DVM, MPH, DACVPM
Esophageal Perforation from Foreign Body

Jonathan Miller, DVM, MS, DACVS
Oradel Animal Hospital
Paramus, New Jersey

Eosophageal foreign bodies (EFBs) can occur in dogs that have ingested a bone, fishhook, dog treat, or other object. These foreign bodies should be addressed quickly to avoid complications (e.g., esophagitis, aspiration pneumonia, stricture, perforation). Treatment typically involves endoscopic removal or dislodging of the EFB to redirect it into the stomach for either digestion or surgical removal.

In the Literature

FROM THE PAGE …

Brief Summary: Before using please consult the product insert, a summary of which follows.

ANADIA 200, 591, Approved by FDA

Carprieve® (carprofen)
Chewable Tablets

Non-steroidal anti-inflammatory drug

For oral use in dogs only

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

INDICATIONS: Carprieve is indicated for the relief of pain and inflammation associated with osteoarthritis and for the control of postoperative pain associated with soft tissue and orthopedic surgeries in dogs.

CONTRAINDICATIONS: Carprieve should not be used in dogs exhibiting previous hypersensitivity to carprofen.


All dogs should undergo a thorough history and physical examination before initiation of NSAID therapy. Appropriate laboratory tests to establish hematological and serum biochemical baseline data prior to, and periodically during, administration of any NSAID should be considered. Owners should be advised to observe for signs of potential drug toxicity.

PRECAUTIONS: As a class, cyclooxygenase inhibitory NSAIDs may be associated with gastrointestinal, renal, and hepatic toxicity. The most frequently reported effects have been gastrointestinal signs. Events involving suspected renal, hematologic, neurologic, dermatologic, and hepatic effects have also been reported.

Patients at greatest risk for renal toxicity are those that are dehydrated, on concomitant diuretic therapy, or those with renal, cardiovascular, and/or hepatic disorders. The safe use of Carprieve in animals less than 6 weeks of age, pregnant bitches, bitches used for breeding purposes, or in lactating bitches has not been established. Willebrand's disease), as safety has not been established.

Gastrointestinal: Vomiting, diarrhea, constipation, inappetence, melena, hematemesis, gastrointestinal ulceration, gastrointestinal bleeding, pancreatitis.

Renal: Hematuria, polyuria, polydipsia, urinary incontinence, urinary tract infection, azotemia, acute renal failure, tubular abnormalities including acute tubular necrosis, renal tubular acidosis, glomerulonephritis.

Hepatic: Hepatomegaly, vomiting, jaundice, acute hepatic toxicity (e.g., hepatic enzyme elevation, abnormal liver function tests), hepatoxicity, bilirubinemia, hyperbilirubinemia. Approximately one fourth of hepatic reports were in Labrador Retrievers.

Neurologic: Ataxia, paresis, paralysis, seizures, vestibular signs, disorientation. Urinary: Hematuria, polyuria, polydipsia, urinary incontinence, urinary tract infection, azotemia, acute renal failure, tubular abnormalities including acute tubular necrosis, renal tubular acidosis, glomerulonephritis.

Behavioral: Sedation, lethargy, hyperactivity, restlessness, aggressiveness.

Hematologic: Immune-mediated hematologic anemia, immune-mediated thrombocytopenia, blood loss anemia, splenomegaly.

Dermatologic: Pruritus, increased shedding, alopecia, pyotraumatic dor dermatitis (hot spots), necrotizing panniculitis/vasculitis, ventral ecchymosis.

Immunologic or hypersensitivity: Facial swelling, hives, anaphylaxis.

In rare situations, death has been associated with some of the adverse reactions listed above.

To report a suspected adverse reaction call 1-866-581-5777.

DOSAGE AND ADMINISTRATION: Always provide Client Information Sheet with prescription. Carefully consider the potential benefits and risk of Carprieve and other treatment options before deciding to use Carprieve. Use the lowest effective dose for the shortest duration consistent with individual response. The recommended dosage for oral administration to dogs is 2 mg/lb of body weight daily. The total daily dose may be administered as 2 mg/lb of body weight once daily or divided and administered as 1 mg/lb twice daily. For the control of postoperative pain, administer approximately 2 hours before the procedure.

See product insert for complete dosing and administration information.

STORAGE: Store 25 mg and 75 mg Carprieve chewable tablets at 59-86°F (15-30°C). Store-100 mg Carprieve chewable tablets at controlled room temperature, 68°F (20°C) and 75% relative humidity (RH). HOW SUPPLIED: Carprieve chewable tablets are scored, and contain 25 mg, 75 mg, or 100 mg of carprofen per tablet. Each tablet size is packaged in bottles containing 30, 90, or 180 tablets.

Made in the UK. Manufactured by Norbrook Laboratories Limited, Newry, BT35 6PU, Co. Down, Northern Ireland. The Norbrook logos are registered trademarks of Norbrook Laboratories Limited.
Records spanning a 9-year period from 2 veterinary schools were retrospectively evaluated for this study. EFBs were identified in 125 dogs. Data from their records were assessed to determine the likelihood of esophageal perforation and to characterize clinical findings, treatment, and outcomes of dogs with EFB.

The most common EFBs detected were bones (44%) and fishhooks (30%). Perforation was diagnosed in 15 (12%) dogs; of these, 10 had a fishhook EFB and 5 had a bone EFB. Overall, dogs with fishhooks were 6.1 times more likely to perforate as compared with dogs with other types of EFB. No association between body weight and perforation was identified.

Endoscopic removal was successful in 90.9% of cases, including 95% of dogs with no perforation. Overall, 6 dogs with perforation of the esophagus required surgical intervention (i.e., thoracotomy, exploration of the cervical region); 5 of these had a fishhook EFB.

... TO YOUR PATIENTS
Key pearls to put into practice:

1. Radiography followed by endoscopic examination should be a part of the diagnostic investigation in patients with suspected EFBs.
2. Owners of dogs with fishhook and bone foreign bodies should be warned of the potential for perforation and need for surgery.
3. Timely identification of a foreign body may lead to higher treatment success rates.
Nutrient Deficiencies During Weight Loss in Dogs

Martha G. Cline, DVM, DACVN
Red Bank Veterinary Hospital
Tinton Falls, New Jersey

In the Literature

FROM THE PAGE …

In this study, a survey investigating nutrition recommendations for weight loss in dogs was distributed to general practice veterinarians. Of the 178 responses, reducing the patient’s caloric intake (eg, reducing amount fed, reducing/eliminating treats, changing to lower calorie adult maintenance diet) was recommended approximately 55% to 80% of the time. Although more common for patients with a BCS of 6-7/9 as compared with those with a BCS of 8-9/9, this recommendation was still made more than 50% of the time for all overweight or obese patients. Clinicians were more likely to recommend a therapeutic weight loss diet for patients with a BCS of 8-9/9.

To evaluate if nutrient adequacy was met in patients under caloric restriction, feeding guidelines from the labels of each diet used were analyzed for a hypothetical 44.1-lb (20-kg) dog with an ideal body weight of 33.1 lb (15 kg). The nutrients consumed per day for this hypothetical dog were calculated for each level of restriction and compared with recommended allowances. The authors found that nutrient deficiencies increased in number with progressive levels of caloric restriction of up to 60% of calculated maintenance energy requirements for current and ideal body weight. Nutrient deficiencies were more common in dogs fed over-the-counter (OTC) adult maintenance diets as compared with those fed OTC weight management diets. Although all the diets investigated met the Association of American Feed Control Officials recommendations for canine adult maintenance, diets sold OTC are typically not formulated to avoid nutrient deficiency during caloric restriction resulting in weight loss.

The diets investigated had low levels of many essential nutrients; choline was most commonly identified. The biologic functions of choline, a vitamin-like substance, include neurotransmission, hepatic lipid storage and transport, coagulation, and cell signaling. In a previous study, plasma choline concentrations decreased in obese dogs fed a therapeutic weight loss diet, but clinical signs associated with deficiency were not observed.

Limitations of this study included its theoretical nature and lack of available research investigating the nutrient requirements of dogs undergoing weight loss. The authors highlighted the need for future studies investigating the nutritional status and health consequences of potential nutrient deficiencies in dogs undergoing weight loss.

… TO YOUR PATIENTS
Key pearls to put into practice:

1. When making dietary recommendations, clinicians should be mindful that caloric restriction to achieve weight loss with an OTC adult maintenance or OTC weight management diet may result in nutrient deficiencies.

2. Clinicians should perform calculations to estimate a patient’s current caloric intake before initiating weight loss and making weight loss recommendations.

3. Referral to or consultation with a board-certified veterinary nutritionist should be considered to address potential nutrient deficiencies for patients requiring significant caloric restriction to achieve weight loss.

Reference
FAST-ACTING CALMING SUPPORT when it counts

COMPOSURE™ PRO IS CLINICALLY SHOWN TO WORK WITHIN 30 MINUTES AND LAST UP TO 4 HOURS.∗

› Clinical strength behavioral & cognitive support
› Safe to double dosage during times of heightened stress
› Can be used daily—no loading dose required
› May help normalize stress-related GI issues

BUY 5 GET 1 FREE†
› 090023A.060

NEW! SAVE 25%‡
› 090016J.608

HYDROLYZED CHICKEN FLAVORED CHEW / FLAVORLESS LIQUID FORMULA

‡Save 25% on Composure® Pro liquid. Sold in packs of 6.
VETRISCIENCE PRO LINE IS INTENDED FOR DISTRIBUTION EXCLUSIVELY THROUGH LICENSED VETERINARY CLINICS INVOLVED IN THE DIRECT CLIENT-PATIENT RELATIONSHIP.

†CanCog Technology Study on Composure™ “Assessment of Anxiolytic Properties of a Novel Compound in Single Dogs with a Novel-Induced Model of Fear and Anxiety” ∗Manufactured in the U.S.A., with imported and domestic ingredients.
INVEST IN YOURSELF. INVEST IN YOUR PATIENTS.

Practical, world-class CE by day, blissful resort relaxation by night.

Register at wildwest.vetshow.com for $349 with code WILD8.
Hurry! Offer expires June 28.

NEW YORK VET
NEW YORK, NY
NOVEMBER 7 – 8, 2019
16 hours of CE

AUSTIN VET
AUSTIN, TX
APRIL 20 – 21, 2020
16 hours of CE

CHICAGO VET
CHICAGO, IL
MAY 13 – 15, 2020
24 hours of CE

VISIT VETSHOW.COM FOR MORE INFORMATION.
Canine Anxiety Management: Finding Solutions to Fit Both Patients and Owners

Q: Canine anxiety is a common problem. How can veterinarians and staff members build patient screening into their day-to-day practice?

A: The point of screening for fear and anxiety is to identify departures from what’s considered normal. “Normal” can vary a great deal from breed to breed and from animal to animal. If triggers cause behaviors that are outside what is normal for the dog, identifying those triggers is key. It can be as simple as asking the owner to fill out a questionnaire or having the technician ask some basic questions about the dog’s behavior.

Q: What factors could affect success when managing dogs with anxiety?

A: I tell veterinarians who refer to me to do so as early as possible to give me the best chance of success, and the same is true if veterinarians are treating these dogs in their own clinics. Just as you wouldn’t wait to fix a broken leg, when a dog exhibits aggression or destructive behavior, it’s important to intervene as soon as possible to prevent the pattern from becoming established.

This doesn’t mean that dogs with severe anxiety or a long history of fear-based behavior can’t be helped. We can achieve significant improvement, but it may require using a combination of several therapeutic modalities, including behavior modification, medication and supplements.

When assessing a case and how to approach it, I ask myself these questions:

- **How severe is the problem?** Is the safety of the owner or other people at risk? Is the patient at risk of being euthanized or relinquished because of the behavior disorder? Is the behavior predictable?
- **What kind of investment is the owner willing to make in behavior modification?** Can the owner afford the time and money to work with a trainer every two weeks for the next two months, or do we need to lean more heavily on medication and/or supplements?
- **Are the owner’s expectations realistic based on therapeutic options or do they need to be reset?** Owners sometimes have a vision of what they want their pet to be able to do. I recently worked with an owner whose aggressive dog had a history of biting. While the owner didn’t have children herself, she wanted her dog to be able to interact with kids when she took him on walks. We were able to make great strides in managing the dog’s aggression, but I told the owner she had to let go of that particular goal because her dog’s behavior was too unpredictable. It wasn’t necessary for the dog to like kids, he simply needed to avoid them.
- **Does the owner feel strongly about specific modalities?** I have clients who are strongly opposed to giving their dogs anxiolytic medications because they don’t like the idea of “drugging” them. It’s important to be aware of concerns such as these when formulating a treatment plan.

Q: How should veterinarians use a product like Purina® Pro Plan® Veterinary Supplements Calming Care Probiotic Supplement?

A: If the dog has a chronic, complex case of anxiety, chances are that multiple forms of intervention will be needed. I recently worked with a noise-phobic dog that was on two medications for anxiety. Typically, she would get stressed with every storm, refuse to go outside and later develop diarrhea. Neither medication was being given at the maximum dosage because we had concerns about side effects. Rather than raise the dose, we added Calming Care and it was like the cherry on the sundae. We saw improvements in anxious behavior overall.

If veterinarians are going to use Calming Care as a first-line treatment, I recommend trying it for mild cases of fear, anxiety and stress. An acclimation period of 45 days should indicate what kind of response they will see.
How Changing the Gut Microbiota Can Modify Behavior

Raj Naik, DVM
Veterinary Communications Manager
Nestlé Purina PetCare

Over the past several decades, veterinarians have learned that feeding certain probiotic strains to patients in order to alter the composition of their gut microbiota can produce benefits such as modulation of the immune system and improvement in gut health.3 As other probiotic strains are studied, we’ve learned that changing the gut microbiota can have benefits that extend well beyond improving GI health. The probiotic *Bifidobacterium longum* BL999 has been shown to have an anxiolytic effect on dogs exhibiting anxious behavior and thus can serve as a useful tool in management plans for these patients.3

Connecting gut health and behavior
Understanding the potential of *B. longum* BL999 (the active ingredient in Purina® Pro Plan® Veterinary Supplements Calming Care) to influence dogs with anxious behavior requires understanding how the gut and the brain communicate with each other via the gut-brain axis.

The connection between anxious behavior and the gut microbiota was established in a study at McMaster University, when gut bacteria from laboratory mice exhibiting anxiety behavior were transferred to germ-free, non-anxious mice via fecal transplantation. The result: the previously non-anxious mice began demonstrating anxious behavior.4

Potential pathway to anxiolytic effect
While multiple mechanisms may play a role in relaying the influence of both the resident and exogenous microflora, recent studies suggest a role for the vagus nerve as a pathway of bidirectional communication between the gut and brain.

It is theorized that *B. longum* BL999 may produce a metabolite in the gut. This metabolite acts as a neurotransmitter that activates the enteric nervous system and in turn activates the vagus nerve, which has a direct connection to the brain.3

Clinical effect in canine patients
The end result is that, from both a behavioral and physiological standpoint, *B. longum* BL999 can have an anxiolytic effect on dogs exhibiting anxious behaviors. In a blinded, placebo-controlled, crossover study of 24 Labrador Retrievers exhibiting anxious behavior, dogs supplemented with *B. longum* BL999 showed statistically significant improvement in displaying day-to-day anxious behavior, as well as reduced salivary cortisol concentrations, decreases in heart rates and increases in heart rate variability compared to non-supplemented controls.3

The benefits of probiotics extend beyond promoting gut health, and it is important to note that different probiotic strains have different benefits and effects on the body. Thanks to pathways that link the brain and gut, researchers are discovering new ways to help manage patients with conditions like anxiety.

STEP 1: Identify anxiety triggers
The first goal with any anxious patient is to pinpoint possible triggers and try to either eliminate or moderate them. I ask clients when the anxious behaviors began, then we review everything that changed at that time, whether it was a move, a family member coming or going from the home or even a medical procedure for someone in the household. Depending on the patient’s situation, I might encourage the owner to keep a journal of behaviors for a period of time to help identify a cause. Pacing, panting and crying are three of the most common signs of generalized anxiety reported by my clients.

STEP 2: Determine a plan of action
If no obvious stressors are identified or if we are unable to completely eliminate those that we can identify, I often recommend behavior modification in conjunction with another therapeutic modality, such as a six-week trial of Purina® Pro Plan® Veterinary Supplements Calming Care Canine probiotic. Calming Care has been a welcome addition to our clinic’s repertoire of options. I recommend it for dogs with generalized anxiety as well as for patients with more specific issues like separation anxiety.

MANAGING ANXIETY USING PROBIOTICS

Managing dogs with anxiety is complex and always requires a multimodal approach, which could include behavior modification, anxiolytic medications and/or probiotic supplementation. While canine anxiety is something my clients are highly motivated to manage in their pets, many are reluctant to medicate their dogs because of potential side effects such as lethargy and personality changes. “It’s great the anxiety has improved,” they say, “but this isn’t my dog.”

Here are some steps I take and modalities I use to manage my canine patients exhibiting anxious behavior(s).

STEP 3: Evaluate results
As with any other chronic condition, anxious behaviors in dogs should be re-evaluated on a regular basis. A number of my clients who administer Calming Care have noted improvements in their dogs’ anxious behavior(s). They often tell me that Calming Care has taken the edge off their dogs’ symptoms and reduced the anxiety to a manageable level. The dogs are more comfortable and able to rest—and that can be life-changing.

Calming Care presents a research-backed alternative Few proven therapeutic modalities are available for managing dogs with anxiety. As a result, many clients resort to products with no efficacy and/or studies to back up their claims. Calming Care has provided our clinic with a non-drug alternative for management of dogs displaying anxious behaviors that is backed by research. That’s something my clients appreciate. And for those dogs that require anxiolytic medications, the good news is that Calming Care can be an effective add-on to their multimodal therapeutic plan. This has opened the door to having a new and different conversation with owners of anxious dogs because it allows me to present an additional option that may be appealing to my clients.

Key Takeaways

- Dogs with chronic anxiety may need multiple forms of intervention, including behavior modification, medication and/or probiotic supplementation.
- *Bifidobacterium longum* BL999 is believed to activate the enteric nervous system and, in turn, the vagus nerve to produce an anxiolytic effect on dogs displaying anxious behavior.
- A research-backed supplement, such as Calming Care, can be an effective add-on to a multimodal treatment plan for dogs exhibiting anxious behaviors.
The vagus nerve is theorized to be the pathway for the anxiolytic effects of *Bifidobacterium longum* BL999.

It is theorized that *B. longum* BL999 may produce a metabolite in the gut. This metabolite acts as a neurotransmitter that activates the enteric nervous system and in turn activates the vagus nerve, which has a direct connection to the brain.6

**Clinical effect in canine patients**

The end result is that, from both a behavioral and physiological standpoint, *B. longum* BL999 can have an anxiolytic effect on dogs exhibiting anxious behaviors. In a blinded, placebo-controlled, crossover study of 24 Labrador Retrievers exhibiting anxious behavior, dogs supplemented with *B. longum* BL999 showed statistically significant improvement in displaying day-to-day anxious behavior, as well as reduced salivary cortisol concentrations, decreases in heart rates and increases in heart rate variability compared to non-supplemented controls.1

The benefits of probiotics extend beyond promoting gut health, and it is important to note that different probiotic strains have different benefits and effects on the body. Thanks to pathways that link the brain and gut, researchers are discovering new ways to help manage patients with conditions like anxiety.

**Key Takeaways**

- Dogs with chronic anxiety may need multiple forms of intervention, including behavior modification, medication and/or probiotic supplementation.
- *Bifidobacterium longum* BL999 is believed to activate the enteric nervous system and, in turn, the vagus nerve to produce an anxiolytic effect on dogs displaying anxious behavior.
- A research-backed supplement, such as Calming Care, can be an effective add-on to a multimodal therapeutic plan for dogs exhibiting anxious behaviors.
WHAT IF…
A PROBIOTIC COULD HELP ANXIOUS DOGS FEEL CALMER?

Introducing Purina® Pro Plan® Veterinary Supplements Calming Care with *Bifidobacterium longum* (BL999), a probiotic strain shown to help dogs maintain calm behavior. In a blinded crossover design study, 90% of dogs showed an improvement in displaying anxious behaviors such as jumping, pacing, and spinning.*

LEARN MORE ABOUT NESTLÉ PURINA’S PROBIOTIC RESEARCH AT PURINAPROPLANVETS.COM.

Helps dogs cope with external stressors like separation, unfamiliar visitors, novel sounds, or changes in routine and location

Helps dogs maintain positive cardiac activity during stressful events, promoting a positive emotional state

Helps blunt cortisol response to anxious events and supports a healthy immune system

1-800-222-8387 (8:00 AM - 4:30 PM CST M-F) Talk to your Purina Veterinary Consultant


Purina trademarks are owned by Société des Produits Nestlé S.A.
Laryngeal & Intratesticular Lidocaine for Feline Anesthetic Techniques

Rebecca Johnson, DVM, PhD, DACVAA
University of Wisconsin–Madison

In the Literature

FROM THE PAGE …

Use of lidocaine as part of a multimodal analgesic plan in cats is increasing in popularity. For example, topical administration of lidocaine to the larynx is recommended to desensitize laryngeal tissue and facilitate tracheal intubation (Figure 1). Similarly, intratesticular administration of lidocaine in cats is used to reduce hemodynamic changes associated with surgical neutering (Figure 2). Although these techniques...

▲ FIGURE 1 Feline larynx demonstrating the narrow opening of the rima glottidis into the trachea. A laryngoscope (silver, bottom right) is used to depress the caudal aspect of the tongue (bottom left) to visualize the tracheal opening. Lidocaine is commonly applied via syringe to desensitize tissue, facilitating tracheal intubation.

▲ FIGURE 2 Feline intratesticular block being performed using 2% lidocaine (0.1 mL/kg). Lidocaine is injected into the parenchymal tissue to provide reduced nociceptive signaling during surgical neutering.
JOIN THE VOLUNTEER TEAMS WORKING TO ELIMINATE RABIES ACROSS THE GLOBE.

MISSION RABIES HELPS MORE THAN JUST ANIMALS.

JOIN THE VOLUNTEER TEAMS WORKING TO ELIMINATE RABIES ACROSS THE GLOBE.

MISSION RABIES
APPLY NOW
at cliniciansbrief.com/mission-rabies

For more information about the Mission Rabies projects, visit missionrabies.com

Volunteer sponsorship brought to you by
clinician's brief
Nobivac
MERCK
Animal Health
are commonly performed, plasma lidocaine concentrations following these procedures are not always considered, even though lidocaine is systemically absorbed and could approach levels associated with toxicity with excessive concentrations or doses. The maximum recommended lidocaine dose in cats is up to 6 mg/kg, with significant toxicity seen at higher intravenous doses (≈11-22 mg/kg).3-5

This study of 14 cats examined these commonly practiced local anesthetic techniques in a 2-part experiment. In the first part, half of the cats (group L2) were randomly assigned to receive 0.1 mL of 2% lidocaine topically administered on the larynx (≈0.6 mg/kg); the remaining cats (group L10) received 0.1 mL of 10% lidocaine topically administered on the larynx (2.8 mg/kg). Plasma lidocaine concentrations were then measured and found to be significantly higher in the L10 group as compared with the L2 group (median maximum plasma lidocaine concentrations, 93.6 ng/mL vs 34.1 ng/mL, respectively).

In the second part of the experiment, cats were randomized to receive topical lidocaine as described for the first part. All cats then received intratesticular administration of 2% lidocaine (0.1 mL) prior to neuter. The concurrent use of topical lidocaine (2% or 10%) with intratesticular administration of 0.1 mL/kg of 2% lidocaine resulted in a maximum total lidocaine dose of approximately 2.54 mg/kg and 4.76 mg/kg, respectively, neither of which exceeds the recommended dose for cats.3,4 In addition, the maximum plasma concentrations increased in a dose-dependent manner and were significantly higher than for topical administration alone, although plasma concentrations remained significantly lower than those required to produce seizures in cats.4 The time to reach maximum plasma concentrations did not differ among treatments.

It is important to note that factors other than dose and route (eg, patient age, concurrent anesthetics, hypotension, hypothermia) can alter pharmacokinetics and plasma lidocaine concentrations. However, this study suggests that, in adult cats (≈8.8 lb [≈4 kg]) undergoing surgical neutering, 2% topical lidocaine administered concurrently with intratesticular 2% lidocaine (0.1 mL/kg) results in plasma concentrations unlikely to approach those associated with systemic toxicity. Thus, these techniques can provide useful adjunctive analgesia when neutering cats.

... TO YOUR PATIENTS

Key pearls to put into practice:

1. A previous study has shown topical 2% lidocaine to be as effective as 10% lidocaine for facilitating intubation in cats.1 Thus, 2% lidocaine, which is associated with lower maximum plasma concentrations, is recommended, and the volume should be adjusted accordingly in smaller patients (eg, young kittens).

2. Use of topical lidocaine alone or in combination with intratesticular lidocaine can result in dose-dependent increases in maximal plasma lidocaine concentrations.

3. For routine surgical neutering in adult cats, the recommended doses of 2% lidocaine are 0.1 mL (=0.6 mg/kg) administered topically on the larynx and 0.1 mL/kg administered intratesticularly. Doses should be appropriately adjusted for smaller patients.

4. Although time to reach peak plasma concentrations does not significantly differ between topical application alone or in combination with intratesticular administration, plasma concentrations may be affected by other patient factors and should be considered on an individual patient basis.

References


**Summary of Adverse Reactions in the Field Study**

<table>
<thead>
<tr>
<th>Adverse Reaction (AR)</th>
<th>Bravecto Group: Percentage of Dogs with the AR During the 105-Day Study (n=224 dogs)</th>
<th>Active Control Group: Percentage of Dogs with the AR During the 84-Day Study (n=100 dogs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vomiting</td>
<td>1.4%</td>
<td>6.0%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>3.4%</td>
<td>4.6%</td>
</tr>
<tr>
<td>Flatulence</td>
<td>1.4%</td>
<td>0.0%</td>
</tr>
<tr>
<td>Lethargy</td>
<td>2.0%</td>
<td>2.0%</td>
</tr>
<tr>
<td>Head Tilt</td>
<td>4.6%</td>
<td>0.0%</td>
</tr>
<tr>
<td>Seizures</td>
<td>4.6%</td>
<td>0.0%</td>
</tr>
<tr>
<td>Atonia</td>
<td>4.6%</td>
<td>0.0%</td>
</tr>
<tr>
<td>Anorexia</td>
<td>1.4%</td>
<td>0.0%</td>
</tr>
<tr>
<td>Weight Loss</td>
<td>4.6%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>

In a well-controlled laboratory dose confirmation study, one dog developed edema and hypothermia of the upper lips within one hour of receiving Bravecto. The reacted dog was removed from the laboratory and allowed to return to the study, and its behavior was monitored daily. The dog had resolved without medical intervention by the next morning.

**Precautions:**

For topical use only. Avoid oral ingestion. Use with caution in cats with a history of seizures. Seizures have been reported in dogs receiving fluralaner, even in dogs without a history of seizures. Bravecto has not been shown to be effective for 12-weeks duration in puppies less than 6 months of age. Bravecto is not effective against *Amblyomma americanum* ticks beyond 8 weeks after dosing.

**Adverse Reactions:**

In a well-controlled U.S. field study, which included 244 dogs (224 dogs were administered Bravecto every 4 weeks and 20 dogs were administered an oral active control every 4 weeks and were provided with a tick collar), there were serious adverse reactions. All potential adverse reactions were recorded in dogs treated with Bravecto over a 162-day period and in dogs treated with the active control over an 84-day period. The most frequently reported adverse reaction in dogs treated in the Bravecto and active control groups was vomiting.

**Percentage of Dogs with Adverse Reactions in the Field Study**

<table>
<thead>
<tr>
<th>Adverse Reaction (AR)</th>
<th>Bravecto Group: Percentage of Dogs with the AR During the 105-Day Study (n=224 dogs)</th>
<th>Active Control Group: Percentage of Dogs with the AR During the 84-Day Study (n=100 dogs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vomiting</td>
<td>1.3%</td>
<td>6.0%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>2.0%</td>
<td>2.0%</td>
</tr>
<tr>
<td>Flatulence</td>
<td>1.3%</td>
<td>0.0%</td>
</tr>
<tr>
<td>Lethargy</td>
<td>2.0%</td>
<td>2.0%</td>
</tr>
<tr>
<td>Head Tilt</td>
<td>4.6%</td>
<td>0.0%</td>
</tr>
<tr>
<td>Seizures</td>
<td>4.6%</td>
<td>0.0%</td>
</tr>
<tr>
<td>Atonia</td>
<td>4.6%</td>
<td>0.0%</td>
</tr>
<tr>
<td>Anorexia</td>
<td>1.3%</td>
<td>0.0%</td>
</tr>
<tr>
<td>Weight Loss</td>
<td>4.6%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>

In the field study, two dogs treated with Bravecto with no prior history of seizures each experienced a seizure. One dog had two seizures a day apart about 10 days after its first dose. The dog was started on antiepileptic medication and had no additional seizures during the study. A second dog had a seizure 76 days after its first dose and 3 days after starting flurazepam for seizure activity. The flurazepam was discontinued due to the dog experiencing no additional seizures during the study. One dog treated with Bravecto was observed by the owner to be ataxic for about 30 minutes five days after its first dose and had no similar observations in the active control group for the second dose. The dog recovered without additional seizures and had a seizure the day after the second dose of the active control.

In a well-controlled laboratory dose confirmation study, one dog developed vomiting and diarrhea on the day of dosing and had resolved without medical intervention by the next morning.

**Precautions:**

For topically use only. Avoid oral ingestion. Use with caution in cats with a history of seizures. Seizures have been reported in dogs receiving fluralaner, even in dogs without a history of seizures. Bravecto has not been shown to be effective for 12-weeks duration in puppies less than 6 months of age. Bravecto is not effective against *Amblyomma americanum* ticks beyond 8 weeks after dosing. The safety of Bravecto has not been established in breeding, pregnant and lactating cats.

**Adverse Reactions:**

In a well-controlled U.S. field study, which included a total of 161 households and 312 treated cats (221 with fluralaner and 100 with a topical active control), there were no serious adverse reactions.

**Percentage of Cats with Adverse Reactions (AR) in the Field Study**

<table>
<thead>
<tr>
<th>Adverse Reaction (AR)</th>
<th>Bravecto Group: Percent of Cats with the AR During the 105-Day Study (n=224 cats)</th>
<th>Active Control Group: Percent of Cats with the AR During the 84-Day Study (n=87 cats)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vomiting</td>
<td>5.5%</td>
<td>0.0%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>2.2%</td>
<td>0.0%</td>
</tr>
<tr>
<td>Lethargy</td>
<td>4.6%</td>
<td>0.0%</td>
</tr>
<tr>
<td>Appetite</td>
<td>2.2%</td>
<td>0.0%</td>
</tr>
<tr>
<td>Skin Lesions</td>
<td>2.2%</td>
<td>0.0%</td>
</tr>
<tr>
<td>Scabs/Ulcerated Skin</td>
<td>2.2%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>

In the field study, two cats treated with fluralaner topical solution experienced ataxia. One cat became ataxic with a right head tilt 36 days after the first dose. The cat improved within one week of starting antibiotics. The ataxia and right head tilt, along with lateral resusitability, recurred 82 days after administration of the first dose. The cat recovered with antibiotics and was redosed with fluralaner topical solution 92 days after administration of the first dose, with no further abnormalities during the study. A second cat became ataxic 15 days after receiving the first dose and recovered the next day. The cat was redosed with fluralaner topical solution 82 days after administration of the first dose, with no further abnormalities during the study. In an European field study, two cats from the same household experienced tremors, lethargy, and anorexia within one day of administration. The signs resolved in both cats within 48-72 hours.

In a European field study, there were three reports of facial dermatitis in humans after close contact with the application site which occurred within 4 days of application. For technical assistance or to report a suspected adverse drug reaction, contact Merck Animal Health at 1-800-224-5318. Additional information can be found at www.fda.gov. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-IVETS or online at http://www.fda.gov/AnimalVeterinary/SafetyHealth.
Pet owners already have a lot to remember.
Give them one less thing to forget.
Protect your patients from fleas & ticks for up to 12 weeks* with BRAVECTO®

Ask your Merck Animal Health Rep about BRAVECTO or Visit Bravectovets.com

*BRAVECTO kills fleas and prevents flea infestations for 12 weeks. BRAVECTO Chew and BRAVECTO Topical Solution for Dogs kill ticks (black-legged tick, American dog tick, and brown dog tick) for 12 weeks and also kill lone star ticks for 8 weeks. BRAVECTO Topical Solution for Cats kills ticks (black-legged tick) for 12 weeks and American dog ticks for 8 weeks.

IMPORTANT SAFETY INFORMATION: BRAVECTO has not been shown to be effective for 12-weeks’ duration in puppies or kittens less than 6 months of age. BRAVECTO Chew: The most common adverse reactions recorded in clinical trials were vomiting, decreased appetite, diarrhea, lethargy, polydipsia, and flatulence. BRAVECTO is not effective against lone star ticks beyond 8 weeks of dosing. BRAVECTO Topical Solution for Dogs: The most common adverse reactions recorded in clinical trials were vomiting, hair loss, diarrhea, lethargy, decreased appetite, and moist dermatitis/rash. BRAVECTO is not effective against lone star ticks beyond 8 weeks of dosing. For topical use only. Avoid oral ingestion. Use caution in dogs with a history of seizures. Seizures have been reported in dogs receiving fluralaner, even in dogs without a history of seizures. BRAVECTO Topical Solution for Cats: The most common adverse reactions recorded in clinical trials were vomiting, itching, diarrhea, hair loss, decreased appetite, lethargy, and scabs/ulcerated lesions. BRAVECTO is not effective against American dog ticks beyond 8 weeks of dosing. For topical use only. Avoid oral ingestion. The safety of BRAVECTO has not been established in breeding, pregnant and lactating cats. Use with caution in cats with a history of neurologic abnormalities. Neurologic abnormalities have been reported in cats receiving BRAVECTO, even in cats without a history of neurologic abnormalities. See full Prescribing Information on page 44.

Copyright © 2018 Intervet Inc. d/b/a Merck Animal Health, a subsidiary of Merck & Co. Inc. All rights reserved. US/BRV/0218/0036
Superficial Bacterial Folliculitis

William Oldenhoff, DVM, DACVD
Leader Animal Specialty Hospital
Cooper City, Florida

In the Literature

FROM THE PAGE …

In this study, samples for bacterial culture were obtained from 14 dogs with superficial bacterial folliculitis. Samples were obtained from 4 to 6 skin lesions per dog and from the gingiva and perineum, both of which are carriage sites for *Staphylococcus pseudintermedius*. Skin lesions sampled included pustules, papules, crusts, and epidermal collarettes.

*S pseudintermedius* isolates were subjected to pulsed-field gel electrophoresis and antimicrobial susceptibility testing to assess the genetic diversity of the isolates. Pustules and papules were associated mostly with pure cultures of *S pseudintermedius*, whereas crusts and collarettes were often associated with multiple bacterial species, likely due to contamination from the environment or surrounding skin. Extensive *S pseudintermedius* strain diversity was observed, with multiple distinct strains isolated from 6 of 14 dogs. Up to 4 strains with varying antimicrobial resistance profiles were detected in one dog. Most dogs (12/14) carried the strain associated with infection on either the perineum or gingiva; this supports the view that dogs are typically infected with their own strains of *S pseudintermedius* rather than as a result of transmission from another animal.

… TO YOUR PATIENTS

Key pearls to put into practice:

1. Pustules and papules are recommended as the first choice for culture testing, as there is less chance for contamination from strains of *S pseudintermedius* that are not involved in the infection. Papules and pustules should both be sampled by gently incising the lesion with the tip of a sterile needle, then cultured.

2. Laboratories usually select a single bacterial colony of the predominant species growing on the agar plate for susceptibility testing. This may cause strains involved in the infection to be missed, which may result in treatment failure. It is recommended that laboratories evaluate their methodology for antimicrobial susceptibility testing.

3. Responsible antimicrobial stewardship is critical. Clinicians should culture animals with superficial bacterial folliculitis if initial empiric treatment fails. Topical therapy is also important, as many superficial skin infections can be resolved using only topical chlorhexidine products.
NO TIME TO WASTE
WHEN CARE IS CRITICAL

NUTRITIONAL SUPPORT CAN SPEED UP RECOVERY AND IMPROVE PATIENT OUTCOMES*
Introducing the most comprehensive range of liquid diets designed for tube feeding.

✔ EASY TO USE
Start feeding in less than a minute—no mixing, reconstituting or blenderizing for NE and NG tubes

✔ INNOVATIVE CAP DESIGN
Specialized cap for quick and easy syringe withdrawal and usage

✔ CRITICAL NUTRITION
Also includes EPA+DHA and an antioxidant complex


© ROYAL CANIN® SAS 2019. All Rights Reserved. M450582
Owner Perceptions of the Treatment of Feline Behavior Problems

Leslie Sinn, DVM, DACVB
Behavior Solutions
Leesburg, Virginia

In the Literature

FROM THE PAGE …
In this survey, researchers queried cat owners about the prevalence and type of behavior problems in their cat. Owner knowledge of and attitudes toward the treatment of behavior problems were also investigated.

Of the 448 responses, 1092 behavior problems were reported. Most respondents (97.8%) reported that their cat had at least one behavior problem. The most common problems in order of prevalence were anxiety or fear (eg, of stranger, carrier, or travel), destructive behavior (eg, scratching furniture), house soiling (ie, urination and/or defecation outside the litter box), excessive vocalization, aggression toward humans and/or animals, and excessive/repetitive grooming resulting in hair loss and/or injury.

Most respondents (93.5%) believed anxiety/emotional problems could result in behavior problems in cats, but nearly half (49.8%) were unaware of the availability of psychotherapeutic medications for the treatment of behavior issues in cats. Responses to being asked if they would consider giving psychoactive medications or supplements to their cat were mixed; 57.4% replied with maybe, 21.4% with yes, and 21.2% with no. The primary reported barriers to medical treatment were concerns about negative side effects (73.3%), excessive sedation (63.9%), and potential for...
Relaxation without Sedation

Solliquin®
BEHAVIORAL HEALTH SUPPLEMENT

Helps support balanced behavior & relaxation in dogs & cats in stressful situations.
Available from all authorized veterinary product distributors.
addiction (39.9%). Important factors respondents noted would impact their decision to medicate included proven effectiveness (89.7%), ease of administration (84.8%), veterinarian recommendation (81.5%), and cost (77%). In addition, only 3.3% of owners indicated that their veterinarian recommended they seek behavioral help for their cat. These data suggest that there are missed opportunities by veterinarians to positively affect the well-being of cats.

... TO YOUR PATIENTS

Key pearls to put into practice:

1. **Veterinarians should understand that behavior problems in cats are pervasive and most frequently involve fear-based behaviors, destructive scratching, and house soiling.**

2. **Behavior issues affect the quality of life of cats and their owners and should be clinically addressed like any other medical condition. Owners should be asked if they have concerns about their cat’s behavior.** A preappointment screening sheet may help identify areas of concern. Because the behavior problems identified in the present study are common, appropriate literature should be available for owner education to enhance veterinary team efficiency (see **Suggested Reading**).

3. **Common barriers to treatment and compliance should be acknowledged.** All owner concerns should be addressed by clearly discussing efficacy and side effects associated with prescribed treatments. A veterinarian’s recommendations can be influential and positively impact an owner’s decision to treat. Owners should be referred to a veterinary behaviorist if their veterinarian does not have the time or is disinclined toward or uncomfortable giving behavioral recommendations (see **Suggested Reading**).

**Suggested Reading**


... FROM PAGE TO PATIENT | CONTINUED FROM PAGE 48
IMPORTANT SAFETY INFORMATION: ENTYCE® (capromorelin oral solution) is for use in dogs only. Do not use in breeding, pregnant or lactating dogs. Use with caution in dogs with hepatic dysfunction or renal insufficiency. Adverse reactions in dogs may include diarrhea, vomiting, polydipsia, and hypersalivation. Should not be used in dogs that have a hypersensitivity to capromorelin. Please see the full Prescribing Information on page 50 for more detail.

©2019 Aratana Therapeutics, Inc. ENTYCE is a registered trademark of Aratana Therapeutics, Inc.

ENT-0364

Don’t wait for weight loss. Stimulate appetite early to treat the whole picture.

Long before you see physical changes, small reductions in eating can deprive patients with chronic medical conditions of the essential nutrition they need to support strength and energy, healing and immune response.

Add ENTYCE® (capromorelin oral solution) at the first sign of decreased eating as part of your overall treatment plan.

✔ Proven safe for long-term use
✔ Effectively stimulates appetite to help improve food consumption
✔ The ONLY FDA-approved appetite stimulant for dogs

Take a closer look at entyce.aratana.com

Gallbladder Mucoceles in Border Terriers

Faith I. Buckley, DVM, DACVIM (SAIM)
Bulger Veterinary Hospital
North Andover, Massachusetts

In the Literature

FROM THE PAGE …

Gallbladder mucoceles (GBMs) are a common cause of biliary disease in dogs. Several breed predispositions have been reported, and several risk factors, including endocrine disease (ie, hyperadrenocorticism, hypothyroidism) and hyperlipidemia, have been recognized.1,2 Multiple factors, including genetic and epigenetic factors, likely contribute to GBM formation.

This study from the United Kingdom sought to evaluate GBM association with the border terrier breed. Medical records of 99 dogs (including 51 border terriers) with a diagnosis of GBM confirmed via ultrasonography were retrospectively reviewed and compared with a control group of 87 border terriers without GBM. The primary objective of this study was to determine whether border terriers have a breed predisposition to GBM and whether there are risk factors, clinical features, and outcomes specific to this breed. Because the odds of diagnosing GBM in a border terrier in this evaluation were 85 times that of all other breeds, a strong case for breed predilection can be made. This higher percentage may also be reflective of the increasing popularity of the breed and subsequent loss of genetic diversity in the pedigree in the United Kingdom. Concurrent endocrinopathies were infrequent in the reported cases, suggesting they may play a minimal role in GBM formation in this breed. Serum chemistry findings, particularly alkaline phosphatase and gamma-glutamyl transferase, in all study dogs were similar to those previously described for dogs with GBM.3 The surgical case fatality rate at 7 days was 11.7%.

… TO YOUR PATIENTS

Key pearls to put into practice:

1. A breed predisposition to GBMs in Shetland sheepdogs, American cocker spaniels, Chihuahuas, Pomeranians, and miniature schnauzers has been reported.2,4 The addition of border terriers to this list may be warranted.

2. Dogs presented with elevated cholestatic liver enzymes (ie, alkaline phosphatase, gamma-glutamyl transferase) along with vomiting, hyporexia, lethargy, and/or icterus warrant evaluation of the gallbladder to rule out GBM.

3. Although not observed in this study, there have been reports on the negative effects of gallbladder rupture on survival. Thus, rapid intervention is warranted in GBM patients, as survival rates of GBM patients that underwent cholecystectomy prior to rupture are good.

4. Although medical management of GBM is possible with appropriate case selection, patients that are candidates for medical management are rarely seen, as GBM patients are often subclinical until disease is advanced, warranting surgical intervention.

References
1750 Veterinarians can’t be wrong!

That’s the number of Veterinarians that chose an iM3 CR7 for their practice.

The number 1 choice worldwide for CR Veterinary Dental Imaging is as clear as the images from our CR7.

- Highest resolution at 25 lp
- Largest range of image plate sizes
- Ideal for extremities & orthopedic surgery
- iM3 unlimited technical support, German made

CR7 VET Dental X-Ray

"I have used a number of DR systems in the past, both in veterinary and human practice (Schick, Sirona, Kodak and Genoray), but I would have to say that the results and image quality that I am getting with the iM3 CR7 Vet is the best so far.

The advantages of the CR7 Vet over other DR systems when used in the veterinary environment include a unique range of plate sizes from size 0 up to size 5, which covers all pets from small to large. There is even an intraoral plate for rabbits."

Dr. Anthony Caiafa
BVSc BDSc MACVSc  (SA Surgery and Veterinary Dentistry)
When treating four-legged patients, make each moment matter.

PNC can help.

We’re making business banking easier.
At PNC, our team of dedicated Healthcare Business Bankers understands your business challenges and the important role that cash flow plays in your success. That’s why we offer a range of solutions to help optimize management of your practice’s revenue cycle and payables, so your business can run with less complexity and payments can be received promptly.

Learn more at pnc.com/hcprofessionals or by calling 877-566-1355
Effects of Noise in the Operating Room

Laura L. Nelson, DVM, MS, DACVS
North Carolina State University

In the Literature

FROM THE PAGE ...

The operating room (OR) can be loud, with noise arising from sources such as power tools, monitoring equipment, forced air blankets, music, human traffic, and conversation. Nonporous surfaces necessary for hygiene in OR environments can prolong noises generated from other sources because sound waves are reflected.

Increased noise in the OR has been associated with detrimental effects on communication, surgeon focus, veterinary staff stress, and incidence of complications and infections.1-3 The World Health Organization has noted that consistent recognition of speech in relaxed conversation is possible at noise levels of 45 dBA and subsequently recommends that workplace noise levels do not exceed 55 dBA.3 High background noise can be stressful and has been correlated with higher endogenous cortisol levels in surgeons.4

In this study, the mean, median, and maximum noise levels during 77 surgeries at an academic teaching hospital were recorded. Overall mean, median, and maximum decibel levels were 71.7 dBA, 69.4 dBA, and 90.3 dBA, respectively. Neurologic procedures had significantly higher mean and median decibel levels, presumably due to use of surgical power tools. Music significantly increased mean and median decibel levels (mean, 73.3 dBA with music vs 70.6 dBA without music; median, 71.3 dBA with music vs 68.2 dBA without music). Neither number of humans present nor number of staff members scrubbed in for a procedure significantly affected decibel levels.5

These results demonstrated decibel levels that substantially exceeded World Health Organization recommendations. To avoid risking miscommunication, verbal communication in this environment would need to exceed normal speaking volume. Although this study did not evaluate effects of high noise levels on outcomes such as complication rates or stress levels, the decibel levels measured were high enough to affect veterinary staff stress, based on results of a previous study.4 In addition, music was associated with significantly higher noise levels, representing a controllable, if controversial, source of noise.

Continues ➤
… TO YOUR PATIENTS

Key pearls to put into practice:

1. Taking inventory of sources of noise in the OR and subsequently considering ways to lower the noise volume (eg, setting monitors at a lower volume) is recommended.

2. Turning down the music volume and polling staff should be considered. Asking staff to note their perceived level of stress or calm before and after the volume is reduced, then evaluating the need for raised voices, the frequency of repeated requests, and whether staff relax after a source of noise is eliminated can be helpful in determining the effect of noise in an OR.

3. A quiet environment should be created throughout the practice. Concentration, communication, and calm are key elements of a successful veterinary practice. Where possible, discussing and reducing unnecessary noise in the practice environment may provide a subtle yet substantive benefit.

References


Taking inventory of sources of noise in the OR and subsequently considering ways to lower the noise volume (eg, setting monitors at a lower volume) is recommended.

Chewable Tablets

For oral use in dogs

Caution:

Federal USA law restricts this drug to use by or on the order of a licensed veterinarian.

Before using Credelio, please consult the product insert, a summary of which follows:

Indications:

CREDIELO kills adult fleas and is indicated for the treatment of flea infestations (Dermacentor variabilis) and the treatment and control of tick infestations (Amblyomma americanum) (lone star tick), Dermacentor variabilis (American dog tick), Ixodes scapularis (black-legged tick) and Rhipicephalus sanguineus (brown dog tick) for one month in dogs and puppies 8 weeks of age and older, and weighing 4.4 pounds or greater.

Dosage and Administration:

CREDIELO is given orally once a month, at the minimum dosage of 9 mg/lb (0.03 mg/kg). See product insert for complete dosing and administration information.

Contraindications:

There are no known contraindications for the use of CREDIELO.

Warnings:

Not for human use. Keep this and all drugs out of the reach of children.

Precautions:

The safety of CREDIELO in breeding, pregnant or lactating dogs has not been evaluated. Use with caution in dogs with a history of seizures (see Adverse Reactions).

Adverse Reactions:

In a well-controlled U.S. field study, which included 284 dogs (186 dogs treated with CREDIELO and 86 dogs treated with an oral active control), there were no serious adverse reactions.

Over the 90-day study period, all observations of potential adverse reactions were recorded. Reactions that occurred at an incidence of 1% or greater are presented in the following table.

Dogs with Adverse Reactions in the Field Study

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>CREDIELO Group: Number (and Percent) of Dogs with the AR</th>
<th>Active Control Group: Number (and Percent) of Dogs with the AR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight Loss</td>
<td>2 (1.3%) 2 (2.3%)</td>
<td></td>
</tr>
<tr>
<td>Elevated Blood Urea Nitrogen (BUN)</td>
<td>2 (1.0%)* 0 (0.0%)</td>
<td>0 (0.0%)</td>
</tr>
<tr>
<td>Polyuria</td>
<td>2 (1.0%) 0 (0.0%)</td>
<td>0 (0.0%)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>2 (1.3%) 2 (2.3%)</td>
<td></td>
</tr>
</tbody>
</table>

Two gonadectomy dogs developed mildly elevated BUN (34 to 54 mg/dL; reference range: 6 to 31 mg/dL) during the study. One of these dogs also developed polyuria and a mildly elevated potassium (8.5 mEq/L; reference range: 3.6 to 5.5 mEq/L) and phosphorus (8.4 mg/dL; reference range: 2.5 to 6.0 mg/dL). The other dog also developed a mildly elevated creatinine (1.7 to 2.0 mg/dL, reference range: 0.5 to 1.6 mg/dL) and weight loss.

In addition, one dog experienced intermittent head tremors within 1.5 hours of administration of vaccines, an ear cleaning performed by the owner, and its first dose of CREDIELO. The head tremors resolved within 24 hours without treatment. The owner elected to withdraw the dog from the study.

In an Australian field study, one dog with a history of seizures experienced seizure activity (tremors and glazed eyes) six days after receiving CREDIELO. The dog recovered without treatment and completed the study. In the U.S. field study, two dogs with a history of seizures received CREDIELO and experienced no seizures throughout the study.

In three well-controlled European field studies and one U.S. laboratory study, seven dogs experienced episodes of vomiting and four dogs experienced episodes of diarrhea between 6 hours and 3 days after receiving CREDIELO. To report suspected adverse events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact Elanco US, Inc. at 1-888-545-5973. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/AnimalVeterinary/SafetyHealth.

Effectiveness:

In well-controlled European laboratory studies, CREDIELO began to kill fleas four hours after administration or infestation, with greater than 99% of fleas killed within eight hours after administration or infestation for 28 days. In a well-controlled U.S. laboratory study, CREDIELO demonstrated 100% effectiveness against adult fleas 12 hours after administration or infestation for 28 days.

In a 90-day well-controlled U.S. field study conducted in households with existing flea infestations of varying severity, the effectiveness of CREDIELO against fleas on Days 30, 60 and 90 compared to baseline was 99.9%, 100% and 100%, respectively. Dogs with signs of flea allergy dermatitis showed improvement in erythema, papules, scaling, alopecia, dermatitis/ pyoderma and pruritus as a direct result of eliminating fleas.

In well-controlled laboratory studies, CREDIELO demonstrated 97% effectiveness against Amblyomma americanum, Dermacentor variabilis, Ixodes scapularis and Rhipicephalus sanguineus ticks 48 hours after administration or infestation for 30 days. In a well-controlled European laboratory study, CREDIELO started killing Ixodes ricinus ticks within four hours after administration.

Storage Information:

Store at 15-25°C (59-77°F), excursions permitted between 5 to 40°C (41 to 104°F).

How Supplied:

CREDIELO is available in five chewable tablet sizes for use in dogs: 56.25, 112.5, 225, 450, and 900/uni00A0mg lotilaner. Each chewable tablet size is available in NADA #141-494, Approved by the FDA.

Manufactured for:

Elanco US Inc
Greenfield, IN 46140 USA

Credelio, Eli Lilly and Company or its affiliates.

Elanco.com

Credelio and the diagonal bar logo are trademarks of Eli Lilly and Company or its affiliates.

PA200456X_Br51

P2a
My world just isn’t the same when I have ticks* and fleas. Prescribe me Credelio® (lotilaner) — a small, tasty* chewable that acts fast1,2 to protect puppies and dogs like me all month long.

*Amblyomma americanum (lone star tick), Dermacentor variabilis (American dog tick), Ixodes scapularis (black-legged tick) and Rhipicephalus sanguineus (brown dog tick).

** IMPORTANT SAFETY INFORMATION **

The safe use of Credelio in breeding, pregnant or lactating dogs has not been evaluated. Use with caution in dogs with a history of seizures. The most frequently reported adverse reactions are weight loss, elevated blood urea nitrogen, increased urination, and diarrhea. For product information, including complete safety information, see page 56.

Long-Term Outcome of Primary Immune-Mediated Thrombocytopenia

Lisa Singer, VMD, DACVIM
Veterinary Specialist Services
Queensland, Australia

In the Literature

FROM THE PAGE …

Immune-mediated thrombocytopenia is a life-threatening disease and one of the most common causes of canine thrombocytopenia. In primary immune-mediated thrombocytopenia (PIMT), autoantibodies adhere to the surface of blood platelets, resulting in platelet destruction by the immune system. Dogs have a high tendency for life-threatening, spontaneous hemorrhage when the platelet count drops below 30 × 10⁹/L to 50 × 10⁹/L. This is clinically seen as petechiae or ecchymoses on the skin and melena from the intestinal tract. Initial first-line treatment should be immunosuppressive therapy with glucocorticoids.

This study retrospectively evaluated the incidence of relapse, the risk factors associated with relapse, and whether the indefinite use of medications influences risk for relapse in dogs with PIMT. Review of records from 2007 to 2016 identified 45 dogs with presumed PIMT, 89.6% of which survived until discharge and 31% of which relapsed after discharge. Initial treatment included prednisone (mean dose, 2.1 mg/kg q24h) with or without vincristine. Additional immunosuppressive agents included azathioprine, mycophenolate, or cyclosporine. A previous study has shown no difference in outcome or relapse based on glucocorticoids alone or compared with another agent.¹ In this study, use of vincristine, a second immunosuppressive agent, or indefinite medication did not reduce relapse rate.

The median time between discontinuation of prednisone and relapse was 79 days. Of the dogs that relapsed, 50% went on to have another relapse. Previous studies have reported relapse rates from 9% to 47%.¹² Most dogs in this study relapsed while still on medication.

Another study reported that melena was a negative prognostic indicator and that dogs were more likely to need a blood transfusion.² That study found that patients were twice as likely to relapse if they had received a blood transfusion. Overall, the response time after relapse is rapid and prognosis for recovery remains good.

… TO YOUR PATIENTS

Key pearls to put into practice:

1. Indefinite immunosuppressive treatment or the addition of a second drug aside from glucocorticoids to treat PIMT in dogs does not reduce risk for relapse.

2. Higher relapse rates have been noted in patients requiring blood transfusion while in the hospital as compared with those that did not.

3. Most relapses occur within 3 months of discontinuing glucocorticoids. Patients should have platelet counts checked regularly—minimally for the first year after remission and discontinuation of medications.

References


PUREVAX® MEANS SAFE.

PURE AND SAFE FELINE PROTECTION

PUREVAX is THE ONLY complete line of feline vaccines with ZERO adjuvants.

✓ All PUREVAX feline vaccines utilize either modified live (ML) or recombinant canarypox-vectored technology, which stimulate both humoral and cell-mediated immune responses 1,2,3.

✓ PUREVAX offers THE ONLY recombinant nonadjuvanted feline rabies vaccines: 1- and 3-year duration of immunity products

✓ PUREVAX offers THE ONLY recombinant nonadjuvanted Feline Leukemia Virus (FeLV) vaccine


©2019 Boehringer Ingelheim Group. All rights reserved. PET-0915-PUR0119.
Salmonella Enteritidis Infection in Guinea Pigs

Radford Davis, DVM, MPH, DACVPM
Iowa State University

In the Literature

FROM THE PAGE …

Although most cases of human salmonellosis in the United States have been attributed to contamination of food with animal feces,1 cases of human salmonellosis associated with pet rodents have been documented.1-3 This report discussed an 8-state outbreak of Salmonella enteritidis infection associated with guinea pigs that resulted in illness in 9 humans on or after January 1, 2015. One hospitalization and no deaths were recorded. Cases were identified as a result of an investigation that began after 2 human cases of Salmonella enteritidis were reported in 2017 and were found to be indistinguishable from a Salmonella strain responsible for a 2010 outbreak also connected to guinea pigs.1

Some guinea pigs that caused infection in the humans from the more recent outbreak came from the same wholesaler that supplied guinea pigs to pet stores in the 2010 outbreak; this emphasizes the difficulties in enforcing proper animal husbandry, welfare, and infection prevention in licensed and unlicensed operations. The pathway from breeder to final home for guinea pigs may involve breeders, vendors, distributors, retailers, significant handling, and lengthy, fragmented transportation, all of which may induce stress in the animal and potential shedding of Salmonella spp.

Multiple points along the supply chain can serve as sources of Salmonella spp infection for naïve guinea pigs (eg, commingling with infected animals, contaminated bedding).4 Shedding may occur with or without concomitant clinical signs.1,3 Morbidity and mortality are variable4 and may include subacute illness with severe diarrhea, emaciation, abortion, and/or sudden death.2 Guinea pigs may harbor subclinical infections and shed Salmonella spp intermittently for weeks to months.1 Prophylactic use of antimicrobials is not uncommon in the rearing of rodents for sale and can lead to multidrug-resistant Salmonella spp in guinea pigs4 and therefore humans.3
Pet rodents are likely an underrecognized source of *Salmonella* spp infection in humans; clinicians and pet store staff should educate owners on the risks of rodent ownership and on prevention measures (eg, frequently discarding pet feces; regularly changing bedding; thoroughly washing hands with soap and water for a minimum of 20 seconds after being in contact with the animal, cage, bedding, or food; supervising hand-washing in children and their handling and caring of rodents; discouraging eating while handling pets; discouraging kissing and holding animals close to the mouth).1,3,4

... TO YOUR PATIENTS

Key pearls to put into practice:

1. Clinicians, breeders, and distributors should consider submitting specimens for *Salmonella* spp isolation when substantial diarrhea-associated morbidity or mortality occurs in rodents intended for sale.4

2. Clinicians should advise owners of the risks of guinea pig ownership and educate them on the basic precautionary measures to protect them from *Salmonella* spp and other zoonoses.2

3. Treating guinea pigs to eliminate carriage of *Salmonella* spp is not reliably successful and may prolong shedding5 and thus is not recommended.

References


The #1 Staph Biologic for Recurrent Canine Pyoderma
Make Staphage Lysate (SPL)® the foundation of your treatment plan. A variety of therapies treat infection and discomfort, but SPL® controls the recurrence of infection, reducing the need for repeated courses of systemic antibiotics that often lead to antibiotic-resistant infection.

delmontlabs.com

Treat the Cause, Block the Itch
Avoid the uncertainty associated with serum allergy testing with RESPIT, the practical allergen immunotherapy option. Other medications may block the itch associated with atopic dermatitis, but allergen immunotherapy is the only modality that treats the underlying cause and offers a long-term solution.

vetrespit.com

Simplify Your Shelves: A New 1-SKU Shampoo
BUY 6 GET 1 FREE
Simplify your shelves with a shampoo clinically proven to reduce pruritus resulting from infection. With no fragrances or dyes, it's ideal for sensitive skin. Reduce your inventory and effectively replace many other shampoos with just one product. Available in 4- and 12-ounce sizes for client convenience.

brief.vet/practice-solutions_AAHA

Stay a Step Ahead of Skin Issues
Great-tasting Prescription Diet® Derm Defense makes compliance manageable and is a key component for multimodal treatment plans. Help normalize pets’ immune response with long-term feeding formulated to reduce signs of environmental allergies. With Prescription Diet® Derm Defense, you’re always a step ahead of skin issues.

hillsvet.com/derm

ZYMOX Otic Enzymatic Solutions for Chronic & Acute Otitis Externa
Improve client compliance with a no-pre-cleaning, once-a-day protocol. Proven, broad-spectrum effectiveness works without antibiotics and is available with hydrocortisone for additional inflammation relief. New Advanced Formula features additional biofilm-degrading enzymes for those resistant infections. Safe for any age dog or cat.

zymox.com

Packaged Allergy Solutions Beyond Comfort Therapies
Don’t just focus on comfort—get your clients real relief. With Spectrum Veterinary’s test and treat program, you get both a comprehensive test and the initial treatment for as little as $225. Get started with Spectrum Veterinary!

info.spectrum.vet/cb-package
TOP 5 KEYS TO SUCCESSFUL MANAGEMENT OF OTITIS EXTERNA

Erin E. Aufox, DVM
Elizabeth R. May, DVM, DACVD
University of Tennessee
Otitis externa is a common inflammatory condition that affects 15% to 20% of dogs and 4% to 7% of cats.\(^1\) Dogs and cats of breeds predisposed to otitis externa may have pendulous ears, canal hypertrichosis, and familial seborrhea or cerumen gland hyperplasia.\(^2,3\)

Although some patients may have irreversible external ear canal changes necessitating surgical management, many cases can be managed medically. Incorporating steps early in the disease course may help prevent chronic changes (eg, proliferation, fibrosis, mineralization of the external ear canal) and recurrence.

Following are the authors’ top 5 steps to manage otitis externa.

1. **Classification**

Successful treatment of otitis externa should begin with clinical assessment of the patient (ie, ear canal palpation, otoscopic examination, cytology). Palpating the ears can aid in determining whether a patient is best managed medically with antimicrobial drugs and glucocorticoids or surgically. Normal ear canals should be pliable. Surgical management should be considered for ear canals that are firm due to fibrosis and calcification and/or ossification (Figure 1).\(^4\)

Otoscopic examination of both ears using a standard handheld otoscope with 2×/4× magnification and a reusable 0.75-inch cone includes assessment of the exudate type (eg, ceruminous, purulent), degree of stenosis, and integrity of the ear canal (eg, presence of ulceration, mass, polypoid changes, ceruminous gland hyperplasia) and tympanic membrane. In patients with stenotic ear canals (and those exhibiting signs of pain with comorbid diseases for which sedation or anesthesia may be initially contraindicated), otoscopy may be delayed and topical and/or oral steroid treatments prescribed to manage patient discomfort.\(^1\) If a sample for cytology can be obtained at the time of initial presentation, topical antimicrobial therapy should be initiated simultaneously with steroid therapy to address the infectious disease.

**TOP 5 KEYS TO SUCCESSFUL MANAGEMENT OF OTITIS EXTERNA**

1. Classification
2. Treatment
3. Monitoring
4. Maintenance
5. Identification

**FIGURE 1** Severe vertical canal epithelium and ceruminous gland hyperplasia impeding medical management of otitis externa. Surgical management is recommended in this case.

**Misdiagnosis and inappropriate therapy are possible if otic cytology results are not considered when culture results are interpreted.**
component. In patients with severely stenotic ear canals, daily oral steroid therapy may be the best treatment option until the patient is comfortable and a cytology sample can be obtained.

Otic cytology is an essential test used to diagnose and characterize otitis externa. Type of organism present (eg, cocci, rods, yeast), relative numbers of organisms (1-4+ scale), and presence or absence of inflammatory cells (typically, neutrophils) should be recorded. Purulent exudate and ulcerative lesions in the canal are typically associated with \textit{Pseudomonas} spp infection (Figure 2) or reaction to a topical medication. Inflammatory cells are not routinely observed when there is ceruminous discharge containing yeast organisms with or without bacteria.

Cytologic presence of neutrophils (with or without rods) and appropriate clinical findings may suggest \textit{Pseudomonas} spp otitis or contact reactions, both of which should prompt aerobic culture; culture should also be performed if bacterial otitis does not respond to appropriate empiric treatment. Diagnosis of infectious otitis using culture results without cytology can be misleading. The ear canal hosts various species of bacteria in the healthy state, and bacterial organisms, including methicillin-resistant \textit{Staphylococcus} spp, can be recovered from culture samples of healthy ears of dogs or cats. Misdiagnosis and inappropriate therapy are possible if otic cytology results are not considered when culture results are interpreted. Culture results should parallel cytology findings, allowing for selection of the appropriate pathogen-specific therapy. Susceptibility data are not used initially to select treatment because topical medications achieve higher local concentrations than those achievable in plasma, upon which susceptibility interpretation is determined. Susceptibility data are used for refractory cases unresponsive to standard treatment protocols.

**Treatment**

Ear canals should first be opened, as ear canal epithelial inflammation and stenosis hinder effective topical treatment, and most cases therefore require topical and/or systemic corticosteroid treatment.

Ears should be cleaned by flushing, which removes dried medication and cerumen that may interfere with examination and treatment. Sterile saline flushing should be selected when tympanic membrane status is unknown to minimize concern for ototoxicity. Squalene is an effective ceruminolytic agent with demonstrated safety in the middle ear and is an alternative option when perforation is suspected. During treatment, at-home flushes containing salicylic acid or other mild ceruminolytics should be administered 2 to 3 times per week to maintain ear canal cleanliness.

Treatment selection is based on pathogen identification (yeast vs \textit{Pseudomonas} spp vs other bacteria), exudate characteristics, and chronic ear canal changes. Because external ear canal volume varies among dog breeds (eg, brachycephalic breeds, 0.47 mL; mesaticephalic and dolichocephalic breeds, up to 5.86 mL), extra-label dosing (0.5-1 mL) of most topical ear medications should...
be used for each affected ear to allow medication to sufficiently coat the ear canals. Antimicrobial medications, excluding long-acting, FDA-approved florfenicol otic medications, are applied twice daily (extra-label) to ensure maintenance of adequate antimicrobial concentrations and inflammation reduction. For stenotic canals, a solution is preferred over an ointment.

Topical antibiotics (eg, fluoroquinolones, amikacin, tobramycin, silver sulfadiazine, ceftazidime) are frequently used to treat *Pseudomonas* spp. Due to drug inactivation, gentamicin and neomycin are ineffective against *Pseudomonas* spp otitis, seemingly more so than other aminoglycosides such as amikacin and tobramycin, which have been effective for treatment of *Pseudomonas* spp otitis in the authors’ experience. Florfenicol is also ineffective against *Pseudomonas* spp otitis due to its spectrum limitations. Using a tris-EDTA–containing flush, which serves as a calcium-chelating agent, can help the effectiveness of topical antimicrobial treatment. These flushes are commercially available and increase the medication permeability of gram-negative organisms by damaging the outer cell wall membrane. The calcium-chelating flush should be applied as pretreatment in conjunction with topical therapy for improved treatment efficacy against *Pseudomonas* spp otitis.

Systemic antibiotics should be reserved for the treatment of otitis media and are ineffective in the treatment of otitis externa.

### Monitoring

The patient should first be assessed 2 to 3 weeks after initiating treatment to determine if the treatment plan is effective based on otoscopic examination and cytology. Otoscopic examination and cytology should also be performed at each follow-up visit to document changes, including resolution. A successful outcome is dependent on timely recheck examinations with diagnostics, including sedation if needed for effective examination.

### Maintenance

Otitis can cause changes to the ear canal, predisposing the patient to future infections. Ear flushing is required long-term unless return of self-cleaning mechanisms of the canal epithelium are documented. In addition, controlling ongoing low-level inflammation should decrease disease recurrence. Once-to–twice-weekly treatments with topical steroid formulations (ie, the least potent form to control clinical signs) are effective when an underlying cause cannot be identified or adequately controlled by other means. Systemic absorption of topical steroids should be considered when performing endocrine testing and, when used long-term, necessitates monitoring clinical signs and performing minimum database testing for adverse effects.

### Identification

After otitis has resolved, the primary cause should be identified to help prevent recurrence, although identification is less useful in cases in which chronic ear canal changes become a perpetuating cause of disease or cases in which recurrence can be prevented by a simple maintenance regimen. Aural conformation, allergic conditions (especially atopy), and endocrinopathies (eg, Cushing’s disease, hypothyroidism) are common causes of otitis externa, with neoplasia and/or foreign bodies considered for patients with unilateral otitis.

### Conclusion

Otitis externa is a common disease of dogs and cats presented for veterinary care. Most patients can be treated quickly, and recurrence can be prevented by incorporating these fundamentals early in the course of disease, which can help patients avoid chronic pain and pathology to the external ear canals.
References


References


Look for these articles in future issues

- Increased & Decreased Intraocular Pressure: Diagnosis & Management
- Burn Management
- Top 5 Bartonella Species of Human Significance
- Step-by-Step Full-Mouth Extraction
- Salter-Harris Fracture Case
Mesenchymal stem cell therapy (MSCT) involves use of adult-derived mesenchymal stem cells to potentially restore health and proper function to damaged or diseased cells, tissue, and/or organs. MSCT has been widely researched in human medicine and used to treat osteoarthritis (OA), tendinopathies, and sports-related injuries, inspiring veterinary research to evaluate this modality in dogs. Research supporting MSCT in veterinary musculoskeletal disease management is still minimal.

There are 2 types of mammalian stem cells: those of embryonic origin and those derived from adult tissue. Embryonic stem cells are totipotent and capable of differentiating into any cell type, whereas adult-derived stem cells are multipotent and capable of differentiating into more than one but not all cell types. Derived from a mesodermal lineage, adult-derived stem cells (ie, mesenchymal stem cells) exist naturally as a reserve in muscle, fat, cartilage, bone and bone marrow, and tissue that make up the circulatory, urinary, and reproductive systems. In their natural state, activated mesenchymal stem cells undergo cell division to give rise to other cells that eventually function in a fully differentiated state, replacing dead cells in the process of tissue renewal. Mesenchymal stem cells may also mobilize and proliferate in response to injury or pathologic conditions, theoretically creating a basis for therapeutic application.
The International Society for Cellular Therapy has proposed a set of minimum criteria to qualify a cell as a therapeutic mesenchymal stem cell. The cell must be able to exhibit plastic adherence, possess specific sets of cell surface markers while lacking others, and be capable of differentiating into adipocytes, chondrocytes, and osteoblasts in vitro. Although these criteria are universal, there has been no standardization of terminology; thus, various terms (eg, stem cell, mesenchymal stem cell, mesenchymal stromal cell) are commonly used interchangeably, which can be confusing when navigating the literature and clinical studies. The International Society for Cellular Therapy has proposed the term mesenchymal stromal cell be used in reference to tissue harvested from bone marrow and fat and processed for MSCT use, based on the contention that these ex vivo isolated cells are a heterogeneous population of fibroblast-like cells that can self-renew and differentiate in culture but may not meet all criteria to be defined as true stem cells. Thus, the term stromal cell has been adopted for the products most commonly used in regenerative medicine. For the purposes of this article, the term mesenchymal stromal cell (MSC) will be used.

MSCs for Therapeutic Use
Adult-derived MSCs for therapeutic use can be subdivided into autologous (ie, those derived from the same animal), allogenic (ie, those derived from a different animal of the same species), and xenogenic (ie, those derived from an animal of a different species). Most research in dogs has been focused on adult-derived autologous MSCs, although investigation of the use of allogenic and xenogenic cells is underway. Adult-derived MSCs for therapeutic use are thought to assist in tissue regeneration and repair through angiogenesis enhancement, inflammation reduction, immune modulation, fibrosis inhibition, and the recruitment, survival, and proliferation of local stem cells at the site of injury. Although much regarding MSCs is known from in vitro and in vivo investigation, a complete understanding of how these cells function in vivo in any species once administered is not known.

There are several sources of therapeutic MSCs (eg, bone marrow, adipose tissue, umbilical cord tissue, amniotic fluid, dental pulp, peripheral blood, skeletal muscle). Common sources in veterinary orthopedics are bone marrow and adipose tissue; however, the processing of this tissue to isolate MSCs varies, and no cell source or isolation method has been established to be superior over the other.

Culture-Expanded & Noncultured Products
MSCs can be divided into culture-expanded and noncultured models.

Culture-Expanded
Culture-expanded models involve harvesting tissue (eg, bone marrow, fat), then isolating, processing, and expanding the stromal cells using culture techniques. An expanded product contains more stromal cells than the original sample, creating a more homogeneous population for administration. In the literature, cultured products are commonly referred to as bone marrow MSCs (BM MSCs) and adipose tissue-derived or adipose-derived MSCs (AD MSCs), among others.

Noncultured
Noncultured models involve harvesting and processing fat or bone marrow so the existing cells become concentrated but not expanded. This more heterogenic product is a combination of MSCs and other cellular components (eg, mononuclear cells normally found in these tissue types). Although cultured products may seem more desirable due...
to the larger number of purified cells in the final product, the harvested sample in cultured products takes 3 to 6 weeks to process before it can be administered. Thus, noncultured products may be more convenient for clinical scenarios and are described below.

Bone marrow aspirate concentrate (BMAC) is a concentrated—but not cultured—heterogeneous population of cells derived from a traditional bone marrow aspirate. As compared with a traditional bone marrow aspirate, BMAC has a higher population of MSCs but not as many as the culture-expanded forms previously described. A benefit of BMAC is the provision of other cell populations, growth factors, and fibrin, which may aid in the healing process and provide a scaffold for cells and other substances at the treatment site. Adipose-derived stromal vascular fraction cells—not to be confused with the culture-expanded AD MSCs—are an alternative to BMAC and are harvested from fat and processed without cultured cellular expansion. The result is a heterogeneous product of MSCs that likely contain a milieu of other cells in its stroma.

**Bone Marrow MSCs vs Adipose-Derived MSCs**

Studies comparing the effectiveness of BM MSCs with AD MSCs in the treatment of orthopedic conditions in dogs or comparing cultured with non-cultured products are lacking. However, there has been some investigation into the basic differences between BM MSCs and AD MSCs, such as cell proliferation, stem cell marker expression, and lineage-specific differentiation potential. Although BM MSCs and AD MSCs resemble each other morphologically and in expression of markers, they display differences in proliferation rate and differentiation potential into chondrogenic and osteogenic directions. In a study comparing AD MSCs with BM MSCs, AD MSCs exhibited faster population doubling but weaker differentiation into chondrogenic and osteogenic directions. In addition, greater numbers of MSCs have been found in adipose tissue, but it is not known if the number of MSCs in a sample is clinically significant.

Although the clinical meaning of these differences and the clear advantages or disadvantages to either tissue source for MSCT are unclear, AD MSCs may offer a potential advantage due to ease of harvesting. Although bone marrow aspiration is a relatively routine procedure, fat can generally be found in abundant quantities in most patients and can be harvested through a surgical procedure that may be less invasive and painful as compared with bone marrow harvesting. Further research is needed to determine which approach, if either, offers greater benefits regarding efficacy and safety or conditions that may potentially be targeted by this therapy.

**Clinical Impact**

MSCT has been investigated and used clinically in dogs to treat OA, ligament injuries (eg, partial cranial cruciate ligament tears), and tendinopathies (eg, supraspinatus tendinopathy). Chondrocytes are easily damaged and heal poorly due to their low mitotic ability and due to their lack of blood and lack of lymphatic and nerve supply, making them an ideal therapeutic target for MSCT in dogs and humans. Several studies have investigated the use of AD MSCs for the treatment of naturally occurring OA affecting the canine hip, elbow, and shoulder joint. Most of these studies were well-designed, placebo-controlled, blinded, and randomized; many demonstrated reduction in pain on manipulation and range of motion and improvement in owner satisfaction and subjective grading scale and objective lameness measurements. It is unclear whether the beneficial effects seen in these studies were due to the anti-inflammatory effects of MSCs, the repair or regeneration of articular cartilage, or a combination of these mechanisms.

The investigation of MSCT in the treatment of other small animal orthopedic conditions (eg, cranial cruciate ligament tears) has been fueled by in vivo studies that have shown the potential for MSCs to engraft into the cranial cruciate ligament, meniscus, and cartilage. Although data are sparse, there is some clinical evidence...
suggested that MSCs may be able to augment healing of early partial tears prior to development of mechanical instability, offering a potential non-surgical solution.31

Use of culture-expanded BM MSCs in the treatment of tendon injuries has been investigated in experimental studies of horses and laboratory animals; MSCs were implanted in surgically or collagenase-induced tendon lesions and had positive effects on tissue organization, composition, and mechanics of these structures.37-40 In a veterinary clinical study, a combination of AD MSCs and platelet-rich plasma was used to treat supraspinatus tendinopathy in 55 dogs, 61.8% of which failed to respond to NSAIDs and 45.5% of which failed to respond to rehabilitation therapy.41 Improvements in objective gait analysis, lameness, and diagnostic ultrasonography results (ie, improved fiber pattern and tendon size) showed that AD MSCs combined with platelet-rich plasma may show promise in the treatment of this condition in dogs.41 Additional studies are needed to better evaluate MSCT in the treatment of this and other tendon injuries in dogs.

**Advantages**

Although the advantages of MSCT have yet to be fully elucidated, a possible advantage of MSCT is its potential in the management of OA. OA affects an estimated 20% of the canine population42 and can be challenging to manage, particularly in patients refractory to traditional medical management (eg, weight control, physical rehabilitation, nutraceuticals, NSAIDs, intra-articular therapies).43-45 MSCT may prove to be an alternative to managing signs in clinically affected dogs.

MSCT is relatively easy to carry out in a small animal practice, owing largely to its point-of-care qualities. With a multitude of products available, preparation, processing, and administration can be performed in a properly equipped veterinary practice as opposed to a referral laboratory or research facility (see **MSC Procurement, Processing, & Administration**).

---

**MSC Procurement, Processing, & Administration**

Although all types of MSCs can be sent to laboratories for processing and culture-expanding procedures, centrifuges that can process both adipose-derived stromal vascular fraction cells and BMACs are available to allow for more convenient processing and administration and to avoid delays between procedures. Laboratories are available to provide culture-expanded products. It is unknown if a single injection or a series of injections over time is needed to optimize therapeutic benefit.

**Procurement**

Patients should be sedated or anesthetized, and a fat retrieval procedure or bone marrow aspiration should be performed. In dogs, bone marrow is most easily obtained from the proximal humerus, tibia, ilium, or femur. Adipose tissue can be harvested from the axillary or inguinal region or where fat is abundant.

**Processing**

For noncultured products, samples should be processed onsite in a specially designed centrifuge or sent to a laboratory for concentration and separation of the mononuclear layer. For culture-expanded products, a further step is performed for cell expansion in a laboratory.

**Administration**

Administration is most commonly performed locally to target tissue (eg, intralesionally into tendons, ligaments, or joints). The method of administration depends on the target tissue. Tendon therapy generally requires ultrasonography guidance under heavy sedation or anesthesia, whereas the treatment of OA or cranial cruciate ligament injuries only requires a joint injection under sedation.

**Recovery**

Most patients recover as outpatients following administration. The author recommends treating patients postinjection with parenterally administered opioids (eg, buprenorphine [0.01-0.015 mg/kg IV or SC]) or oral analgesics (eg, gabapentin [5-10 mg/kg PO]). It is unknown whether administration of NSAIDs after MSCT therapy is detrimental to efficacy. After the procedure, most patients are enrolled in a physical rehabilitation program to further treat the underlying condition being targeted.

---

| AD MSC | adipose-derived mesenchymal stromal cell |
| BM MSC | bone marrow mesenchymal stromal cell |
| BMAC | bone marrow aspirate concentrate |
| MSC | mesenchymal stromal cell |
| MSCT | mesenchymal stem cell therapy |
| OA | osteoarthritis |
Disadvantages

The clinical use of MSCT is still new, and there is little information available to help guide treatment plans, develop treatment protocols, and predict patient outcomes. It is also unclear how MSCs function physiologically to provide clinical benefit to patients and how efficacious MSCT is in the treatment of different disorders and injuries, as many studies on MSCT have used different types of MSC products and vehicles of administration (eg, hyaluronic acid, platelet-rich plasma, saline).\textsuperscript{20-22,25,27,29} Experimental studies have suggested that these factors can influence clinical outcome due to cell–vehicle interaction.\textsuperscript{28} In addition, there are few comparative studies (eg, those comparing intra-articular MSCT with the current standards of care [eg, physical therapy, NSAIDs, nutraceuticals, intra-articular injections of corticosteroids, hyaluronic acid, platelet-rich plasma] in the treatment of conditions such as OA). In addition to these investigative and clinical disadvantages, MSC use in veterinary medicine can be cost-prohibitive.

Conclusion

Despite a lack of comprehensive evidence for the use of MSCT (see Open Questions), its clinical use in veterinary orthopedics is growing. Clinicians must be aware of the known data and have an open discussion with owners to set realistic expectations and inform them that, although MSCT offers clinical promise, it is largely experimental. MSCT may prove beneficial in the treatment of orthopedic-related injuries and conditions, but further investigation into its potential and benefits is needed.

Open Questions

Following are open questions to consider regarding areas of MSCT where data are lacking.

1. Does a specific tissue source offer an advantage over the other (adipose tissue vs bone marrow)? Does the tissue source chosen depend on the target tissue or disease process being treated?

2. What is the concentration or number of stem cells needed to allow for regeneration or repair of damaged tissue? Is treatment success or failure dose-dependent? Is the concentration disease-dependent?

3. How do age and health of the patient affect the outcome or success of treatment? How do pre-existing disease(s), comorbidities, or certain medications (eg, NSAIDs, steroids) affect treatment protocols?

4. What is the best delivery method of stem cells? Should administration always be locally to a target tissue (eg, joint, tendon), or is there a benefit to intravenous administration?

5. How many treatments are necessary to produce a clinical effect? Is this disease-dependent or universal?

References

Cat ownership continues to increase in the United States: 25% of households own at least one cat, and the average cat owner makes 2.4 veterinary visits per year. Preventive care is the cornerstone of pet ownership, and cats are no exception. Parasite prevention is a critical component of preventive care, protecting pets from infectious disease and mitigating the risk for zoonotic infection in humans.

All cats, all year round
Cats are fastidious groomers and often remove fleas and ticks before they are visible to their owners, leading to a false sense of security when it comes to parasitic infestations. A lack of visible parasites on a pet should not equate to a lack of risk. A recent study concluded that pet ownership more than doubled the risk for household tick encounters, potentially increasing the risk for contracting zoonotic diseases.

In addition, warm indoor temperatures may foster an environment that allows parasites, once inside, to remain active throughout the year. Owners can act as a vessel for indoor entrance of fleas and ticks via clothing or shoes. Protection may be especially important in cats that share homes with dogs that frequent the outdoors and therefore increase the risk for carrying parasites indoors. All cats—indoor and outdoor—need appropriate protection.

Prevention is better than treatment
In the mildest cases, flea and tick infestations can lead to pruritus, allergic dermatitis, and intestinal parasitism. More severe diseases can develop secondary to flea and tick parasitism. Flea and tick infestation may result in transmission of infectious disease (e.g., cytauxzoonosis, anaplasmosis), some with potential public health implications (e.g., bartonellosis, hemotropic mycoplasmosis).

Once infestation has occurred, all household pets must be treated, and environmental decontamination is often necessary to prevent reinfection.

Compliance
Many cats can be more challenging to medicate than dogs, and the need for owners to administer medication may hinder effective feline preventive care. The ideal parasite preventive would be effective and long acting with a quick kill and limited stress of administration. An extended duration of protection has been shown to increase owner compliance with preventive administration and is therefore a desirable quality of this category of medicine.

In general, topical preventives are easier to apply than administering oral medications for cats and can decrease stress for both the pet and owner, increasing the likelihood of proper adherence.

Conclusion
The consequences of feline parasite infestation range from mild to severe and can even result in zoonotic disease, putting all household members at risk. Proper prevention helps reduce the risk for exposure to both feline and human members and, if performed correctly, can make treatment of these diseases unnecessary. Compliance with preventive care can improve patient health and can strengthen the bond between the owner and the veterinary team throughout the life of a pet.

REFERENCES

2. Rust MK. Insects. 2017;8:118.

*BRAVECTO kills fleas, prevents flea infestations, and kills ticks (black-legged tick) for 12 weeks. BRAVECTO also kills American dog ticks for 8 weeks.

IMPORTANT SAFETY INFORMATION: The most common adverse reactions recorded in clinical trials were vomiting, itching, diarrhea, hair loss, decreased appetite, lethargy, and scabs/ulcerated lesions. BRAVECTO has not been shown to be effective for 12-weeks’ duration in kittens less than 6 months of age. BRAVECTO is not effective against American dog ticks beyond 8 weeks of dosing. For topical use only. Avoid oral ingestion. The safety of BRAVECTO has not been established in breeding, pregnant and lactating cats. Use with caution in cats with a history of neurologic abnormalities. Neurologic abnormalities have been reported in cats receiving BRAVECTO, even in cats without a history of neurologic abnormalities. See Prescribing Information on page 44.


WSAVA/CVMA 2019
Experience Toronto. Discover the World.

The World Small Animal Veterinary Association (WSAVA), the global platform for veterinarians, is joining forces with the Canadian Veterinary Medical Association (CVMA), for a highly anticipated Congress, that will take place in Toronto, Canada, between 16–19 July 2019.

What to expect:

• international flavor
• phenomenal CE
• Over 50 streams covering numerous topics, including tracks specifically designed for technicians & nurses
• Exclusively at the WSAVA Congress; Global Nutrition, Global Pain, Global One Health & Global Animal Welfare programs
• Specialized workshops such as an Aquatics Wetlab and ultrasound examinations
• Amazing social events, including the signature annual party!

Get Your Congress Pass
Register online and join us in Toronto!

www.wsava2019.com
CO₂ LASER SURGERY — A REWARDING ENDEAVOR

By David Bradley, DVM, FASLMS

Over 20 years ago I attended an all-day seminar on the use of CO₂ surgical lasers in veterinary practice. I went in very skeptically. I left exuberant! The wide range of applications, the ease of use and the versatility and durability of the laser filled me with enthusiasm.

As a busy practitioner in a mixed-animal practice, I perceived the laser to be a tool that would improve the value of the procedures I was already doing because of the inherent benefits that my Aesculight CO₂ laser delivered for my practice, my patients and my clients.

Patient, Client Benefits

The patient benefits because the laser reduces about 80 percent of nuisance bleeding by sealing vessels up to 1 mm in diameter. Larger vessels—anything with a name!—still need to be ligated.

The laser is used in non-contact mode so there is less crushing or tearing of tissue and therefore inflammation is decreased. It may also reduce “seeding” of tumors. By sealing the nerve endings as it cuts without trauma, post-operative pain is diminished and healing and recovery are enhanced. The thermal effects also reduce bacterial contamination.

The client benefits because recovery is usually shorter and post-op complications are lessened. Patients can often go home sooner, may need fewer rechecks and fewer bandage changes. They return to their normal activity levels more quickly. This saves the client money and allows the pet to resume its role as an active member of the family again.

Professional Benefits

Benefits to me and my practice, however, were the most exciting. My laser helped me expand my surgical repertoire. The clear, dry surgical field gave me more confidence in complicated procedures such as oral surgery, perianal surgery, total ear canal ablation and large mass removals.

The precision allowed more control in delicate procedures, such as distichiasis, corneal ulcers, thyroid tumors, etc. Its unique interaction with tissue helped convert some major procedures to more minor ones, such as eyelid tumors, soft palate resection, stenotic nares, everted sacculles and entropion corrections.

The laser also gave me an additional option for some common intractable conditions, such as stomatitis, acral lick granulomas, tumors, aural conditions, and so on. But mainly it gave me a way to add value to what I was already doing every day, e.g., granulomas, tumors, aural conditions, and so on.

But mainly it gave me a way to add value to what I was already doing every day, for example, spays, neuters, lump and bumps.

Therefore I could charge a laser fee for the enhanced benefits and generate more revenue on the procedures I perform every day.

Benefits to the Practice

I did perform more surgery because I expanded my skills and expertise on new procedures. But I also found patients seeking us out for the benefits of laser surgery and we were booking more routine procedures as well. In addition, I found myself doing more “locals” on small lumps and bumps that clients would often point out during routine health appointments. Rather than delaying these for a later date, we were able to inject them with a local anesthetic, provide a quick surgical prep, laser off the offending growth, and send the pet right home with the client. This was efficient; clients were very pleased and impressed.

All these things generated a measurable revenue stream. We consistently and almost immediately generated an additional $2,000 a month to our bottom line.

The chart in Figure 1 allows the veterinarian, using her/his own data, to estimate the potential return on investment (ROI), if the Aesculight laser is used in the practice.

Why the Laser

The laser is a very effective tool for general surgery because it produces a wavelength of energy that is best absorbed by the soft tissue; absorption coefficient at 10,600 nm is over a thousand times greater than at diode laser wavelengths (800-1,100 nm).¹

High absorption in water means that, with proper technique, the laser produces the most efficient photothermal ablation of water-rich soft tissue with extreme precision and minimal collateral thermal effects (sub 100 micrometers). This is what accounts for the unlimited versatility intra-operatively and improved recovery post-operatively.

Benefits for Practitioners

Could laser surgery be just what the doctor ordered to rejuvenate your enthusiasm? Are you looking for a new marketing niche? Do you need something to differentiate your practice from your neighbors? Would you like a new revenue stream to boost the bottom line? The following questions will help you decide.
Do you like surgery? The CO₂ laser is just another tool. It will not improve your surgical skills. But in the right hands, it can enhance your surgical armamentarium.

Are you doing at least six to eight surgeries per week? (Or would you like to be?!) Surveys have shown that when offered as part of the surgical options, laser surgery is accepted over 70 percent of the time by clients for their pets. With an additional fee of $50-

The current cost of a new laser would be $500-$750/ month based on a standard five-year financing option. The laser should not just pay for itself; it should be a new profit center and new marketing niche for your practice.

Has the number of elective surgeries performed in your practice decreased? Many low-cost spay/neuter clinics are providing the same level of high-quality surgery at a lower price due to subsidized financial backing. These facilities are often clean and modern and are no longer held as that stigma they once did for many clients. Laser surgery can be a highly recognized addition to differentiate your practice from them.

Are you already so busy that adding another service would task your schedule or nuisances? The CO₂ laser can add value to many of the procedures that are already part of your day. Adding an additional charge for the benefits of less pain, less bleeding and a quicker recovery is well accepted.

Are you looking for something to rejuvenate your interest and love of veterinary medicine?

Laser surgery has a very short learning curve. It is safe and effective and versatile enough to be used for every surgery that walks in the door. And it is fun!

If you answered “Yes,” the next step is to find the best CO₂ surgical laser for your practice. The equipment and the company should have a history of reliability and innovation. Ease of use, durability and versatility of the delivery system and hand pieces. Adjustability to accommodate the wide variety of surgical procedures that we perform is paramount.

Clean-up and sterilization issues should be seamless and easy for staff to implement and perform. Adding a laser to your surgical armamentarium has a very short learning curve. However, make sure ongoing support is readily available. With the proper equipment and training, you would never have to pick up a scalpel again.

REFERENCE:

WATCH CO₂ LASER SURGERY VIDEOS: www.Aesculight.com/video/
Two dogs developed hypoadrenocorticism during the study: These two dogs had clinical signs consistent with hypoadrenocorticism (lethargy, anorexia, collapse) and post-ACTH cortisol levels ≤ 0.3 μg/L. Both dogs responded to trilostane discontinuation and supportive care, and one dog required continued treatment for hypoadrenocorticism (glucocorticoid and mineralocorticoid) after the acute presentation.

Adverse reactions observed in dogs include:

- Skin: Dermatitis (pruritus, skin rash), haircoat changes, alopecia, skin lesions, seborrhea, rash.
- Integumentary: Hair coat changes, alopecia, skin lesions, seborrhea, rash.
- Gastrointestinal: Vomiting, diarrhea, anorexia, abdominal pain.
- Cardiac: Rare, but possible, include arrhythmias, tachycardia, bradycardia.
- Neurological: Seizures, weakness, tremors, ataxia, behavioral changes.
- Hematological: Anemia, leukopenia, lymphocytosis, thrombocytopenia, elevated liver enzymes.
- Other: Decreased appetite, weight loss, lethargy, inappetence, vomiting, diarrhea, tremors, seizures, dermatitis, alopecia, rash, pruritus, purpura, pyrexia, abdominal pain, weight loss, anorexia, diarrhea, vomiting, skin lesion.

In a long-term follow-up study of dogs in the US effectiveness study, the adverse reactions were similar to the short-term study. Seizures, paralysis, and general paroxysmal signs were most commonly observed. Lethargy, inappetence/anorexia, and weight loss were the most common adverse reactions. In a clinical trial of dogs with adrenocortical insufficiency (AHI), 10 of 11 dogs had post-ACTH serum cortisol levels ≤ 0.3 μg/L. The incidence of any adverse reactions was 100%.

In the US follow-up study of dogs, clinical adverse reactions were reported in 75% of the dogs, with the most common adverse reactions being vomiting, diarrhea, and inappetence. Other adverse reactions included hypoadrenocorticism, weakness, and collapse. These reactions were reported in 43% of the dogs. In a long-term follow-up study of dogs in the US effectiveness study, the adverse reactions were similar to the short-term study.

In a long-term follow-up study of dogs in the US effectiveness study, the adverse reactions were similar to the short-term study. Seizures, paralysis, and general paroxysmal signs were most commonly observed. Lethargy, inappetence/anorexia, and weight loss were the most common adverse reactions. In a clinical trial of dogs with adrenocortical insufficiency (AHI), 10 of 11 dogs had post-ACTH serum cortisol levels ≤ 0.3 μg/L. The incidence of any adverse reactions was 100%.

In the US follow-up study of dogs, clinical adverse reactions were reported in 75% of the dogs, with the most common adverse reactions being vomiting, diarrhea, and inappetence. Other adverse reactions included hypoadrenocorticism, weakness, and collapse. These reactions were reported in 43% of the dogs. In a long-term follow-up study of dogs in the US effectiveness study, the adverse reactions were similar to the short-term study.

In a long-term follow-up study of dogs in the US effectiveness study, the adverse reactions were similar to the short-term study. Seizures, paralysis, and general paroxysmal signs were most commonly observed. Lethargy, inappetence/anorexia, and weight loss were the most common adverse reactions. In a clinical trial of dogs with adrenocortical insufficiency (AHI), 10 of 11 dogs had post-ACTH serum cortisol levels ≤ 0.3 μg/L. The incidence of any adverse reactions was 100%.

In the US follow-up study of dogs, clinical adverse reactions were reported in 75% of the dogs, with the most common adverse reactions being vomiting, diarrhea, and inappetence. Other adverse reactions included hypoadrenocorticism, weakness, and collapse. These reactions were reported in 43% of the dogs. In a long-term follow-up study of dogs in the US effectiveness study, the adverse reactions were similar to the short-term study.
Introducing ... Clinician’s Brief: THE PODCAST

Listen along as we continue the conversation.

The content you love in a new format—listen as host Beckie Mossor, RVT, talks with the authors of your favorite Clinician’s Brief articles. We will dig deeper and explore the conversations behind the content.

Subscribe anywhere you listen to podcasts, visit cliniciansbrief.com/podcasts, or scan the QR code below.

Using QR codes from your mobile device is easy and quick!
Simply focus your phone’s camera on the QR code as if taking a picture (but don’t click!). A notification banner will pop up at the top of your screen; tap the banner to view the linked content.
1. **CONSULT THE EXPERTS** **PAGE 13**
   The most common complication noted with desmopressin therapy is ___________.
   A. Hypernatremia
   B. Hyponatremia
   C. Hyperkalemia
   D. Hypokalemia

2. **DIAGNOSTIC/MANAGEMENT TREE** **PAGE 19**
   Which of the following is **not** true of simple corneal ulcers?
   A. They can occur acutely.
   B. They can occur in any signalment.
   C. Corneal stromal loss is present.
   D. Distinct edges and/or margins are present.

3. **TOP 5** **PAGE 28**
   A positive diascopy result occurs when applied pressure does not result in skin blanching.
   A. True
   B. False

4. **TOP 5** **PAGE 63**
   Which of the following might predispose a dog or cat to otitis externa?
   A. Ear canal hypertrichosis
   B. Familial seborrhea or cerumen gland hyperplasia
   C. Pendulous ears
   D. All of the above

5. **CUTTING EDGE** **PAGE 68**
   Although the best delivery method for mesenchymal stem cell therapy is not yet known, administration is commonly performed _________________.
   A. Subcutaneously
   B. Intramuscularly
   C. Intravenously
   D. Locally to the target tissue

**Answer Key:** 1: B 2: C 3: B 4: D 5: D
Why treat just the signs of canine osteoarthritis when you can proactively treat the disease?

Only Adequan® Canine (polysulfated glycosaminoglycan) empowers you to proactively treat the disease and not just the signs of canine osteoarthritis (OA). In fact, it’s the only FDA-approved injectable, disease-modifying osteoarthritis drug (DMOAD) that inhibits cartilage loss in a dog’s joint.* It may also help to:

• **restore** joint lubrication
• **relieve** inflammation
• **renew** the building blocks of healthy cartilage

*The specific mechanism of action of Adequan® in canine joints is not known. Discover if Adequan® Canine is the right choice for your patients.

The difference between feeling better and getting better.™

Visit adequancanine.com or contact your distributor.

INDICATIONS Adequan® Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.

IMPORTANT SAFETY INFORMATION Adequan® Canine should not be used in dogs who are hypersensitive to PSGAG or who have a known or suspected bleeding disorder. It should be used with caution in dogs with renal or hepatic impairment. Adverse reactions in clinical studies (transient pain at injection site, transient diarrhea, and abnormal bleeding) were mild and self-limiting. In post approval experience, death has been reported in some cases; vomiting, anorexia, depression/lethargy and diarrhea have also been reported. The safe use of PSGAG in breeding, pregnant or lactating dogs has not been evaluated. Please see Full Prescribing Information at adequancanine.com.

1. Adequan Canine Prescribing Information, Rev. 1/18.

Adequan and the Dog Head design are registered trademarks of American Regent, Inc.

© 2019, American Regent, Inc. PP-AC-US-0061 11/2018
TRESADERM® (thiabendazole, dexamethasone, neomycin sulfate solution) Dermatologic Solution

Brief Summary: Before using TRESADERM, please consult the product insert, a summary of which follows: CAUTION: Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian. WARNING: For topical use in dogs and cats. Avoid contact with eyes. Keep this and all drugs out of the reach of children. DESCRIPTION: TRESADERM Dermatologic Solution contains the following active ingredients in units per mL: 40mg thiabendazole, 1mg dexamethasone, 3.2mg neomycin (from neomycin sulfate); and inactive ingredients: glycerin, propylene glycol, purified water, hypophosphorus acid, calcium hypophosphite, about 8.5% ethyl alcohol and about 0.5% benzyl alcohol. INDICATIONS and USAGE: TRESADERM aids in the treatment of certain bacterial, mycotic, and inflammatory dermatoses and otitis externa in dogs and cats. The amount to apply and frequency of treatment are dependent upon the severity and extent of lesions. Five to fifteen drops of TRESADERM should be instilled in the ear twice daily. In treating dermatoses affecting areas other than the ear, the surface of the lesions should be well moistened (2-4 drops per square inch) twice daily. The volume required will be dependent upon the size of the lesion. PRECAUTIONS: Application of TRESADERM should be limited to a period not longer than 1 week. On rare occasions, application of the product may result in erythema or discomfort in the treated area. Erythema of the treated area can last from 24 to 48 hours. When applied to fissured or denuded areas, transient discomfort can follow with the expression of pain usually lasting 2-5 minutes. While systemic side effects are not likely with topically applied corticosteroids, the possibility of such side effects should be considered if use is prolonged or extensive. If signs of salt and water retention or potassium excretion are noticed, such as increased thirst, weakness, lethargy, reduced urine output, gastrointestinal disturbances or increased heart rate, treatment should be discontinued and appropriate measures taken to correct the electrolyte and fluid imbalance. The full FDA-approved product insert can be found at http://www.merial.us/SiteCollectionDocuments/TRESADERM-PI.pdf. For technical assistance, to request a Safety Data Sheet or to report suspected adverse events, call 1-877-217-3543. For additional information about adverse event reporting for animal drugs, contact FDA at 1-888-FDA-VETS, or http://www.fda.gov/AnimalVeterinary.

TRESADERM® is for topical use only in dogs and cats. On rare occasions, application of the product may result in erythema or discomfort in the treated area. Discomfort in the treated area can last from 24 hours to 48 hours.

IMPORTANT SAFETY INFORMATION: TRESADERM is for topical use only in dogs and cats. On rare occasions, application of the product may result in erythema or discomfort in the treated area. Discomfort in the treated area can last from 24 hours to 48 hours.
Managing Canine Hyperadrenocorticism

Once hyperadrenocorticism (HAC) is diagnosed, focus should turn to management. Client education and communication are vital, as clients must monitor for certain clinical signs at home. Successful management often requires a substantial time and financial commitment from clients; however, a decrease in signs can be seen in as little as a few weeks. The following discussion highlights tips for discussing treatment with clients and managing this lifelong endocrinopathy.

Dr. Zimmerman: How do you approach the subject of treatment with clients?

Dr. Lathan: It’s important to emphasize that the goals of treatment for Cushing’s are to control the clinical signs and to prevent negative side effects. I talk to clients about how they are in charge of monitoring their pet and reporting in their journal how the pet is doing at home. Then when they come to see us, we’ll assess that and run tests, mostly to tell us whether the current dose is safe and efficacious or whether we need to adjust it.

Dr. Byers: I usually tell owners there are a lot of therapies available or that have been tried anecdotally, but right now there is only one drug for both pituitary- and adrenal-dependent hyperadrenocorticism that has gone through the extensive FDA approval process, and that is VETORYL Capsules. For the vast majority of patients, that is the drug that I recommend as initial therapy. Where my therapy may change from the labeled q24h dosing in the morning to a lower dose q12h is, for example, when I encounter diabetes in a patient. We’ll discuss that it is an off-label use as well as the benefits and potential risks. But, without question, we start with the FDA-approved drug, VETORYL Capsules.

Dr. Lathan: I don’t really discuss mitotane with owners much anymore, primarily because I think that a major

ABBREVIATIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>HAC</td>
<td>Hyperadrenocorticism</td>
</tr>
<tr>
<td>PD</td>
<td>Polydipsia</td>
</tr>
<tr>
<td>PU</td>
<td>Polyuria</td>
</tr>
<tr>
<td>UTI</td>
<td>Urinary tract infection</td>
</tr>
</tbody>
</table>

PARTICIPANTS

Patty Lathan, VMD, MS, DACVIM (Small Animal)
Associate Professor, Small Animal Internal Medicine
Mississippi State University

Christopher Byers, DVM, DACVECC, DACVIM (Small Animal), CVJ
CriticalCareDVM.com

Brett Wasik, DVM, DACVIM (SAIM)
Endocrinology Fellow
University of California, Davis

MODERATOR

Nancy Zimmerman, DVM
Dechra Veterinary Products
benefit of the FDA-approved drug is that it’s a lot easier for clients and referring veterinarians to understand how to use it and monitor the pet. It doesn’t require teaching about how to break therapy into induction and maintenance phases.

Dr. Wasik: I think veterinarians overall feel more comfortable and safe with trilostane.

Dr. Lathan: Once we have established VETORYL Capsules as the drug of choice, I talk to clients first about dosing. Although the label states starting with once-daily dosing, I feel dogs exhibit regulation more quickly when I start with dosing twice a day. I begin at around 1 mg/kg twice a day. I recognize that the cost of the pills increases when using the drug twice a day: 2 30-mg capsules cost more than one 60-mg capsule. But in the long-term, you’re probably changing the dose less, pursuing less testing, and probably seeing a cost advantage to the point where it all evens out—and we get the patient regulated faster.

We also discuss the side effects. I send clients home with a few doses of dexamethasone oral tablets at 0.1 mg/kg. I tell them that if over the next few days the dog has an episode of vomiting or diarrhea, especially more than once, but is doing okay otherwise, they can call us to make sure they don’t need to come into the hospital. If not, they can give the dexamethasone until our next appointment.

Dr. Wasik: For clients trying to operate on tighter budgets, many dogs will be adequately controlled on the labeled once-a-day recommendation. But there are certain cases, too, where I absolutely want to initiate therapy twice a day: Diabetics and patients with calcinosis cutis tend to do better on twice-a-day dosing. If a client is tending toward euthanasia because he is overwhelmed with the clinical signs and something has to happen right away, twice a day is probably a better idea.

Dr. Byers: There are so many options. Yes, the label dosing frequency is every 24 hours, based on the original FDA study in which 86% of patients completed the study successfully with very happy owners. That’s great, but as with any good therapy, we’ve continued to study it and we have evidence-based data showing a viable option is using a lower-dose, albeit off-label, twice-daily regimen. Anecdotal evidence, similar to published evidence, suggests that dogs actually respond more quickly, to the delight of their owners.

Dr. Lathan: I used to start all patients on once-a-day because my experience was they improved and most clients were happy. Then we started a study that involved giving trilostane twice daily. Patients were relieved of their clinical signs so much faster and dosage changes became less necessary. So now I start them on twice-a-day.

Given that trilostane doesn’t last for 24 hours in the blood, it makes sense that giving it twice a day would work better. But until I saw the clinical change, I didn’t see any point in giving it twice a day because of the cost. I do a 50/50 split between day and night. I’ve heard of people giving a different dose in the morning versus the evening to fit better with the capsule sizes, but patient monitoring should really be after their highest dose.

We ask the owner to call if the dog stops eating or has vomiting or diarrhea. Sometimes within the first couple of days dogs will show a slight decrease in appetite and maybe vomit once or twice. I tell them to make sure that they contact me if so; then we can decide our next
steps. I make sure they understand to contact us if anything emergent is happening.

Dr. Wasik: This is where the critical aspect of a strong technician team comes in. They can be checking in during those first initial days, or a couple of times during the first week, to make sure things are going well. If things are going south, you can intervene sooner rather than later.

Dr. Lathan: I dispense trilostane for 3 weeks and tell clients to come back for a recheck in 2 weeks, and definitely before they run out of medication.

Dr. Byers: I also recheck at 10 to 14 days, at which time they fill out a brief questionnaire, confirming the drug was given that day, that it was given with food, and the time it was given so we can plan a 4- to 6-hour post-pill testing if we are doing the traditional treatment per the FDA label. We also review their journal and obtain a complete patient history and a thorough physical examination. We re-evaluate electrolytes and the biochemical profile. We do have patients come in fasted, with the exclusion of the food they receive with their VETORYL Capsules dose. We evaluate only a post-ACTH stimulation cortisol level as a cost-saving measure.

Dr. Zimmerman: The VETORYL Capsules package insert says the ACTH stimulation test should be done 6 hours after administration. A study by Audrey Cook examined basal cortisol after the medication, and then a recent UK publication looked at basal cortisol before the medication was given. What are some pros and cons of those methods?

Dr. Lathan: Measuring the pre-pill cortisol makes sense in that if the value is above our concern range (eg, >2 µg/dL) and the patient is doing great otherwise, then I think it’s logical that we can continue with the current dose. If the pre-pill cortisol is <2 and the dog is doing great, I think an ACTH stimulation test is needed. The benefit of the pre-pill cortisol is it takes less time and it’s less expensive. The caveat: You cannot identify iatrogenic Addison’s based on its results.

In addition, there are some dogs that may have consistently lower pre-pill cortisols but their post-stim cortisol results are fine. Pre-pill cortisol is probably most useful in patients whose HAC has been successfully controlled and that are undergoing 6-month monitoring. We then know the patient is doing well clinically on the current monitoring. We then just need to determine whether continuing is safe.

I tell referring veterinarians to, for the first few ACTH stimulation tests, have patients come in first thing in the morning (before their dose) and collect blood for a pre-pill cortisol. Then give VETORYL Capsules with food, start an ACTH stimulation test 3 hours after giving VETORYL Capsules, and submit all 3 samples together because 3 samples of cortisol are not much more expensive than 2. They can then look at the trends and see if they would have done anything different based on the pre-pill value. That helps people get more comfortable with actually using the test.

Dr. Byers: Obviously when we’re talking about an FDA-approved drug used in an off-label fashion, we tell owners that and ideally have them sign an informed consent. When you’re using pre-pill cortisol levels or alternative monitoring strategies, not the ACTH stimulation test, which is the label recommendation, how does that conversation go with your clients?

Dr. Lathan: I tell owners and residents that the normal monitoring test can be used, but it takes a bit of time and costs $200 or more. We have begun monitoring a steroid, a cortisol concentration, before your dog gets the medication to see if that tells us that it’s safe to continue the medication. There haven’t been many studies on this yet, but especially if you are having a hard time affording all the testing and the medication together, then this is a way that we can try to decrease the expense and still regulate your dog. There are some pitfalls to this approach, and sometimes we need to do an ACTH stimulation test anyway, but I think this works in the majority of patients.

Dr. Zimmerman: Any other thoughts on monitoring tests?

Dr. Lathan: The most frequent question I get from veterinarians is, “Do we really have to monitor?” Yes, we have to monitor in some way. I understand that people have financial constraints, but we first must do no harm. If we continue a dog on medica-
We have to monitor. If we continue a dog on medication that might be resulting in Addison’s and we haven’t checked it, we are morally and legally liable.

—Dr. Lathan

Dr. Wasik: But here’s the great news. We’ve got multiple modalities by which we can safely monitor most patients: ACTH stimulation, pre-pill cortisol levels, basal cortisol levels. Work with the client to figure out what’s possible. If they’re not able to do any objective monitoring or close monitoring of resolution of clinical signs, they should not be giving the drug.

Dr. Lathan: There are different ways that a patient can develop Addison’s when on trilostane. The first is because trilostane inhibits cortisol production excessively. In these situations, it’s usually temporary: You stop the medication, wait for the clinical signs of HAC to return, ideally measure cortisol prior to restarting the medication at a lower dose, and continue monitoring as usual long-term.

Dr. Zimmerman: When you get your post-ACTH stimulation result after the first dose of trilostane, what is your expectation and next step?

Dr. Lathan: I want to make sure the dog is not Addisonian. The key is making sure that it’s safe to continue. If at the 2-week mark it were below even 2.5 µg/dL, I would probably be nervous because trilostane should have even more effect at 4 weeks at the same dose, so I would worry that at 4 weeks we would bottom out. That isn’t always the case, but it is a worry.

Also, look at clinical signs and specifically ask the owner about water intake and urination. I don’t necessarily change the dose even if it is higher than my ideal stimulation number (2-6 µg/dL). But if it’s 10 at 2 weeks, there is a good chance it will continue coming down. If it’s 20 at 2 weeks, I might increase the dose.

Dr. Wasik: It depends what’s going on clinically. If the dog is dramatically improved, then I’m not so worried about a 20. My preferred cortisol concentration range for dogs with controlled signs is 2 to 6 µg/dL pre- and post-ACTH stimulation.

Dr. Lathan: It also depends on the owner. If he or she is very attentive, you are less worried about a 3.

Dr. Wasik: My sweet spot is approximately >2, <6 at the 2-week mark.

As to clinical signs, patients should be more active. They look like they feel better. The owners perceive that there is a definite improvement, whether in PU, panting, or overall.

Dr. Lathan: Certain patients that are doing better clinically still have PU/PD and are not well controlled. If so, we would increase the dose. But if we just heard it’s doing great we would not. Each clinical sign is really important.

Dr. Zimmerman: So the report from the client is that the patient is doing well with no adverse effects. If you’re happy with the cortisol results, what’s your next step?

Dr. Byers: Repeat the process another month. If all continues to go well, review the patient’s journal, get a patient history, perform the examination, re-evaluate chemistry and electrolytes, and run a post-ACTH stimulation cortisol level.

Dr. Lathan: I often have them come back 2 weeks later, but I’m fine with 2 to 4 weeks after the initial recheck.

Dr. Byers: The more important point in terms of when you have them return is anytime you do decide to make a change to the VETORYL Capsules dose,
see them in 2 weeks. One reason for this is that I want the family to report that there has been an improvement in the clinical signs. But I also want to see the ACTH number to help me gauge if it’s safe to make a dosage adjustment. Clinical signs help me decide whether treatment is effective; the number helps me know whether making needed adjustments is safe.

Dr. Zimmerman: When you do decide to make a dosage adjustment, even if it’s a rare event, what is your typical increase and what do you expect from it?

Dr. Lathan: It depends on 3 things: 1) how bad are the clinical signs, 2) how much are they driving the owner crazy, 3) how high is the pre-pill or post-ACTH stimulation cortisol. If the ACTH value is 8 to 9, maybe a 15% to 20% increase. If the ACTH value is 20, then I might do a little bit more. Pill size is a guiding factor in the adjustment. If I can change to get just one pill twice a day, that would be optimal.

Dr. Wasik: My dose reductions are typically just dropping down a capsule size. I’ve not found this to be too dramatic clinically. I’m a bit more cautious when ramping up the dose. I’ll usually increase the daily dose or one or both of the doses if giving it twice daily by 5 to 10 mg per administration. I’m comfortable taking a dog on 60 mg once a day down to 30 mg if I’m worried I may be pushing too hard with respect to how the cortisol values are trending. How the dog is doing clinically and the cortisol values (emphasis on clinical signs) help me decide. A lot of it is more an “art” than a “science.” From a cost-savings standpoint, I’ve become comfortable just decreasing down to the next pill size, as many dogs I see are still controlled with a 50% dose reduction. Obviously, everyone is less worried about causing a crisis when decreasing the dose versus increasing the dose.

Dr. Byers: It’s important that the decision is based on the individual patient and not on cost. I bring this up because I know many colleagues would reach for a compounded formulation here to save money. While I can appreciate that, it’s just not acceptable.

Dr. Zimmerman: Tell me a little bit more about your thoughts and understanding of compounded trilostane.

Dr. Byers: I am not anti-compounding. I don’t think a veterinarian today can be anti-compounding, but one should follow compounding best practices. One of those is simply a straight up fact: that as a veterinarian no one should compound to save money—period.

If one feels that absolutely an 18.5-mg capsule or a liquid formulation is needed because perhaps an owner is at risk for being bitten and they have immunosuppressive disease themselves, then the compounded formulation should be from the FDA-approved drug, not from the active pharmaceutical ingredient.

If you are using a compounding pharmacy, clients must understand the compound is not a generic drug and that the pharmacy should be approved by the Pharmacy Compounding Accreditation Board. I would never work with a non-accredited pharmacy.

Dr. Lathan: Compounded trilostane from bulk chemical is less consistent, and even though it might be less expensive initially, if you have variations in regulation and you have to keep changing the dose, then that is not less expensive in the long run.

Dr. Zimmerman: Are there any other points you can share about monitoring VETORYL Capsules therapy?

Dr. Lathan: We look to clinical signs to decide whether we need to increase the dose. Then we need to use a cortisol monitoring technique to determine whether it’s safe at the current dose and an increase is safe.

Dr. Wasik: Trends are important, too. Have cortisol values been consistently 1 to 3 for 6 months, or is this the first 1 to 3 result you are seeing? And what’s the overall picture? How’s the dog doing? What is the history? It’s putting all the pieces of the puzzle together versus just trying to make a decision based on one single data point.

Dr. Zimmerman: What are some of the conversations that you have with the client as the dog is being treated? Do they report a notice-
In general, I want the panting, lethargy, and PU/PD to no longer be an issue within 8 to 12 weeks.

—Dr. Byers

able difference in the dog? Do they see the value of the diagnostic procedures and treatment?

Dr. Lathan: The biggest thing that I have reported is the degree of PU/PD. But several have definitely noted that their older dog, who they thought just didn’t play with toys anymore because of age, is playing again, or who would stay right beside the owner during walks previously will now wander off more energetically and show interest in the surroundings. One of my friends actually said that in hindsight she was pretty certain that her dog had been depressed, which is interesting because it is such a common finding in people that have HAC.

Dr. Byers: The difference clients see in pets is very important. I’ve had many pet owners tell me that they had started to resent their dog from always having to fill the water bowl, clean up urinary accidents, return to my office repeatedly for various problems, be woken during the night by the dog’s panting.

All that stops once therapy is initiated. The bond between owner and dog is restored. They don’t care about having to give the pet medication; they actually look forward to doing it because the annoyances have stopped. It is an overall positive experience for owners.

Dr. Lathan: When owners come in the first time, you can tell they are at wit’s end. They love their dog, but they are not the most enthusiastic. But when the clinical signs have improved, you can just tell they are happier people overall. No more sleep deprivation!

Dr. Byers: In some dogs, it takes 4 to 6 weeks to start seeing improvement. Those clients are a bit grumpier about having to go through the whole process.

With lethargy, just about anything can cause it, so it does not always respond to treatment. But improvement in activity, responsiveness, and interaction with the family coupled with reduced panting makes for a happy client.

Dr. Zimmerman: How quickly do owners report a change in polyuria and panting?

Dr. Wasik: Usually pretty quickly, within a week or 2. The panting seems to respond most quickly in my experience, followed by lethargy. PU may take a bit longer.

Dr. Lathan: I would say exactly the opposite. I feel the PU/PD and attitude improve within the first 2 to 4 weeks, whereas the panting takes a month or 2 to really get under control.

Dr. Zimmerman: Could that be related to their weight? Is the panting worse in severely obese dogs, and does it improve as they start losing weight?

Dr. Lathan: There is more panting in the more obese dogs. The answer to whether it gets better as they lose weight is kind of difficult because they are losing weight as they have more treatment, so I don’t know whether it’s the weight loss or the treatment itself.

Dr. Zimmerman: What do you tell clients about how long it’s going to take for their dogs to start to feel better with treatment?

Dr. Byers: Effective treatment requires the owner to be an active participant. I need owners to keep a journal because what they record and bring to me at each recheck is just as important as a number on paper. In general, I want the panting, lethargy, and PU/PD to no longer be an
issue within 8 to 12 weeks. I do tell them that some dogs will see unusual improvement within 2 weeks, and that is supported by the initial FDA trial of VETORYL Capsules, but I try not to set unrealistic expectations. For dermatologic manifestations, I set an expectation of 4 to 6 months.

Dr. Lathan: I tell clients to expect at least 6 months for dermatologic resolution to begin. In general, I tell them not to expect any significant changes in any sign for at least a month. Then they are pleasantly surprised if something happens in a week or 2.

I agree about keeping a journal. Monitoring clinical signs is more important than numbers, as long as the numbers are in a safe range. For that reason, I think it’s really helpful to have clients fill out a questionnaire regarding the severity of the clinical signs at every visit. Then you can show them the difference over time.

Dr. Byers: Clients like to keep the journal. They feel that they are an active participant in their pet’s care.

Dr. Lathan: They do enjoy doing the journal! Those who are most engaged in their pet’s treatment and progression like it best.

Dr. Zimmerman: What are some of the most common concerns that pet owners voice about therapy for HAC?

Dr. Wasik: That they are going to kill their dog with therapy. Because of Dr. Google or Facebook groups, they have some information and seem to be scared to treat before they even walk in the door.

Dr. Lathan: I find it helps to explain that we are using lower doses of trilostane these days than is reflected in many consumer sources.

Dr. Zimmerman: We talked about recurrent infections. How do you handle such secondary conditions, and what expectations do you set for the client?

Dr. Wasik: Although usually less likely in the age group that develops hyperadrenocorticism, if T4 levels remain low despite improvement in clinical signs, particularly if hair is not growing back to the owner’s satisfaction, screening further for hypothyroidism may be appropriate. I generally instruct veterinarians to suspend any thyroid testing until we get the HAC under better control. I try to be minimalistic with regard to systemic antimicrobials during that time, which helps in preventing development of methicillin resistance. Then if 3, 4, 5 months down the line we are still having some dermatologic problems or the hair is not growing and the T4 is still low, I consider a more extensive profile, especially if any hypercholesterolemia isn’t improving either.

Dr. Lathan: In patients with dermatologic signs, especially if they have infections or atopy on top of that, I sometimes think that the excess cortisol has been decreasing the inflammation, so when you start treatment, they may have exacerbation. We need to warn owners about this phenomenon and then come up with a treatment plan for those affected. I usually consult with our dermatologist.

Dr. Zimmerman: Do you ever find in dogs with recurrent infections that once the hyperadrenocorticism is stabilized the infection responds as expected to topical or systemic therapy?

Dr. Byers: Yes. I see more UTIs than bacterial pyoderma. With effective management of hypercortisolemia, the recurrence of UTIs is dramatically reduced. You will have patients that develop a hardy biofilm in the urinary bladder, and those are more challenging. But, at least in my experience, that has not been common.

Dr. Wasik: I don’t know if the infection is eradicated. But instead of an incident every couple of months, maybe the dog has a couple per year.

Dr. Zimmerman: Are there any other pitfalls that can occur beyond just monitoring for this disease? When you are treating the patient for other things that come up in its life, like common drug interactions or otherwise?

Dr. Byers: If you are dealing with a concurrent endocrine combination like Cushing’s and diabetes, you have to prepare the client for the inevitability that

It’s important that the decision is based on the individual patient and not on cost. I know many of my colleagues would reach for a compounded formulation here to save money. While I can appreciate that, it’s just not acceptable.

—Dr. Byers
the patient’s insulin requirements are going to drop—and if you don’t prepare them and empower them with tactics to address it, or if you just keep the insulin dose the same as you are addressing the hypercortisolemia, prepare the team for an iatrogenic hypoglycemic event. I ask them to monitor urine glucose on a daily basis around the same time of day and I give them guidelines by which to adjust their insulin dose.

Dr. Zimmerman: What do you see more commonly: the diabetic who then gets Cushing’s, or the Cushing’s who then becomes diabetic?

Dr. Lathan: I feel like we definitely see both of them. They were probably cushingoid before we diagnosed the diabetes as well. I don’t think it’s that Cushing’s came afterwards—I think the Cushing’s had been there all the time.

One drug side effect to note is with ketoconazole: You do not want to give ketoconazole concurrently with trilostane, as this can precipitate hypocortisolism.

Dr. Zimmerman: Many of these patients are also overweight and they tend to have a lot of abdominal fat. Do you ever recommend a weight loss diet or a diet change?

Dr. Lathan: I try to prescribe a metabolic and mobility diet for every single one.

Dr. Byers: I take a more human–animal bond approach. If an overweight or obese human’s physician tells her to get more exercise, the likelihood of her doing so is low. If you tell her that her dog needs to lose weight and needs to achieve at least 30 minutes of exercise per day so the dog loses weight, she is going to do it. I counsel to increase their activity level and feed 5% to 10% less per day (and help them with a calculation), but I don’t change the diet.

Dr. Lathan: Some of these dogs also have joint disease. We start treating them for Cushing’s, and their joint disease can worsen because the anti-inflammatory effects of cortisol are decreased, so I use a metabolic and mobility diet with other joint supplements, which, to me, is an ideal combination.

Dr. Byers: I’m always hesitant to change diets because I’m concerned the patient is going to develop food aversion. However, a potential negative effect of my approach includes a regular comment of, “She’s just staring at me. She wants the food.” We encourage clients to use that time to further enhance the human–animal bond: Go do an activity with the pet and get food off the mind. Now they’re getting more exercise, expending more calories, and, theoretically, improving the bond.

Dr. Zimmerman: Are there any major developments other than necrosis that you see when you’re treating dogs with Cushing’s?

Dr. Lathan: I have learned, with all endocrinopathies, not to micromanage or rely so much on the numbers and to put the focus back on treating patients, addressing clinical signs, and monitoring to avoid causing harm. If the clinical signs are well-controlled, even if the number is a little higher than the norm, don’t adjust the dose.
REAL-WORLD VETERINARY CE
in an out-of-this-world setting

REGISTER BEFORE JUNE 28 FOR $349 $499 WITH CODE CB1
With 200+ hours of RACE-approved CE presented by 40+ internationally recognized speakers, Wild West Vet 2019 is an exciting new approach to an already successful event.

Wild West Vet offers practical, real-world CE for real-world veterinary professionals. More than 80% of Vet Shows attendees report putting their new knowledge into practice within 2 weeks after the event. Regardless of your area of practice—or your role in it—Wild West Vet has the sessions and speakers you need to enhance your skills.

You’ll definitely want to experience this fresh format for yourself! The sooner you book, the more you save: Prices increase as the conference date approaches.

The 2019 show offers numerous staggered sessions, allowing you to explore a much wider range of topics and sessions and learn from numerous experts. Our enhanced conference format offers high-quality content and a larger group of fellow veterinary professionals to network with. Of course, the amazing setting in Reno, Nevada, a mere 30 minutes from the stunning Lake Tahoe, has remained the same.

Register now at wildwest.vetshow.com or call (646) 437-9080

October 23–26, 2019 • Grand Sierra Resort in Reno, NV

$349*  

*WITH PROMO CODE CB1 expires June 28
Khursheed Mama, DVM, DACVAA (Anesthesia & Analgesia)
Professor, Veterinary Anesthesiology at Colorado State University
Dr. Mama pursued an anesthesia and critical care residency at University of California, Davis, and worked at UC Davis for 3 years before moving to Colorado State University in 1996. She enjoys working with a variety of species while also teaching DVM and graduate students and has pursued research interests directed at improving patient care and safety.

Denis Marcellin-Little, DEDV, DACVS, DECVS, DACVSMR (Orthopedics)
Professor, Surgical and Radiological Sciences at University of California, Davis
Dr. Marcellin-Little is a diplomate of the American and European Colleges of Veterinary Surgeons and a charter diplomate of the American College of Veterinary Sports Medicine and Rehabilitation. His research focuses on the management of complex orthopedic problems, including joint replacement and the management of limb deformities.

Mary Gardner, DVM (Geriatrics)
Cofounder and CTO, Lap of Love Veterinary Hospice
Dr. Gardner's professional goal is to increase awareness and medical care for the geriatric veterinary patient and to help make the final life stage as peaceful as possible. She is the cofounder and CTO of Lap of Love, which has over 130 veterinarians around the country dedicated to in-home end-of-life care.

Meredyth Jones, DVM, MS, DACVIM (Small Ruminants)
Associate Professor at Oklahoma State University
Owner of Large Animal Consulting & Education
Dr. Jones earned her DVM from Oklahoma State University in 2002, later completing a residency in large animal internal medicine with an emphasis on food animals and earning an MS degree in veterinary biomedical sciences at Oklahoma State University. She is the owner of an online continuing education company and joined the food animal faculty at Oklahoma State in the fall of 2018.

Darci Palmer, BS, LVT, VTS (Anesthesia & Analgesia)
Veterinary Anesthetist, Southeastern Veterinary Surgery Center
Darci has been a credentialed veterinary technician since 2000. She became certified as a VTS in anesthesia and analgesia in 2006 and currently holds the executive secretary position for the Academy of Veterinary Technicians in Anesthesia and Analgesia (AVTAA). She also serves on the Committee of Veterinary Technician Specialists (CVTS). Darci is a board moderator and CE instructor for the Veterinary Support Personnel Network (VSPN) and has lectured at several veterinary conferences.

Find the entire speaker selection at wildwest.vetshow.com.
<table>
<thead>
<tr>
<th>Time</th>
<th>Theater</th>
<th>Session</th>
<th>Speaker Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 AM</td>
<td>TAHOE</td>
<td>Cat Corneas: FHV-1 &amp; More</td>
<td>Thomas Chen</td>
</tr>
<tr>
<td>8:45 AM</td>
<td>CARSON 2</td>
<td>“It’s Okay… Be Nice…” Canine Aggression During Veterinary Visits</td>
<td>Waiani Song</td>
</tr>
<tr>
<td>9:00 AM</td>
<td>CARSON 3</td>
<td>Follow Your Heart: The Essential Cardiology Examination</td>
<td>Kursten Pierce</td>
</tr>
<tr>
<td>9:45 AM</td>
<td>TAHOE</td>
<td>No Hydro? No Problem! Alternatives for Perioperative Pain Management</td>
<td>Khursheed Mama</td>
</tr>
<tr>
<td>10:45 AM</td>
<td>CARSON 2</td>
<td>Survival Guide to Managing Chronic Ophthalmic Conditions</td>
<td>Thomas Chen</td>
</tr>
<tr>
<td>11:00 AM</td>
<td>CARSON 1</td>
<td>Tips &amp; Tricks for Oral &amp; Dental Emergencies in General Practice</td>
<td>Speaker details</td>
</tr>
</tbody>
</table>
| 1:00 PM      | CARSON 1| Start Now! Tibial & Radial Fracture Repair in Dogs in Daily Practice                        | Denis Marcellin-
| 1:15 PM      | CARSON 3| Haven’t Got Time for the Pain: Prevention & Treatment of Dental Extraction Complications     | Little        |
| 1:30 PM      | CARSON 3| Fiery Felines: How to Handle Your Aggressive Feline Patients                                 | Speaker details |
| 2:15 PM      | CARSON 1| Clinical Pathology Bootcamp: Immunology Under the Microscope                                | Speaker details |
| 2:45 PM      | CARSON 2| Start Now! Veterinary Rehabilitation for Common Orthopedic Conditions                         | Speaker details |
| 4:45 PM      | CARSON 2| What's Next in Adnexal Procedures?                                                            | Thomas Chen     |
| 4:45 PM      | CARSON 3| Come Fly With Me: Avian Parasitology                                                          | Speaker details |
| 5:00 PM      | CARSON 1| Paranoid! How to Manage the Paranoid Patient                                                 | Dan Johnson     |

Program subject to change.
<table>
<thead>
<tr>
<th>BUSINESS THEATER</th>
<th>VETERINARY NURSING THEATER</th>
<th>APHIS, EQUINE, &amp; FARM</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRYSTAL 1-2</td>
<td>CRYSTAL 3-4</td>
<td>CRYSTAL 5</td>
</tr>
<tr>
<td>9:10 AM – 10:00 AM</td>
<td>Keep Your Cool: Handling the Top 3 Emergencies in Practice</td>
<td>9:10 AM – 10:00 AM</td>
</tr>
<tr>
<td>Recruitment Strategies</td>
<td>Louise Dunn Founder and CEO Snowgoose Veterinary Management Consulting</td>
<td>Module 5: Vesicular Diseases</td>
</tr>
<tr>
<td>Louise Dunn Founder and CEO Snowgoose Veterinary Management Consulting</td>
<td>Courtney Maxman CVT, VTS (ECC) Instructional Technologist Purdue University</td>
<td></td>
</tr>
<tr>
<td>11:30 AM – 12:20 PM</td>
<td>The Role of Technicians in Veterinary Behavioral Medicine</td>
<td>10:20 AM – 11:10 AM</td>
</tr>
<tr>
<td>Top Tips for Employee Retention</td>
<td>Louise Dunn Founder and CEO Snowgoose Veterinary Management Consulting</td>
<td>Module 30: The Role of Veterinarians in Honey Bee Health</td>
</tr>
<tr>
<td>Louise Dunn Founder and CEO Snowgoose Veterinary Management Consulting</td>
<td>Monique Feyrecilde BA, LVT, VTS (Behavior) Founder Teaching Animals</td>
<td></td>
</tr>
<tr>
<td>1:30 PM – 2:20 PM</td>
<td>Desert Dangers: Heatstroke</td>
<td>11:30 AM – 12:20 PM</td>
</tr>
<tr>
<td>3:50 PM – 4:40 PM</td>
<td>Risky Personnel Practices You Are Doing Every Day</td>
<td>Module 29: Veterinary Feed Directive</td>
</tr>
<tr>
<td>Karl Salzieder DVM, JD, CVA Valuation Analyst Total Practice Solutions Group</td>
<td>Courtney Maxman CVT, VTS (ECC) Instructional Technologist Purdue University</td>
<td></td>
</tr>
<tr>
<td>3:50 PM – 4:40 PM</td>
<td>Bites &amp; Scratches &amp; Bruises, No More! Fear-Free Animal Handling</td>
<td>1:00 PM – 1:50 PM</td>
</tr>
<tr>
<td>6:00 PM – 7:40 PM</td>
<td>Bites &amp; Scratches &amp; Bruises, No More! Fear-Free Animal Handling</td>
<td>Module 23: Antibiotic Use in Animals</td>
</tr>
<tr>
<td>Session Delivered by Total Practice Solutions Group</td>
<td>Monique Feyrecilde BA, LVT, VTS (Behavior) Founder Teaching Animals</td>
<td></td>
</tr>
<tr>
<td>1:30 PM – 2:20 PM</td>
<td>Desert Dangers: Heatstroke</td>
<td>2:10 PM – 3:00 PM</td>
</tr>
<tr>
<td>Module 9: Interstate &amp; International Health Certificates for Category I Animals</td>
<td>3:20 PM – 4:10 PM</td>
<td></td>
</tr>
<tr>
<td>2:10 PM – 3:00 PM</td>
<td>Module 11: Sheep &amp; Goat Diseases &amp; Health Certificates</td>
<td>3:20 PM – 4:10 PM</td>
</tr>
<tr>
<td>3:20 PM – 4:10 PM</td>
<td>Module 11: Sheep &amp; Goat Diseases &amp; Health Certificates</td>
<td>3:20 PM – 4:10 PM</td>
</tr>
<tr>
<td>10:20 AM – 11:10 AM</td>
<td>Module 30: The Role of Veterinarians in Honey Bee Health</td>
<td>3:20 PM – 4:10 PM</td>
</tr>
<tr>
<td>11:30 AM – 12:20 PM</td>
<td>Module 29: Veterinary Feed Directive</td>
<td>1:00 PM – 1:50 PM</td>
</tr>
<tr>
<td>1:30 PM – 2:20 PM</td>
<td>Desert Dangers: Heatstroke</td>
<td>2:10 PM – 3:00 PM</td>
</tr>
<tr>
<td>2:10 PM – 3:00 PM</td>
<td>Module 23: Antibiotic Use in Animals</td>
<td>3:20 PM – 4:10 PM</td>
</tr>
<tr>
<td>3:20 PM – 4:10 PM</td>
<td>Module 11: Sheep &amp; Goat Diseases &amp; Health Certificates</td>
<td>3:20 PM – 4:10 PM</td>
</tr>
<tr>
<td>3:20 PM – 4:10 PM</td>
<td>Module 11: Sheep &amp; Goat Diseases &amp; Health Certificates</td>
<td>3:20 PM – 4:10 PM</td>
</tr>
<tr>
<td>10:20 AM – 11:10 AM</td>
<td>Module 30: The Role of Veterinarians in Honey Bee Health</td>
<td>3:20 PM – 4:10 PM</td>
</tr>
<tr>
<td>11:30 AM – 12:20 PM</td>
<td>Module 29: Veterinary Feed Directive</td>
<td>1:00 PM – 1:50 PM</td>
</tr>
<tr>
<td>1:30 PM – 2:20 PM</td>
<td>Desert Dangers: Heatstroke</td>
<td>2:10 PM – 3:00 PM</td>
</tr>
<tr>
<td>2:10 PM – 3:00 PM</td>
<td>Module 23: Antibiotic Use in Animals</td>
<td>3:20 PM – 4:10 PM</td>
</tr>
<tr>
<td>3:20 PM – 4:10 PM</td>
<td>Module 11: Sheep &amp; Goat Diseases &amp; Health Certificates</td>
<td>3:20 PM – 4:10 PM</td>
</tr>
<tr>
<td>3:20 PM – 4:10 PM</td>
<td>Module 11: Sheep &amp; Goat Diseases &amp; Health Certificates</td>
<td>3:20 PM – 4:10 PM</td>
</tr>
</tbody>
</table>

REGISTER FOR $349 WITH CODE CB1

REGISTRATION IS SIMPLE!

- Register online at [wildwest.vetshow.com](http://wildwest.vetshow.com)
- Call us at (646) 437-9080
- Email us at [wildwestvet@closerstillmedia.com](mailto:wildwestvet@closerstillmedia.com)

Price offer expires June 28, 2019.
<table>
<thead>
<tr>
<th>Time</th>
<th>THEATER</th>
<th>SPEAKER NAME</th>
<th>POSITION/INSTITUTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 AM – 8:50 AM</td>
<td><strong>TAHOE ROOM</strong></td>
<td><strong>Rebecca Windsor</strong></td>
<td>DVM, DACVIM (Neurology/Neurosurgery) Specialist, Wheat Ridge Animal Hospital</td>
</tr>
<tr>
<td>8:15 AM – 9:00 AM</td>
<td><strong>Clinical Theater 2</strong></td>
<td><strong>Khursheed Mama</strong></td>
<td>DVM, DACVIM, Professor, Anesthesiology, Colorado State University</td>
</tr>
<tr>
<td>8:30 AM – 9:00 AM</td>
<td><strong>Clinical Theater 3</strong></td>
<td><strong>Karl Salzsieder</strong></td>
<td>DVM, JD, CVA, Valuation Analyst, Total Practice Solutions Group</td>
</tr>
<tr>
<td>9:15 AM – 10:05 AM</td>
<td><strong>Clinical Theater 2</strong></td>
<td><strong>Kursten Pierce</strong></td>
<td>DVM, DACVIM (Cardiology) Veterinary Specialist, James L. Voss Veterinary Teaching Hospital, Colorado State University</td>
</tr>
<tr>
<td>9:15 AM – 10:05 AM</td>
<td><strong>Clinical Theater 2</strong></td>
<td><strong>Speaker details to come.</strong></td>
<td>-</td>
</tr>
<tr>
<td>9:15 AM – 10:05 AM</td>
<td><strong>Clinical Theater 3</strong></td>
<td><strong>Speaker details to come.</strong></td>
<td>-</td>
</tr>
<tr>
<td>9:15 AM – 10:05 AM</td>
<td><strong>Clinical Theater 3</strong></td>
<td><strong>Narda Robinson</strong></td>
<td>DO, DVM, MS, FAAMA, President and CEO, CuraCore Integrative Medicine and Education Center</td>
</tr>
<tr>
<td>10:15 AM – 10:55 AM</td>
<td><strong>Clinical Theater 2</strong></td>
<td><strong>Speaker details to come.</strong></td>
<td>-</td>
</tr>
<tr>
<td>10:15 AM – 10:55 AM</td>
<td><strong>Clinical Theater 3</strong></td>
<td><strong>Speaker details to come.</strong></td>
<td>-</td>
</tr>
<tr>
<td>10:15 AM – 10:55 AM</td>
<td><strong>Clinical Theater 3</strong></td>
<td><strong>Linda Kidd</strong></td>
<td>DVM, PhD, DACVIM, Associate Professor, Small Animal Internal Medicine, Western University of Health Sciences</td>
</tr>
<tr>
<td>10:55 AM – 11:35 AM</td>
<td><strong>Clinical Theater 2</strong></td>
<td><strong>Bonnie Campbell</strong></td>
<td>DVM, PhD, DACVS, Clinical Associate Professor, Washington State University</td>
</tr>
<tr>
<td>10:55 AM – 11:35 AM</td>
<td><strong>Clinical Theater 3</strong></td>
<td><strong>Speaker details to come.</strong></td>
<td>-</td>
</tr>
<tr>
<td>10:55 AM – 11:35 AM</td>
<td><strong>Clinical Theater 3</strong></td>
<td><strong>Linda Kidd</strong></td>
<td>DVM, PhD, DACVIM, Associate Professor, Small Animal Internal Medicine, Western University of Health Sciences</td>
</tr>
<tr>
<td>11:35 AM – 12:15 PM</td>
<td><strong>Clinical Theater 2</strong></td>
<td><strong>Denis Marcellin-Little</strong></td>
<td>DEIV, DACVS, DECVS, DAVSMSR, Professor, Surgical and Radiological Sciences, University of California, Davis</td>
</tr>
<tr>
<td>11:35 AM – 12:15 PM</td>
<td><strong>Clinical Theater 3</strong></td>
<td><strong>Anthony Pease</strong></td>
<td>DVM, MS, DACVR, Chief Veterinary Medical Officer, WVC</td>
</tr>
<tr>
<td>11:35 AM – 12:15 PM</td>
<td><strong>Clinical Theater 3</strong></td>
<td><strong>Speaker details to come.</strong></td>
<td>-</td>
</tr>
<tr>
<td>11:35 AM – 12:15 PM</td>
<td><strong>Clinical Theater 3</strong></td>
<td><strong>Linda Kidd</strong></td>
<td>DVM, PhD, DACVIM, Associate Professor, Small Animal Internal Medicine, Western University of Health Sciences</td>
</tr>
<tr>
<td>12:15 PM – 1:15 PM</td>
<td><strong>Clinical Theater 3</strong></td>
<td><strong>Speaker details to come.</strong></td>
<td>-</td>
</tr>
<tr>
<td>12:15 PM – 1:15 PM</td>
<td><strong>Clinical Theater 3</strong></td>
<td><strong>Linda Kidd</strong></td>
<td>DVM, PhD, DACVIM, Associate Professor, Small Animal Internal Medicine, Western University of Health Sciences</td>
</tr>
<tr>
<td>1:15 PM – 1:55 PM</td>
<td><strong>Clinical Theater 2</strong></td>
<td><strong>Julia Albright</strong></td>
<td>DVM, MA, DACVB, Associate Professor, Small Animal Clinical Sciences, University of Tennessee</td>
</tr>
<tr>
<td>1:15 PM – 1:55 PM</td>
<td><strong>Clinical Theater 2</strong></td>
<td><strong>Speaker details to come.</strong></td>
<td>-</td>
</tr>
<tr>
<td>1:15 PM – 1:55 PM</td>
<td><strong>Clinical Theater 2</strong></td>
<td><strong>Anthony Pease</strong></td>
<td>DVM, MS, DACVR, Chief Veterinary Medical Officer, WVC</td>
</tr>
<tr>
<td>1:15 PM – 1:55 PM</td>
<td><strong>Clinical Theater 3</strong></td>
<td><strong>Speaker details to come.</strong></td>
<td>-</td>
</tr>
<tr>
<td>1:15 PM – 1:55 PM</td>
<td><strong>Clinical Theater 3</strong></td>
<td><strong>Linda Kidd</strong></td>
<td>DVM, PhD, DACVIM, Associate Professor, Small Animal Internal Medicine, Western University of Health Sciences</td>
</tr>
<tr>
<td>1:55 PM – 2:35 PM</td>
<td><strong>Clinical Theater 2</strong></td>
<td><strong>Elaine Blythe</strong></td>
<td>PharmD, Associate Professor, Veterinary Pharmacology, St. Matthews University School of Veterinary Medicine</td>
</tr>
<tr>
<td>1:55 PM – 2:35 PM</td>
<td><strong>Clinical Theater 2</strong></td>
<td><strong>Speaker details to come.</strong></td>
<td>-</td>
</tr>
<tr>
<td>1:55 PM – 2:35 PM</td>
<td><strong>Clinical Theater 2</strong></td>
<td><strong>Bonnie Campbell</strong></td>
<td>DVM, PhD, DACVS, Clinical Associate Professor, Washington State University</td>
</tr>
<tr>
<td>1:55 PM – 2:35 PM</td>
<td><strong>Clinical Theater 2</strong></td>
<td><strong>Anthony Pease</strong></td>
<td>DVM, MS, DACVR, Chief Veterinary Medical Officer, WVC</td>
</tr>
<tr>
<td>2:35 PM – 3:15 PM</td>
<td><strong>Clinical Theater 2</strong></td>
<td><strong>Linda Kidd</strong></td>
<td>DVM, PhD, DACVIM, Associate Professor, Small Animal Internal Medicine, Western University of Health Sciences</td>
</tr>
<tr>
<td>2:35 PM – 3:15 PM</td>
<td><strong>Clinical Theater 2</strong></td>
<td><strong>Speaker details to come.</strong></td>
<td>-</td>
</tr>
<tr>
<td>2:35 PM – 3:15 PM</td>
<td><strong>Clinical Theater 2</strong></td>
<td><strong>Anthony Pease</strong></td>
<td>DVM, MS, DACVR, Chief Veterinary Medical Officer, WVC</td>
</tr>
<tr>
<td>2:35 PM – 3:15 PM</td>
<td><strong>Clinical Theater 2</strong></td>
<td><strong>Speaker details to come.</strong></td>
<td>-</td>
</tr>
<tr>
<td>3:15 PM – 3:55 PM</td>
<td><strong>Clinical Theater 2</strong></td>
<td><strong>Linda Kidd</strong></td>
<td>DVM, PhD, DACVIM, Associate Professor, Small Animal Internal Medicine, Western University of Health Sciences</td>
</tr>
<tr>
<td>3:15 PM – 3:55 PM</td>
<td><strong>Clinical Theater 2</strong></td>
<td><strong>Speaker details to come.</strong></td>
<td>-</td>
</tr>
<tr>
<td>3:15 PM – 3:55 PM</td>
<td><strong>Clinical Theater 2</strong></td>
<td><strong>Anthony Pease</strong></td>
<td>DVM, MS, DACVR, Chief Veterinary Medical Officer, WVC</td>
</tr>
<tr>
<td>3:55 PM – 4:35 PM</td>
<td><strong>Clinical Theater 2</strong></td>
<td><strong>Linda Kidd</strong></td>
<td>DVM, PhD, DACVIM, Associate Professor, Small Animal Internal Medicine, Western University of Health Sciences</td>
</tr>
<tr>
<td>3:55 PM – 4:35 PM</td>
<td><strong>Clinical Theater 2</strong></td>
<td><strong>Speaker details to come.</strong></td>
<td>-</td>
</tr>
<tr>
<td>3:55 PM – 4:35 PM</td>
<td><strong>Clinical Theater 2</strong></td>
<td><strong>Anthony Pease</strong></td>
<td>DVM, MS, DACVR, Chief Veterinary Medical Officer, WVC</td>
</tr>
<tr>
<td>4:35 PM – 5:15 PM</td>
<td><strong>Clinical Theater 2</strong></td>
<td><strong>Linda Kidd</strong></td>
<td>DVM, PhD, DACVIM, Associate Professor, Small Animal Internal Medicine, Western University of Health Sciences</td>
</tr>
<tr>
<td>4:35 PM – 5:15 PM</td>
<td><strong>Clinical Theater 2</strong></td>
<td><strong>Speaker details to come.</strong></td>
<td>-</td>
</tr>
<tr>
<td>4:35 PM – 5:15 PM</td>
<td><strong>Clinical Theater 2</strong></td>
<td><strong>Anthony Pease</strong></td>
<td>DVM, MS, DACVR, Chief Veterinary Medical Officer, WVC</td>
</tr>
<tr>
<td>5:15 PM – 5:30 PM</td>
<td><strong>Clinical Theater 2</strong></td>
<td><strong>Linda Kidd</strong></td>
<td>DVM, PhD, DACVIM, Associate Professor, Small Animal Internal Medicine, Western University of Health Sciences</td>
</tr>
<tr>
<td>5:15 PM – 5:30 PM</td>
<td><strong>Clinical Theater 2</strong></td>
<td><strong>Speaker details to come.</strong></td>
<td>-</td>
</tr>
<tr>
<td>5:15 PM – 5:30 PM</td>
<td><strong>Clinical Theater 2</strong></td>
<td><strong>Anthony Pease</strong></td>
<td>DVM, MS, DACVR, Chief Veterinary Medical Officer, WVC</td>
</tr>
<tr>
<td>5:30 PM – 6:00 PM</td>
<td><strong>Clinical Theater 2</strong></td>
<td><strong>Linda Kidd</strong></td>
<td>DVM, PhD, DACVIM, Associate Professor, Small Animal Internal Medicine, Western University of Health Sciences</td>
</tr>
<tr>
<td>5:30 PM – 6:00 PM</td>
<td><strong>Clinical Theater 2</strong></td>
<td><strong>Speaker details to come.</strong></td>
<td>-</td>
</tr>
<tr>
<td>5:30 PM – 6:00 PM</td>
<td><strong>Clinical Theater 2</strong></td>
<td><strong>Anthony Pease</strong></td>
<td>DVM, MS, DACVR, Chief Veterinary Medical Officer, WVC</td>
</tr>
<tr>
<td>6:00 PM – 7:00 PM</td>
<td><strong>Clinical Theater 2</strong></td>
<td><strong>Linda Kidd</strong></td>
<td>DVM, PhD, DACVIM, Associate Professor, Small Animal Internal Medicine, Western University of Health Sciences</td>
</tr>
<tr>
<td>6:00 PM – 7:00 PM</td>
<td><strong>Clinical Theater 2</strong></td>
<td><strong>Speaker details to come.</strong></td>
<td>-</td>
</tr>
<tr>
<td>6:00 PM – 7:00 PM</td>
<td><strong>Clinical Theater 2</strong></td>
<td><strong>Anthony Pease</strong></td>
<td>DVM, MS, DACVR, Chief Veterinary Medical Officer, WVC</td>
</tr>
</tbody>
</table>
## THURSDAY, OCTOBER 24, 2019 | THEATERS

### BUSINESS THEATER  CRYSTAL 1-2

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:10 AM – 10:00 AM</td>
<td>Caregiver Burden &amp; Relief: When Loving Hurts</td>
<td>Mary Gardner DVM, Cofounder and CTO Lap of Love Veterinary Hospice</td>
</tr>
<tr>
<td>10:20 AM – 11:10 AM</td>
<td>Driving Financial Success</td>
<td>Karen Felsted CPA, MS, DVM, CVFHM, CVPH, CVA, Founder and President PanteraT</td>
</tr>
<tr>
<td>11:30 AM – 12:20 PM</td>
<td>Workplace Happiness: Is It Possible?</td>
<td>Mary Gardner DVM, Cofounder and CTO Lap of Love Veterinary Hospice</td>
</tr>
<tr>
<td>1:30 PM – 2:20 PM</td>
<td>Using Effective Pricing Strategies</td>
<td>Karen Felsted CPA, MS, DVM, CVFHM, CVPH, CVA, Founder and President PanteraT</td>
</tr>
<tr>
<td>2:40 PM – 3:30 PM</td>
<td>Get Your Veterinary Groove Back</td>
<td>Mary Gardner DVM, Cofounder and CTO Lap of Love Veterinary Hospice</td>
</tr>
</tbody>
</table>

### VETERINARY NURSING THEATER  CRYSTAL 3-4

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:10 AM – 10:00 AM</td>
<td>Minutes Count: Traumatic Brain Injury</td>
<td>Courtney Waxman CVT, VTS (ECC) Instructional Technologist Purdue University</td>
</tr>
<tr>
<td>10:20 AM – 11:10 AM</td>
<td>Behavior Essentials: Preventive Care for Puppies &amp; Kittens</td>
<td>Monique Feyrecide BA, LVT, VTS (Behavior) Founder Teaching Animals</td>
</tr>
<tr>
<td>11:30 AM – 12:20 PM</td>
<td>The Perils of Parasites: How to Protect More Patients</td>
<td>Beckie Mossor RVT Director of Operations 3K3 Working Dogs, Inc</td>
</tr>
<tr>
<td>1:30 PM – 2:20 PM</td>
<td>Dr. Dolittle Is on Duty! Communicating With Animals the Fear-Free Way</td>
<td>Monique Feyrecide BA, LVT, VTS (Behavior) Founder Teaching Animals</td>
</tr>
<tr>
<td>2:40 PM – 3:30 PM</td>
<td>Desert Dangers: Rattlesnake Envenomation</td>
<td>Courtney Waxman CVT, VTS (ECC) Instructional Technologist Purdue University</td>
</tr>
</tbody>
</table>

### APHIS, EQUINE, & FARM  CRYSTAL 5

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:40 AM – 10:30 AM</td>
<td>Module 12: Animal Disease Traceability</td>
<td>Speaker details to come.</td>
</tr>
<tr>
<td>1:00 PM – 1:50 PM</td>
<td>The Small Ruminant Physical Examination Made Easy</td>
<td>Nicole Scherrer DVM, MS, DACVIM Associate Professor Oklahoma State University</td>
</tr>
<tr>
<td>2:10 PM – 3:00 PM</td>
<td>Equine Corneal Disease: Ulceration &amp; More</td>
<td>Meredyth Jones DVM, MS, DACVIM President and CEO PantheraT Inc</td>
</tr>
<tr>
<td>3:20 PM – 4:10 PM</td>
<td>Parasites in Small Ruminants: What You Need to Know</td>
<td>Meredyth Jones DVM, MS, DACVIM President and CEO PantheraT Inc</td>
</tr>
<tr>
<td>4:30 PM – 5:20 PM</td>
<td>A Focus on Equine Medicine</td>
<td>Speaker details to come.</td>
</tr>
</tbody>
</table>

### REGISTER TODAY FOR $349 WITH CODE CB1.

Price offer expires June 28, 2019.

wildwest.vetshow.com
**The Eyelid**

**CLINICAL THEATER 1**  
**TAHOE ROOM**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 AM – 8:50 AM</td>
<td>Complicated Wound Care Cases Made Easy</td>
</tr>
<tr>
<td>9:10 AM – 10:00 AM</td>
<td>Cancer Palliation: Oral Therapies &amp; Beyond</td>
</tr>
<tr>
<td>11:30 AM – 12:20 PM</td>
<td>In-House Compounding: Do’s &amp; Don’ts in General Practice</td>
</tr>
<tr>
<td>1:30 PM – 2:20 PM</td>
<td>Veterinary Hospice &amp; Palliative Care From the Trenches</td>
</tr>
<tr>
<td>2:40 PM – 3:30 PM</td>
<td>Diversion Concerns in Veterinary Practice</td>
</tr>
<tr>
<td>5:00 PM – 5:50 PM</td>
<td>Dermatology or Ophthalmology? The Eyelid Margin Wars</td>
</tr>
</tbody>
</table>

**CLINICAL THEATER 2**  
**CARSON 1-2**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:45 AM – 10:00 AM</td>
<td>A Focus on Diabetes</td>
</tr>
<tr>
<td>10:30 AM – 11:45 AM</td>
<td>Assessing Quality of Life</td>
</tr>
<tr>
<td>1:15 PM – 2:30 PM</td>
<td>Top 5 Emergency Room Procedures You Can Use in General Practice</td>
</tr>
<tr>
<td>3:00 PM – 4:15 PM</td>
<td>Queen of Denial: How Cats Show (&amp; Hide) Pain &amp; What to Do About It</td>
</tr>
</tbody>
</table>

**CLINICAL THEATER 3**  
**CARSON 3-4**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:15 AM – 9:00 AM</td>
<td>Navigating the Muddy Waters of Pharmacy: Improving Communication &amp; Reducing Error</td>
</tr>
<tr>
<td>10:45 AM – 12:00 PM</td>
<td>Mast Cell Tumors, Melanoma, &amp; Beyond: Clinical Approach to Cutaneous Masses</td>
</tr>
<tr>
<td>1:30 PM – 2:45 PM</td>
<td>Lessons From the Street: Opioid Diversions in the Veterinary Clinic</td>
</tr>
<tr>
<td>3:15 PM – 4:30 PM</td>
<td>Retching Rufus: The Clinical Approach to Chronic Vomiting in Dogs</td>
</tr>
</tbody>
</table>

**REGISTRATION INFORMATION**

**REGISTER TODAY FOR $349 WITH CODE CB1.**

Price offer expires June 28, 2019.

**wildwest.vetshow.com**
<table>
<thead>
<tr>
<th>BUSINESS THEATER</th>
<th>VETERINARY NURSING THEATER</th>
<th>APHIS, EQUINE, &amp; FARM THEATER</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRYSTAL 1-2</td>
<td>CRYSTAL 3-4</td>
<td>CRYSTAL 5</td>
</tr>
<tr>
<td><strong>9:00 AM – 10:00 AM</strong></td>
<td><strong>9:10 AM – 10:00 AM</strong></td>
<td><strong>8:30 AM – 9:20 AM</strong></td>
</tr>
<tr>
<td>Top Tips to Stay Sane</td>
<td>Stayin' Alive: The RECOVER Guidelines</td>
<td>Complications of Equine Field Surgery</td>
</tr>
<tr>
<td>Mary Gardner DVM</td>
<td>Jo Woodison RVT</td>
<td>Shane Miller DVM, DACVS</td>
</tr>
<tr>
<td>Lap of Love Veterinary Hospice</td>
<td>Representative California Veterinary Medical Association</td>
<td>Equine Surgeon Comstock Equine Hospital</td>
</tr>
<tr>
<td><strong>10:20 AM – 11:10 AM</strong></td>
<td><strong>10:20 AM – 11:10 AM</strong></td>
<td><strong>9:40 AM – 10:30 AM</strong></td>
</tr>
<tr>
<td>Block Pain Before It Starts: Local &amp; Regional Blocks in Clinical Practice</td>
<td><strong>11:30 AM – 12:20 PM</strong></td>
<td>Blood Work in Small Ruminants: What to Run &amp; How to Interpret</td>
</tr>
<tr>
<td>Eric Garcia CEO</td>
<td>Darci Palmer BS, LVT, VTS (Anesthesia &amp; Analgesia) Veterinary Anesthetist Southeastern Veterinary Surgery Center</td>
<td>Meredith Jones DVM, MS, DACVIM Associate Professor Oklahoma State University</td>
</tr>
<tr>
<td>Simply Done Tech Solutions</td>
<td><strong>1:30 PM – 2:20 PM</strong></td>
<td>A Focus on Equine Medicine</td>
</tr>
<tr>
<td>Megan Brashear BS, CVT, VTS (ECG), Specialty Technician Trainer VCA Northwest Veterinary Specialists</td>
<td><strong>1:30 PM – 2:20 PM</strong></td>
<td><strong>1:00 PM – 1:50 PM</strong></td>
</tr>
<tr>
<td><strong>11:30 AM – 12:20 PM</strong></td>
<td><strong>1:00 PM – 1:50 PM</strong></td>
<td><strong>10:50 AM – 11:40 AM</strong></td>
</tr>
<tr>
<td>Self-Care: Why There Needs to Be an ‘I’ in ‘Team’</td>
<td>It's Not Over Yet: Managing Anesthesia Recovery</td>
<td><strong>1:00 PM – 1:50 PM</strong></td>
</tr>
<tr>
<td>Karen Felsted CPA, MS, DVM, CVPM, CVA, Founder and President PantherAT</td>
<td><strong>1:30 PM – 2:20 PM</strong></td>
<td><strong>1:00 PM – 1:50 PM</strong></td>
</tr>
<tr>
<td><strong>11:30 AM – 12:20 PM</strong></td>
<td><strong>1:00 PM – 1:50 PM</strong></td>
<td><strong>10:50 AM – 11:40 AM</strong></td>
</tr>
<tr>
<td>Why Are Performance Reviews So Overwhelming?</td>
<td>Compassion Versus Burnout</td>
<td><strong>1:00 PM – 1:50 PM</strong></td>
</tr>
<tr>
<td>Megan Brashear BS, CVT, VTS (ECG), Specialty Technician Trainer VCA Northwest Veterinary Specialists</td>
<td><strong>2:40 PM – 3:30 PM</strong></td>
<td><strong>2:10 PM – 3:00 PM</strong></td>
</tr>
<tr>
<td><strong>2:40 PM – 3:30 PM</strong></td>
<td><strong>2:40 PM – 3:30 PM</strong></td>
<td><strong>2:10 PM – 3:00 PM</strong></td>
</tr>
<tr>
<td>Translate Management Decisions into Dollars &amp; Cents</td>
<td><strong>3:50 PM – 4:40 PM</strong></td>
<td><strong>2:10 PM – 3:00 PM</strong></td>
</tr>
<tr>
<td>Karen Felsted CPA, MS, DVM, CVPM, CVA, Founder and President PantherAT</td>
<td><strong>3:50 PM – 4:40 PM</strong></td>
<td><strong>2:10 PM – 3:00 PM</strong></td>
</tr>
<tr>
<td><strong>3:50 PM – 4:40 PM</strong></td>
<td><strong>3:50 PM – 4:40 PM</strong></td>
<td><strong>2:10 PM – 3:00 PM</strong></td>
</tr>
<tr>
<td>Why Do They Do That? Generational Conflicts in Your Practice</td>
<td>The Do's &amp; Don'ts of Blood Transfusions</td>
<td>Speaker details to come.</td>
</tr>
<tr>
<td>Megan Brashear BS, CVT, VTS (ECG), Specialty Technician Trainer VCA Northwest Veterinary Specialists</td>
<td><strong>3:50 PM – 4:40 PM</strong></td>
<td><strong>2:10 PM – 3:00 PM</strong></td>
</tr>
<tr>
<td><strong>3:50 PM – 4:40 PM</strong></td>
<td><strong>3:50 PM – 4:40 PM</strong></td>
<td><strong>2:10 PM – 3:00 PM</strong></td>
</tr>
<tr>
<td>Eric Garcia CEO</td>
<td><strong>3:50 PM – 4:40 PM</strong></td>
<td><strong>2:10 PM – 3:00 PM</strong></td>
</tr>
<tr>
<td>Simply Done Tech Solutions</td>
<td><strong>3:50 PM – 4:40 PM</strong></td>
<td><strong>2:10 PM – 3:00 PM</strong></td>
</tr>
<tr>
<td><strong>3:50 PM – 4:40 PM</strong></td>
<td><strong>3:20 PM – 4:10 PM</strong></td>
<td><strong>2:10 PM – 3:00 PM</strong></td>
</tr>
<tr>
<td>Speaker details to come.</td>
<td>A Focus on Equine Medicine</td>
<td>Speaker details to come.</td>
</tr>
<tr>
<td><strong>3:50 PM – 4:40 PM</strong></td>
<td><strong>3:20 PM – 4:10 PM</strong></td>
<td><strong>2:10 PM – 3:00 PM</strong></td>
</tr>
<tr>
<td><strong>4:30 PM – 5:20 PM</strong></td>
<td><strong>3:20 PM – 4:10 PM</strong></td>
<td><strong>2:10 PM – 3:00 PM</strong></td>
</tr>
<tr>
<td><strong>4:30 PM – 5:20 PM</strong></td>
<td><strong>3:20 PM – 4:10 PM</strong></td>
<td><strong>2:10 PM – 3:00 PM</strong></td>
</tr>
<tr>
<td>THEATERS</td>
<td>SATURDAY, OCTOBER 26, 2019</td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td></td>
</tr>
<tr>
<td><strong>CLINICAL THEATER 1</strong>&lt;br&gt;Tahoe Room</td>
<td><strong>CLINICAL THEATER 2</strong>&lt;br&gt;Carson 1-2</td>
<td></td>
</tr>
<tr>
<td><strong>8:00 AM – 9:15 AM</strong></td>
<td><strong>8:00 AM – 9:15 AM</strong></td>
<td></td>
</tr>
<tr>
<td>What’s New? Emerging Issues in Small Animal Toxicology</td>
<td>Picky Kitty: Feeding the Inappetent or Anorectic Cat</td>
<td></td>
</tr>
<tr>
<td>Raegan Wells&lt;br&gt;DVM, MS, DACVECC&lt;br&gt;Medical Director Phoenix Veterinary Referral and Emergency</td>
<td>Margie Scherk&lt;br&gt;DVM, DABVP (Feline Practice)&lt;br&gt;Veterinary Specialist Cat Healthy</td>
<td></td>
</tr>
<tr>
<td><strong>9:35 AM – 10:25 AM</strong></td>
<td><strong>9:35 AM – 10:25 AM</strong></td>
<td></td>
</tr>
<tr>
<td>Food Allergy: Dr. Google Debunked</td>
<td>A Focus on Endocrinology</td>
<td></td>
</tr>
<tr>
<td>Alexander Werner&lt;br&gt;VMD, DACVD&lt;br&gt;Veterinary Specialist Animal Dermatology Center</td>
<td>Peter Chapman&lt;br&gt;BVetMed (Hons), DECVIM-CA, DACVIM, MRCVS&lt;br&gt;Internal Medicine Specialist Veterinary Specialty and Emergency Center—Blue Pearl Philadelphia</td>
<td></td>
</tr>
<tr>
<td><strong>10:55 AM – 12:10 PM</strong></td>
<td><strong>10:55 AM – 11:45 AM</strong></td>
<td></td>
</tr>
<tr>
<td>Hyperthyroidism &amp; Beyond: Feline Endocrine Case Studies</td>
<td>Cutaneous Adverse Drug Reactions: Blame the Drug, Not Your Choice!</td>
<td></td>
</tr>
<tr>
<td>Margie Scherk&lt;br&gt;DVM, DABVP (Feline Practice)&lt;br&gt;Veterinary Specialist Cat Healthy</td>
<td>Alexander Werner&lt;br&gt;VMD, DACVD&lt;br&gt;Veterinary Specialist Animal Dermatology Center</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>BUSINESS THEATER</strong>&lt;br&gt;Crystal 1-2</th>
<th><strong>VETERINARY NURSING THEATER</strong>&lt;br&gt;Crystal 3-4</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>8:00 AM – 9:15 AM</strong></td>
<td><strong>8:00 AM – 9:15 AM</strong></td>
</tr>
<tr>
<td>Getting Your Team on Board With Change: Hospital Protocols</td>
<td>Beyond Opioids: Balanced Anesthesia Meets Multimodal Analgesia—Developing a Patient-Specific Drug Protocol</td>
</tr>
<tr>
<td>Megan Brashear&lt;br&gt;BS, CVT, VTS (ECC)&lt;br&gt;Specialty Technician Trainer VCA Northwest Veterinary Specialists</td>
<td>Darci Palmer&lt;br&gt;BS, LVT, VTS&lt;br&gt;(Anesthesia &amp; Analgesia) Veterinary Anesthetist Southeastern Veterinary Surgery Center</td>
</tr>
<tr>
<td><strong>9:35 AM – 10:25 AM</strong></td>
<td><strong>9:35 AM – 10:25 AM</strong></td>
</tr>
<tr>
<td>Top Marketing Mistakes &amp; How You Can Fix Them</td>
<td>Just Breathe: Respiratory Emergencies</td>
</tr>
<tr>
<td>Eric Garcia&lt;br&gt;CEO Simply Done Tech Solutions</td>
<td>Jo Woodison&lt;br&gt;RVT Representative California Veterinary Medical Association</td>
</tr>
<tr>
<td><strong>10:55 AM – 12:10 PM</strong></td>
<td><strong>10:55 AM – 12:10 PM</strong></td>
</tr>
<tr>
<td>Top Communication Mistakes Online &amp; Off</td>
<td>Oh, Baby! Anesthesia &amp; Analgesia Management for C-Sections &amp; Neonatal Care</td>
</tr>
<tr>
<td>Megan Brashear&lt;br&gt;BS, CVT, VTS (ECC)&lt;br&gt;Specialty Technician Trainer VCA Northwest Veterinary Specialists</td>
<td>Darci Palmer&lt;br&gt;BS, LVT, VTS&lt;br&gt;(Anesthesia &amp; Analgesia) Veterinary Anesthetist Southeastern Veterinary Surgery Center</td>
</tr>
<tr>
<td>Eric Garcia&lt;br&gt;CEO Simply Done Tech Solutions</td>
<td>Eric Garcia&lt;br&gt;CEO Simply Done Tech Solutions</td>
</tr>
</tbody>
</table>

Program subject to change.

wildwest.vetshow.com
LOOKING FOR MORE?
These hands-on laboratories and masterclasses are the perfect opportunity to enhance your experience at Wild West Vet. Tackle a new procedure or freshen up an existing skill in a small-group environment, led by one of our top-tier instructors. Be sure to reserve your spot when you register, as space is limited.

<table>
<thead>
<tr>
<th>WEDNESDAY, OCTOBER 23</th>
<th>THURSDAY, OCTOBER 24</th>
<th>FRIDAY, OCTOBER 25</th>
</tr>
</thead>
<tbody>
<tr>
<td>NEVADA 10</td>
<td>NEVADA 9</td>
<td>NEVADA 9</td>
</tr>
<tr>
<td>1:00 PM – 4:00 PM</td>
<td>9:00 AM – 1:00 PM</td>
<td>1:00 PM – 3:00 PM</td>
</tr>
<tr>
<td>Surgeries of the Equine Eyelid</td>
<td>How to Intubate Almost Any Exotic Companion Mammal</td>
<td>In-House Compounding Laboratory</td>
</tr>
</tbody>
</table>

Nicole Scherrer  
DVM  
Clinical Assistant Professor, Ophthalmology  
University of Pennsylvania

Dan Johnson  
DVM, DABVP (Exotics)  
Founder  
Avian and Exotic Animal Care Veterinary Hospital

Lauren Eichstadt Forsythe  
PharmD, DICVP, FSVHP  
Pharmacy Director  
University of Illinois College of Veterinary Medicine

Contact us via email at wildwestvet@closerstillmedia.com for pricing and CE information.

Program subject to change. Availability is limited. Registration is on a first come, first served basis.

More hands-on opportunities to come! Visit wildwest.vetshow.com for updates.
Stay & Play
Hit the books, then hit the trails!

Register now at wildwest.vetshow.com or call (646) 437-9080. $349 with promo code CB1 (expires June 28)

Wild West Vet will be hosted at the Grand Sierra Resort and Casino. This newly remodeled hotel has everything you need—and want—under one roof. Take a chance in the casino or bring your entire family for some poolside fun or a round of bowling. You can enjoy our special room rates, starting at $115 + tax. Visit our website for more information: wildwest.vetshow.com/hotel.

Reno is a fun city, set amid the gorgeous scenery of the Sierra Nevada mountain range. The Biggest Little City has it all: from food trucks to fine dining, and from urban murals to gleaming alpine lakes. With 300 days of sunshine every year, there is no rest for adventure seekers here. Bring your hiking shoes and unwind in nature—beautiful Lake Tahoe is less than 40 miles away.

Rooms starting at $115 + tax.
Visit our website for more information: wildwest.vetshow.com/hotel.
Join us for the third year of New York Vet.

WORLD-CLASS CE IN A WORLD-CLASS CITY

REGISTER BEFORE JULY 26 FOR $499/$299 WITH CODE PEG299

NOVEMBER 7-8, 2019
JAVITS CENTER, NEW YORK CITY
newyork.vetshow.com
FAST-ACTING CALMING SUPPORT when it counts

COMPOSURE™ PRO IS CLINICALLY SHOWN TO WORK WITHIN 30 MINUTES AND LAST UP TO 4 HOURS.*

› Clinical strength behavioral & cognitive support

› Safe to double dosage during times of heightened stress

› Can be used daily—no loading dose required

› May help normalize stress-related GI issues


VETRISCIENCE® PRO LINE IS INTENDED FOR DISTRIBUTION EXCLUSIVELY THROUGH LICENSED VETERINARY CLINICS INVOLVED IN THE DIRECT CLIENT-PATIENT RELATIONSHIP.

HYDROLYZED CHICKEN FLAVORED CHEW / FLAVORLESS LIQUID FORMULA

*CanCog Technologies Study on Composure™ “Assessment of Anxiolytic Properties of a Novel Compound in Beagle Dogs with a Noise-Induced Model of Fear and Anxiety”
WHY ATTEND?

Like most of your colleagues, you probably struggle to get away from the practice for weeklong CE events.

Try something different this year.

Curated by the practicing veterinarians behind Clinician’s Brief, New York Vet delivers the content you trust and the speakers you enjoy in the practical, efficient format you need. With intimate sessions and a bustling, high-energy exhibit hall, New York Vet strikes the ideal balance, allowing you to earn up to 16 hours of RACE-approved CE in 2 days.

Build Your Itinerary
New York Vet has something for every member of the team. Session topics range from small animal medicine and practice management to veterinary nursing and exciting industry innovations. Explore the program on page 4.

Make Your New York Bucket List
What’s on your must-see list for New York? Whether you’ve been before or you’re visiting for the first time, we’ve got you covered. Explore our list of attractions and experiences on page 10.

Pricing

<table>
<thead>
<tr>
<th></th>
<th>Special Rate for Clinician’s Brief Readers (Expires July 26)</th>
<th>June 29 – September 27</th>
<th>September 28 – November 1</th>
<th>On-Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full Conference Pass</td>
<td>$399</td>
<td>$399</td>
<td>$449</td>
<td>$499</td>
</tr>
<tr>
<td>Exhibition Only</td>
<td>$99</td>
<td>$99</td>
<td>$99</td>
<td>$99</td>
</tr>
<tr>
<td>Students</td>
<td>$79</td>
<td>$79</td>
<td>$79</td>
<td>$79</td>
</tr>
</tbody>
</table>

For information on group discounts, guest tickets, and rates for commercial attendees, please contact us.

Register for New York Vet for $299* with promo code PEG299.

Registration is simple!
- Register online at newyork.vetshow.com
- Call us at (646) 437-9080
- Email us at newyorkvet@closerstillmedia.com

*Price offer expires July 26, 2019.
TRAVEL

All roads lead to New York, whether you live across the Hudson or across the United States. No matter how you get here, you’ll be glad you came.

PACKING TIPS
Fall in New York City is typically mild, with temperatures ranging between 40°F and 60°F. Be sure to pack layers! In addition, rain is likely this time of year, and both an umbrella and waterproof footwear are highly recommended if you anticipate exploring Manhattan on foot.

PLANE
There’s nothing quite like the view of New York City from the window seat of an airplane. If you plan to fly, LaGuardia Airport (LGA) is the most conveniently located destination for travel into midtown Manhattan. Both American Airlines and Delta Air Lines offer discounted airfare into New York City for registered New York Vet attendees. Visit newyork.vetshow.com/travel for details and discount codes.

TAXI & RIDESHARE
Grabbing a cab or a rideshare can be ideal when you’re weighed down with heavy luggage or you reach your capacity for walking. New York City’s yellow and green taxis are available 24 hours a day and accept cash and cards. Special discounts for Lyft and Uber will be available for attendees if you prefer rideshares.

SHUTTLE
Need a ride from the airport? We’ve partnered with SuperShuttle to ensure a smooth ride from any of New York’s 3 airports. Shared and private ride options are available. Visit supershuttle.com for more information.

CAR
Planning to drive? Google Maps will be your best resource for driving directions and traffic alerts in town. Be sure to plan ahead for parking: Apps like SpotHero and BestParking help you find and reserve affordable spots.

BUS
If you’re traveling from an East Coast city, let someone else do the driving. New York City is served by several companies, including Megabus, BoltBus, and Greyhound, which offer affordable service from a number of cities.

newyork.vetshow.com
ACCOMMODATION

From shimmering luxury hotels that reflect the bright lights of New York City to family-friendly spots near lush stretches of greenery, these hotels will make New York City your home away from home.

Featured Hotels

Through a partnership with onPeak, we are able to offer a variety of convenient and affordable options for your stay. onPeak’s pay delay feature and flexibility make booking at one of these hotels a no-brainer.

- **Four Points by Sheraton – Manhattan Midtown West**
  - 4 stars
  - $249 USD/night
  - 0.2 miles from the Javits Center

- **DoubleTree by Hilton Hotel New York – Times Square South**
  - 4 stars
  - $259 USD/night
  - 0.4 miles from the Javits Center

- **Candlewood Suites New York City - Times Square**
  - 4 stars
  - $239 USD/night
  - 0.5 miles from the Javits Center

- **The New Yorker – A Wyndham Hotel**
  - 4 stars
  - $209 USD/night
  - 1 mile from the Javits Center

- **New York Marriott Marquis**
  - 5 stars
  - $379 USD/night
  - 1.3 miles from the Javits Center

- **Yotel New York**
  - 4 stars
  - $199 USD/night
  - 0.6 miles from the Javits Center

BOOK YOUR ROOM

Rates vary depending on your hotel selection. Additional hotel options are available. To select your hotel and reserve a room, visit newyork.vetshow.com/accommodation. A limited number of reduced-rate rooms are available—book soon to take advantage of your discount.

EXPLORE NEW YORK CITY

New York City is a land of opportunity, offering breathtaking views, unparalleled museums and live performances, and an endless selection of culinary experiences. There’s something here for everyone. Learn more on page 10.
<table>
<thead>
<tr>
<th>TIME</th>
<th>THEATER 1</th>
<th>THEATER 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 AM – 9:50 AM</td>
<td>Prepubertal Neutering: What’s the Evidence?</td>
<td>Beyond the Nose: Challenges of Brachycephaly in All Body Systems</td>
</tr>
<tr>
<td>Laura Selmic</td>
<td>BVetMed (Hons), MPH, DACVS-SA, DECVS, MRCVS, ACVS Founding Fellow, Surgical Oncology Professor, Surgical Oncology The Ohio State University</td>
<td>Dan Brockman BVSc, CertVR, CertSAO, DACVS, DECVS Professor, Small Animal Surgery, Head of CSS Royal Veterinary College</td>
</tr>
<tr>
<td>10:25 AM – 11:15 AM</td>
<td>Surgical Extractions: Numb It &amp; Remove It!</td>
<td></td>
</tr>
<tr>
<td>Mark Smith</td>
<td>VMD, DACVS, DAVDC Co-Owner Center for Veterinary Dentistry and Oral Surgery</td>
<td></td>
</tr>
<tr>
<td>9:15 AM – 10:05 AM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:45 AM – 11:35 AM</td>
<td>Breathe Deeply: Dyspnea Toolkit</td>
<td></td>
</tr>
<tr>
<td>Lisa Powell</td>
<td>DVM, DACVECC Associate Critical Care Clinician BluePearl Veterinary Partners</td>
<td></td>
</tr>
<tr>
<td>11:45 AM – 12:35 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Steve Castillo</td>
<td>CEO Fee Technology Inc</td>
<td></td>
</tr>
<tr>
<td>12:15 AM – 1:05 PM</td>
<td>Can’t Touch This: Sedation Strategies for Fractious Patients</td>
<td></td>
</tr>
<tr>
<td>Stephanie Krein</td>
<td>DVM, DACVAA Veterinary Anesthesiologist MSPCA-Angell</td>
<td></td>
</tr>
<tr>
<td>Andrew Rosenberg</td>
<td>DVM, DACVD Veterinary Dermatologist and Practice Owner Animal Dermatology and Allergy Specialists</td>
<td></td>
</tr>
<tr>
<td>1:45 PM – 2:35 PM</td>
<td>Taking the Fear Out of Brachycephalic Anesthesia</td>
<td></td>
</tr>
<tr>
<td>Stephanie Krein</td>
<td>DVM, DACVAA Veterinary Anesthesiologist MSPCA-Angell</td>
<td></td>
</tr>
<tr>
<td>3:00 PM – 3:50 PM</td>
<td>Feline Orthopedics: Cats Are Not Small Dogs</td>
<td></td>
</tr>
<tr>
<td>Sue Casale</td>
<td>DVM, DACVS Veterinary Surgeon (Orthopedic and Soft Tissue) MSPCA-Angell</td>
<td></td>
</tr>
<tr>
<td>4:05 PM – 4:55 PM</td>
<td>Your Essential Guide to Insulin: So Many Choices, Which Do I Choose?</td>
<td></td>
</tr>
<tr>
<td>Thomas Schermerhorn</td>
<td>VMD, DACVIM (SAIM) Professor, Small Animal Internal Medicine Kansas State University</td>
<td></td>
</tr>
<tr>
<td>5:10 PM – 6:00 PM</td>
<td>Is That Normal for a Dachshund? Recognizing Radiographic Breed Variants in Every Body System</td>
<td></td>
</tr>
<tr>
<td>Anthony Pease</td>
<td>DVM, MS, DACVR Chief Veterinary Medical Officer WVC</td>
<td></td>
</tr>
<tr>
<td>7:00 PM – 7:50 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Speaker details to come.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Program subject to change.
<table>
<thead>
<tr>
<th>TIME</th>
<th>THEATER</th>
<th>SPEAKERS</th>
<th>TOPICS</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30 AM</td>
<td>CLINICAL THEATER 3</td>
<td>Lisa Penny, RPh, FSVHP, FAVCP</td>
<td>Controlled Substance: Prescribing, Reporting, Record Keeping, &amp; Diversion Prevention (Part 1)</td>
</tr>
<tr>
<td>10:25 AM</td>
<td>BUSINESS THEATER</td>
<td>Josh Vaismen, CCPN, CCLP, Positive Change Ninja</td>
<td>Rehabilitate Your Protocols: Rehab Tips for General Practice</td>
</tr>
<tr>
<td>12:00 PM</td>
<td>VETERINARY NURSING THEATER</td>
<td>Heather Hopkinson, RVT, VTS-EVN, CCRP</td>
<td>Happy Team, Happy Bottom Line</td>
</tr>
<tr>
<td>1:50 PM</td>
<td></td>
<td>Lisa Penny, RPh, FSVHP, FAVCP</td>
<td>What a Relief! How to Maximize Your Career as a Relief Veterinarian</td>
</tr>
<tr>
<td>3:10 PM</td>
<td></td>
<td>Monique Feyrecilde, BA, VET, VTS (Behavior)</td>
<td>Kitty Cooperative Care</td>
</tr>
<tr>
<td>4:20 PM</td>
<td></td>
<td>Mark Smith, DVM, DACVS, DAVIDC</td>
<td>Extraction Complications: Tips &amp; Tricks to Get Out of Trouble</td>
</tr>
<tr>
<td>5:25 PM</td>
<td></td>
<td>Sue Casale, DVM, DACVS, DAVIDC</td>
<td>Pediatric Orthopedics: Sprains, Strains, &amp; Salter-Harris</td>
</tr>
<tr>
<td>9:00 AM</td>
<td></td>
<td>Lisa Penny, RPh, FSVHP, FAVCP</td>
<td>Controlled Substance: Prescribing, Reporting, Record Keeping, &amp; Diversion Prevention (Part 2)</td>
</tr>
<tr>
<td>10:00 AM</td>
<td></td>
<td>Cindy Trine, DVM</td>
<td>Rehabilitate Your Protocols: Rehab Tips for General Practice</td>
</tr>
<tr>
<td>11:00 AM</td>
<td></td>
<td>Heather Prendergast, RVT, CVPM, SPHR</td>
<td>Happy Team, Happy Bottom Line</td>
</tr>
<tr>
<td>1:40 PM</td>
<td></td>
<td>Caleb Frankel, DVM, CEO, Instinct Science</td>
<td>What a Relief! How to Maximize Your Career as a Relief Veterinarian</td>
</tr>
<tr>
<td>2:40 PM</td>
<td></td>
<td>Lance Roasa, DVM, MS, JD, Founder, The Roasa Law Group</td>
<td>What a Relief! How to Maximize Your Career as a Relief Veterinarian</td>
</tr>
<tr>
<td>3:40 PM</td>
<td></td>
<td>Steve Castillo, CEO, Fee Technology Inc</td>
<td>What a Relief! How to Maximize Your Career as a Relief Veterinarian</td>
</tr>
<tr>
<td>4:40 PM</td>
<td></td>
<td>Joseph Axne, Owner, IT-Guru</td>
<td>What a Relief! How to Maximize Your Career as a Relief Veterinarian</td>
</tr>
<tr>
<td>Time</td>
<td>Session Title</td>
<td>Speaker</td>
<td>Institution</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>----------------------------------------------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>8:00 AM – 8:50 AM</td>
<td>Red Light, Green Light Cases</td>
<td>Lauren Trepanier DVM, PhD, DACVIM (SAIM), DACUCP Professor and Director, Clinical Research University of Wisconsin–Madison</td>
<td></td>
</tr>
<tr>
<td>9:00 AM – 9:50 AM</td>
<td>Getting the Most From Your Stethoscope: Practical Cardiology Toolkit in Primary Care (Part 2)</td>
<td>Amar Estrada DVM, DACVIM (Cardiology) Professor, Cardiology University of Florida</td>
<td></td>
</tr>
<tr>
<td>10:00 AM – 10:50 AM</td>
<td>Survival Guide to Inflammatory Nervous System Diseases</td>
<td>Simon Platt BVM&amp;S, DACVIM (Neurology), DECVM, RCVS Professor, Neurology and Neurosurgery University of Georgia</td>
<td></td>
</tr>
<tr>
<td>11:10 AM – 12:00 PM</td>
<td>Stop Going Rogue &amp; Start Doing Right: Essential Practices in Evidence-Based Medicine</td>
<td>Adrian Boswood MA, VetMB, MRCVS, DVC, DECVM-CA (Cardiology) Professor, Veterinary Cardiology Royal Veterinary College</td>
<td></td>
</tr>
<tr>
<td>1:00 PM – 1:50 PM</td>
<td>Fact vs Fiction: Sound Clinical Nutrition in a World Driven by Nutritional Pseudoscience</td>
<td>Martha Cline DVM, DACVN Veterinarian (Clinical Nutrition) Red Bank Veterinary Hospital</td>
<td></td>
</tr>
<tr>
<td>2:05 PM – 2:55 PM</td>
<td>Immune-Mediated Diseases &amp; Immunosuppressive Therapy: What You Might Be Missing (Case-Based Review)</td>
<td>Todd Archer DVM, MS, DACVIM (SAIM) Associate Professor and Service Chief Mississippi State University</td>
<td></td>
</tr>
<tr>
<td>3:10 PM – 4:00 PM</td>
<td>Dry Your Tears: Managing Tear Production Disorders</td>
<td>A. Brady Beale VMD, DACVO Instructor, Clinical Ophthalmology University of Pennsylvania</td>
<td></td>
</tr>
<tr>
<td>4:10 PM – 5:00 PM</td>
<td>More Than One Problem: Wound Management in Complicated Patients</td>
<td>Bryden Stanley BVMS, MVetSc, DACVS Section Head, Surgery Michigan State University</td>
<td></td>
</tr>
<tr>
<td>9:30 AM – 10:20 AM</td>
<td>Managing Collapsing Trachea: Beyond Hydrocodone</td>
<td>Todd Archer DVM, MS, DACVIM (SAIM) Associate Professor and Service Chief Mississippi State University</td>
<td></td>
</tr>
<tr>
<td>10:35 AM – 11:25 AM</td>
<td>Recognizing &amp; Managing Self-Harming Dogs &amp; Cats</td>
<td>E'lise Christensen Bell DVM, DACVB Veterinary Behaviorist Animal Care Center of Castle Pines</td>
<td></td>
</tr>
<tr>
<td>11:40 AM – 12:30 PM</td>
<td>Mastering Vestibular Diseases in Dogs &amp; Cats: All You Need to Know</td>
<td>Simon Platt BVM&amp;S, DACVIM (Neurology), DECVM, RCVS Professor, Neurology and Neurosurgery University of Georgia</td>
<td></td>
</tr>
<tr>
<td>1:00 PM – 1:50 PM</td>
<td>Beyond the Curve: Monitoring Blood Glucose in Dogs &amp; Cats</td>
<td>Thomas Schermerhorn VMD, DACVIM (SAIM) Professor, Small Animal Internal Medicine Kansas State University</td>
<td></td>
</tr>
<tr>
<td>2:00 PM – 2:50 PM</td>
<td>Not Just Laryngeal Paralysis: Understanding GOLPP (Geriatric Onset Laryngeal Paralysis Polyneuropathy)</td>
<td>Bryden Stanley BVMS, MVetSc, DACVS, DACVS Section Head, Surgery Michigan State University</td>
<td></td>
</tr>
<tr>
<td>3:00 PM – 3:50 PM</td>
<td>SESSION SUPPORTED BY zoetis</td>
<td>Steve Castillo CEO Fee Technology Inc</td>
<td></td>
</tr>
<tr>
<td>3:55 PM – 4:45 PM</td>
<td>Dust Off Your Ultrasound Machine: The Nonradiologist’s Guide to Ultrasound in General Practice</td>
<td>Anthony Pease DVM, MS, DACVR Chief Veterinary Medical Officer VHC</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Business Theater</td>
<td>Veterans Nursing Theater</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>9:00 AM – 9:50 AM</td>
<td>Not All Melanomas Are the Same: Understanding the Importance of Location, Malignancy, Species</td>
<td>The First 48: Certified Veterinary Practice Manager (CVPM) Certification: Informational Session</td>
<td></td>
</tr>
<tr>
<td>10:00 AM – 10:50 AM</td>
<td>Certified Veterinary Practice Manager (CVPM) Certification: Informational Session</td>
<td>Steve Castillo, CEO, Fee Technology Inc</td>
<td></td>
</tr>
<tr>
<td>10:00 AM – 10:50 AM</td>
<td>How to Handle Confrontational Clients</td>
<td>Jason Coe, DVM, PhD, Associate Professor, Ontario Veterinary College</td>
<td></td>
</tr>
<tr>
<td>11:00 AM – 11:50 AM</td>
<td>Ready to Grow: When, Why, &amp; How to Expand Your Practice</td>
<td>Peter Weinstein, DVM, MBA, Executive Director, Southern California Veterinary Medical Association</td>
<td></td>
</tr>
<tr>
<td>12:00 PM – 12:50 PM</td>
<td>Food Allergy: Is It Really as Common as Owners &amp; Pet Stores Think?</td>
<td>Dr. Peter Weinstein, Southern California Veterinary Medical Association</td>
<td></td>
</tr>
<tr>
<td>1:00 PM – 1:50 PM</td>
<td>What Goes Up Must Come Down: Diagnosis &amp; Management of Intraocular Pressure Disorders</td>
<td>Dr. Peter Weinstein, Southern California Veterinary Medical Association</td>
<td></td>
</tr>
<tr>
<td>2:00 PM – 2:50 PM</td>
<td>The Value of Valuation</td>
<td>David McCormick, MS, CVA, Veterinary Appraiser, Consultant, and Broker, Simmons Mid-Atlantic</td>
<td></td>
</tr>
<tr>
<td>3:00 PM – 3:50 PM</td>
<td>What to Say When Things Go Wrong: Communication in Challenging Situations</td>
<td>David McCormick, MS, CVA, Veterinary Appraiser, Consultant, and Broker, Simmons Mid-Atlantic</td>
<td></td>
</tr>
<tr>
<td>4:00 PM – 4:50 PM</td>
<td>How You Can Afford to Give Your Team a Raise</td>
<td>Denise Tumblin, CPA, Owner and President, WTA Veterinary Consultants Inc</td>
<td></td>
</tr>
<tr>
<td>4:00 PM – 5:00 PM</td>
<td>Urine for the Win</td>
<td>Dr. Peter Weinstein, Southern California Veterinary Medical Association</td>
<td></td>
</tr>
<tr>
<td>5:00 PM – 5:50 PM</td>
<td>Negotiation: How to Get What You Want at Work</td>
<td>Dr. Peter Weinstein, Southern California Veterinary Medical Association</td>
<td></td>
</tr>
<tr>
<td>6:00 PM – 6:50 PM</td>
<td>Caring for Your Critical Trauma Patient</td>
<td>Dr. Peter Weinstein, Southern California Veterinary Medical Association</td>
<td></td>
</tr>
</tbody>
</table>

**Clinician's Brief**

- **Clinical Theater 3**
- **Not All Melanomas Are the Same: Understanding the Importance of Location, Malignancy, Species**
- **Food Allergy: Is It Really as Common as Owners & Pet Stores Think?**
- **What Goes Up Must Come Down: Diagnosis & Management of Intraocular Pressure Disorders**
- **Mitrail Valve Management**
- **When You're Scared of Your Patients: Human-Directed Aggression (Clinical Cases)**
- **Stereotactic Radiosurgery: Data-Driven Treatment Recommendations**

**Speaker Details**

- **Brooke Britton**
- **Martha Cline**
- **Andrew Rosenberg**
- **A. Brady Beale**
- **Dan Brockman**
- **Adrian Boswood**
- **E’lise Christensen Bell**
- **Neal Mauldin**

**Business Theater**

- **Susan Savage**
- **Jason Coe**
- **Peter Weinstein**
- **Denise Tumblin**
- **David McCormick**
- **Jason Coe**
- **Heather Sidari**
- **Monique Feyrecilde**
- **Courtney Waxman**

**Veterinary Nursing Theater**

- **Brooke Britton**
- **Martha Cline**
- **Andrew Rosenberg**
- **A. Brady Beale**
- **Dan Brockman**
- **Adrian Boswood**
- **E’lise Christensen Bell**
- **Neal Mauldin**

**Other Information**

- **New York Vet Show**
- **Event Details**
- **Venue Information**
- **Networking Opportunities**
- **Registration Information**
- **Sponsorship Opportunities**
- **Accommodation Information**
- **Travel Information**
- **Safety and Security**
BIG IDEAS IN THE BIG APPLE

Big Ideas in the Big Apple is a workshop run by New York State Veterinary Medical Society (NYSVMS) for attendees of New York Vet. This 2-day program brings veterinary professionals together to engage in meaningful discussions about current issues in the profession. This year, the program is focused on animal welfare and personal well-being for private practice veterinarians. For more information, visit vets.nysvms.org/events/bigideas.

THURSDAY, NOVEMBER 7

NEW YORK STATE VETERINARY MEDICAL SOCIETY THEATER

10:00 AM – 10:50 AM
An Overview of the Law & Reporting Animal-Related Crimes

11:10 AM – 12:00 PM
Real Case Examples: Reporting Animal-Related Crimes

2:30 PM – 3:20 PM
Walking Through a Case & How to Handle It

3:40 PM – 4:30 PM
Testimony Workshop

10:00 AM – 10:50 AM
Overwhelmed by Compassion Fatigue & Burnout? There Are Solutions!

11:10 AM – 12:00 PM
Imposter Syndrome: How Feeling “Not Good Enough” Might Be a Symptom of Success

2:30 PM – 3:20 PM
Workplace Culture & Well-Being: How to Make a Change

3:40 PM – 4:30 PM
Drafting Your Well-Being Framework: A Hands-On Workshop

Laura Niestat
DVM
Forensic Veterinarian

Erin Satterthwaite
JD
Legal Advocacy Bronx Counsel

Makenzie Peterson
MSc
Well-Being Program Director

Program subject to change.
New York Vet Welcome Party

Thursday, November 7
5:30 PM – 6:30 PM
Central Catering Area
Javits Center, New York City

Grab a drink and soak up the excitement of the conference at an event where colleagues, speakers, and exhibitors all come together to build new connections and meaningful relationships.

DON’T MISS IT.

WE’VE GOT THE PARTY.
All that’s missing is you.

Save the Date
Thursday, November 7

After Party with the NYCVMA

The NYCVMA will be hosting an after-hours social gathering for all attendees of New York Vet. Proceeds from the party will go to NYSAVE, a nonprofit foundation in New York City that helps animals in need of medical care.

Join us for music and drinks in support of this important foundation.

For more information and to purchase tickets, visit newyork.vetshow.com/faqs.
FIND YOUR NEW YORK CITY

Whether you love the bustle of New York City or find it a bit intimidating, we’ve got you covered. From hidden pearls of art, culture, and food to the sights and flavors that have made New York famous, here’s your guide to the best the Empire City has to offer.

UPPER EAST SIDE
1. The Metropolitan Museum of Art
   Tackling the permanent collection at The Met can prove a challenge. If you’re short on time, focus on must-see works by Georgia O’Keeffe, Pablo Picasso, Claude Monet, and Vincent Van Gogh. Looking for more? The Guggenheim is a few steps down Museum Mile, and the Jewish Museum and El Museo del Barrio are also close by.

2. Meijin Ramen | $$
   Ramen cravings are common during the rainy season in New York City. If you find yourself on the Upper East Side looking for something soothing and slurpable, stop in Meijin for a steaming bowl of ramen and a side of soft-shell crab tempura.

UPPER WEST SIDE
3. Jacob’s Pickles | $$
   Don’t let the name distract you; this isn’t a restaurant just for pickles. Jacob’s offers the warmth and charm of Southern-style comfort food in a lively New York City atmosphere.

4. American Museum of Natural History
   A New York icon, this museum is packed with must-see exhibitions. Be sure to visit the dinosaur wing, and take a moment in the Milstein Hall of Ocean Life to gaze in awe at the life-size model of a blue whale.

5. Central Park
   Central Park is a model for green spaces across the country. An urban oasis of wooded gardens, rolling meadows, sculptures, and skyline vistas, this 843-acre park is a welcome respite from concrete and skyscrapers.

6. Levain Bakery | $$
   This tiny basement bakery is primarily known for monstrous cookies that have been proclaimed the best in New York City. If you’re looking for something more savory, Levain also offers a line of fine breads, from olive herb semolina and sourdough to walnut raisin loaves. If you’re in a hurry, stop by Levain’s new expanded location around the corner.

7. Parm | $$
   Parm is best known for its carefully braised meatball parm hero and airy pizza knots, among several other handcrafted and thoughtfully prepared Italian-American culinary delights. It’s a small spot, but worth the wait for a table or a seat at the bar.

HELL’S KITCHEN
8. Press Lounge | $$$
   Enjoy 360-degree vistas of midtown’s stunning skyline from this comfortably elegant rooftop bar. Press offers an expansive cocktail and wine list and plenty of indoor and outdoor seating.

9. Gotham West Market | $$
   A spacious full-service food hall, Gotham West offers casual cuisine from 8 critically-acclaimed restaurants; it’s the perfect spot for groups with varied preferences. Grab a taco from Choza and treat yourself to ice cream or baked goods from Ample Hills, one of the best ice cream shops in New York City.

MIDTOWN MANHATTAN
10. Broadway
   There’s nothing quite like the energy of a live show in New York City. If you’re a fan of the theater, be sure to check into upcoming shows and book early, as tickets go quickly.

11. Top of the Rock – Rockefeller Plaza
   The Top of the Rock at the Rockefeller Plaza offers sweeping, panoramic views of both Central Park and Manhattan’s skyscrapers. Book a ticket to go up at sunset and take in the unforgettable views.

LOOKING FOR DEALS?
Take advantage of the New York City Delegate Discount Pass to get discounts and offers at more than 75 restaurants, attractions, museums, and retailers throughout the city. See our website for details.
CHELSEA
12. Vessel at Hudson Yards
Be among the first to climb the 2,500 steps of over 150 different staircases that comprise the Vessel, the striking new landmark of Chelsea and Hudson Yards, just steps from Javits Center. The stunning views from the top are worth the near mile of vertical incline.

13. The High Line
Once a rail line, now nearly a mile and a half of footpath punctuated by gardens, overlooks, and art installations, the High Line winds through Chelsea and Hudson Yards, with an entrance facing the Javits Center. Stroll along the High Line for views of Chelsea, the Hudson River, and other urban delights.

FLATIRON DISTRICT
14. Eataly | $$$
Called both a "wonderland" and a "temple," Eataly is a must-see mélange of sit-down pasta and pizza restaurants, and butcher counter as well as a range of Italian dining and shopping. Home to a market, bakery, cheese counter, and butcher counter as well as a range of sit-down pasta and pizza restaurants, Eataly is a mecca of Italian delights.

15. Thai Villa | $$
Nestled in an unassuming shopfront just around the corner from the famous Flatiron building, Thai Villa is a lush, sumptuously decorated tribute to Thai style. Treat yourself to a classic curry or traditional gai yang under a canopy of glittering gold leaves.

LOWER MANHATTAN
16. Milk Bar | $$
Milk Bar believes in seizing every opportunity to celebrate. Revel in the simple joy of being in New York City with a slice of their famous Milk Bar Pie, a sky-high piece of confetti cake, or a truly decadent cookie.

17. Katz’s Delicatessen | $$
Whether you order Katz’s legendary pastrami on rye or go for a classic corned beef, savor the bustling experience of a true Jewish deli, complete with turnstiles and lunch tickets.

18. SoHo
One of the city’s most eclectic shopping districts, SoHo (an acronym for ‘South of Houston Street!’) is home to everything from big name brands like Chanel to one-of-a-kind boutiques and bargain emporiums. Stop for lunch at the district’s best vegetarian spot, West-Bourne, to fuel up for an afternoon of shopping.

FINANCIAL DISTRICT
20. Le District | $$
Treat yourself to an impressive array of French-inspired fare at Le District. Enjoy river views and outdoor seating at their two stand-alone restaurants, Beaubourg and L’Appart, or simply wind down with a glass of wine or craft cocktail at Le Bar.

21. Brooklyn Bridge
Looking for an iconic New York City experience (and the best photo opportunities)? Take a stroll across the Brooklyn Bridge to admire this iconic architectural marvel and take in views of New York Harbor, the Brooklyn and Manhattan skylines, and the Statue of Liberty.

22. One World Trade Center & The Oculus
Built on the site of the original Six World Trade Center, the One World Trade Center rises 1,776 feet into the sky above Manhattan. Nearby, The Oculus—a transit hub, shopping concourse, and architectural marvel—spreads its white, dove-like wings over the streets of New York.

23. Staten Island Ferry
Embark on a 25-minute voyage from Lower Manhattan to Staten Island via New York’s free Staten Island Ferry, which provides passengers with spectacular vistas of New York Harbor, the Manhattan skyline, and the Statue of Liberty.

newyork.vetshow.com | 13
New York City is known for its walkability, and getting around on foot is the best way to familiarize yourself with the city’s many neighborhoods. For destinations that lie beyond the reach of your feet, hop on the subway, climb aboard a bus, or flag down a cab or rideshare.

**TIP**

Download Google Maps or use Apple Maps for simple directions, whether you’re driving, walking, or relying on public transit.
New York City’s rail and bus system reaches virtually every corner of the city and is inexpensive, environmentally friendly, and operates 24 hours a day, 7 days a week.

For $2.75, you can use the subway system citywide and transfer to other subway lines as many times as you need, as long as you don’t exit through a turnstile. Pay-per-ride MetroCards cost $1 and can be purchased and reloaded at any subway station.

If you find navigating the subway daunting, be sure to download Google Maps and select the transit directions to easily locate the right train, platform, and stop.

Lyft and Uber are also widely available in New York City. Download one of the free apps, add your payment information, and schedule a ride from your phone.

Download New York’s new official cab-hailing app, Waave, to easily connect with a nearby cabbie. The app allows you to get upfront fares, surge-free pricing, and estimated arrival times before you even hail the cab.

New York’s waterways offer a unique opportunity to skip the street traffic and see the city from an entirely new vantage point. The extensive ferry system can get you to uptown or downtown Manhattan and across the rivers to Staten Island, Brooklyn, Queens, and New Jersey.

For all the details on navigating New York City, visit nycgo.com/transportation.
Can’t Touch This: Sedation Strategies for Fractious Patients

Examine the various pharmacologic options for pre-hospital and in-hospital sedation and antianxiety medication. Review a variety of pharmacologic agents as well as specific drug combinations for both cats and dogs.

Stephanie Krein, DVM, DACVAA, is currently a veterinary anesthesiologist at MSPCA-Angell. She earned her DVM from University of Illinois in 2007 and went on to complete a rotating internship in Chicago and work as an emergency doctor at Cape Cod Veterinary Specialists. In 2013, Dr. Krein completed an anesthesia residency at Tufts University and joined the team at University of Pennsylvania as a clinical lecturer. She passed the ACVAA board exam the following year and joined the team at Angell in March of 2015. She has a strong interest in emergency and critical care anesthesia and the effect of various drugs on the cardiovascular system.

Clinician’s Brief Clinical Theater 2 | Thursday, November 7 | 12:15 PM – 1:05 PM

Red Light, Green Light Cases

Review a series of clinical cases and consider possible drug interactions or drug contraindications specific to each patient during this in-depth, case-based session.

Lauren Trepanier, DVM, PhD, DACVIM (SAIM), DACVCP, is a professor of internal medicine and assistant dean for clinical and translational research at University of Wisconsin–Madison, where she has worked for 22 years. She earned her DVM with honors from Cornell University and completed an internship and residency in small animal internal medicine at the Animal Medical Center in New York. She then earned a PhD in pharmacology at Cornell. Her job involves managing internal medicine referral cases; training students, interns, and residents; conducting pharmacogenetics research; and developing initiatives to support clinical and collaborative research by veterinarians.

Clinician’s Brief Clinical Theater 1 | Friday, November 8 | 8:00 AM – 8:50 AM

Beyond the Curve: Monitoring Blood Glucose in Dogs & Cats

Monitoring a diabetic dog or cat is a crucial part of diabetes management. Unfortunately, expert recommendations for optimal monitoring protocols vary to the point of frustration for many veterinarians. This session will cover the physiologic basis for a variety of tests used to monitor glycemia, as well as the pros and cons of each test. Get recommendations for developing and implementing a useful strategy for managing patients with chronic diabetes.

Thomas Schermerhorn, VMD, DACVIM (SAIM), is currently professor and Jarvis Chair of Veterinary Medicine at Kansas State University. He earned his VMD from University of Pennsylvania in 1990. He completed an internship at South Shore Veterinary Associates and then a residency in small animal internal medicine and a research fellowship in molecular medicine at Cornell University. His clinical and research interests are focused on endocrinology—particularly diabetes mellitus and related metabolic disorders—in dogs and cats.

Clinician’s Brief Clinical Theater 2 | Thursday, November 8 | 1:00 PM – 1:50 PM

See the program on page 4.
Immune-Mediated Diseases & Immunosuppressive Therapy: What You Might Be Missing (Case-Based Review)

Explore the differing options surrounding immunosuppressive therapy in a case-based review that emphasizes strategies for not only achieving initial disease remission but also tapering medications over the chronic phase of treatment.

Todd Archer, DVM, MS, DACVIM (SAIM), is currently an associate professor and service chief of small animal internal medicine at Mississippi State University. His teaching and clinical interests include hematology, immunology, and endocrine disorders. He earned his DVM and completed his internship and residency at Mississippi State University.

Clinician’s Brief Clinical Theater 1 | Friday, November 8 | 2:05 PM – 2:55 PM

All Sewn Up: Am I Choosing the Right Suture for My Procedure?

How do you choose suture material? Which needle type is best? Matching the biomechanical characteristics of suture material with those of the healing tissues can provide optimal support during healing and prevent early failure. In this session, explore common tissues, suture materials, and needle recommendations that will make life easier in your operating room.

Laura Selmic, BVetMed (Hons), MPH, DACVS-SA, DECVS, MRCVS, ACVS Founding Fellow, Surgical Oncology, is an assistant professor of soft tissue and oncologic surgery at The Ohio State University. She graduated from Royal Veterinary College in 2004. After 2 years in private practice and an internship, she completed a residency in small animal surgery at Texas A&M University as well as a clinical fellowship in oncologic surgery and a master of public health.

Clinician’s Brief Clinical Theater 2 | Thursday, November 7 | 4:15 PM – 5:05 PM

Fact vs Fiction: Sound Clinical Nutrition in a World Driven by Nutritional Pseudoscience

Myths and half-truths plague veterinary nutrition. It is difficult for many clients to make sense of pet food packaging and sometimes even more difficult for us to educate them. This lecture will address popular nutrition myths, provide key client communication tips, and review how best to judge the quality of pet food.

Martha Cline, DVM, DACVN, is a board-certified veterinary nutritionist at Red Bank Veterinary Hospital in Tinton Falls, New Jersey, where she has practiced clinical nutrition since 2013. She earned her DVM from University of Tennessee, completed a rotating small animal internship at Oradell Animal Hospital, and then completed her residency in small animal clinical nutrition at University of Tennessee. She is the coeditor and an author for the textbook Obesity in the Dog and Cat and has contributed to several other textbooks and peer-reviewed publications. She is president of the American Academy of Veterinary Nutrition (2017-2019) and has served on their executive board since 2013.

Clinician’s Brief Clinical Theater 1 | Friday, November 8 | 1:00 PM – 1:50 PM

Register today at newyork.vetshow.com for $299 with code PEG299.
NEW AT NEW YORK VET 2019

We’re raising the bar for New York Vet with a variety of new programs and features to help you get the most out of your CE. See what’s new and noteworthy at New York Vet this year.

NEW YORK VET BUILDS

New York Vet Builds is a state-of-the-art practice design program for veterinarians who are looking to expand, renovate, or build a veterinary hospital.

Why New York Vet Builds?

Attendees will gain a variety of strategies to help avoid costly mistakes during each phase of practice design. Topics include:

- Questions to ask during each phase of the design process
- How to qualify and identify the best industry partners
- How to determine an appropriate budget
- Key success factors for staying within the budget
- Regulations, codes, and financing requirements for meeting long-term financial goals

This program will help prepare attendees to take the next steps toward executing a successful hospital design business plan.

BIG IDEAS IN THE BIG APPLE

Big Ideas in the Big Apple is a 2-day workshop program run by New York State Veterinary Medical Society (NYSVMS) for attendees of New York Vet.

Day 1: Animal Welfare for Private Practice Veterinarians

Supported by the ASPCA, this series of presentations and workshops will help you understand how the animal welfare system works, what to do when caring for abused or stray animals, and how to help your local shelter.

Day 2: Putting the Well Into Your Well-Being

This program is focused on issues such as debt reduction and career development as well as strategies for managing difficult clients and reducing workplace stress.

See the program on page 8.

To attend, simply register for New York Vet to drop into any session or take part in the whole program. To access the New York Vet NYSVMS member discount, visit vets.nysvms.org/events/bigideas.

THE NEW YORK VET MOTHER’S AREA

Supporting veterinary parents is an important component of New York Vet’s goal to deliver a high-quality experience for all attendees. Access private pumping areas, seating, refrigeration, and other amenities in a private space away from the bustle of the event.

JOHNSON & JOHNSON WET LABS

Get hands-on education at New York Vet during 2 full days of wet labs created and supported by Johnson & Johnson. This program presents a meaningful opportunity to enhance your CE experience at New York Vet and pick up a few new skills.
NOVEMBER 8-9, 2018 | GENERAL INFORMATION

VISIT VETSHOW.COM FOR MORE INFORMATION.

NEW YORK VET
NOVEMBER 7 – 8, 2019
Javits Center, New York City, NY
16 hours of CE

WILD WEST VET
OCTOBER 23 – 26, 2019
Grand Sierra Resort and Casino, Reno, NV
36 hours of CE

CE INSPIRED BY YOU

AUSTIN VET
APRIL 20 – 21, 2020
Palmer Event Center, Austin, TX
16 hours of CE

NEW YORK VET
NOVEMBER 7 – 8, 2019
Javits Center, New York City, NY
16 hours of CE

CHICAGO VET
MAY 13 – 15, 2020
Navy Pier, Chicago, IL
24 hours of CE

The Vet Shows are curated by practicing veterinarians to help you conquer your daily challenges in practice.

There’s a Vet Show for everyone—find yours.

VISIT VETSHOW.COM FOR MORE INFORMATION.
Who can attend New York Vet?
Every member of the team can attend. Family and friends are welcome; guest passes are available for $49 and allow entry into the exhibit hall. Conference theater attendance is reserved for those with attendee registration.

Will food be provided?
Complimentary lunch and beverages will be available daily in the exhibit hall for all registered attendees.

What are the event rates?
The special rate for Clinician's Brief readers is $299 (using code PEG299). This rate ends July 26. The full-price rate is $499.

Are proceedings included in the registration fee?
Proceedings are included with your registration fee and will be available at the start of the conference at newyork.vetshow.com. Attendees can also access proceedings at VIN.com for free during and after the conference.

How do I obtain my certificate?
Certificates will be available on-site at the end of the second day of the conference. Certificates will also be emailed to you a few weeks after you have returned to practice. (Veterinary professionals licensed in Texas must pick up their certificates on-site.)

Are there any special rates or discounts available?
Yes! Discounts are available for groups and students. For more information, please call (646) 437-9080.

How do I register?
Visit newyork.vetshow.com and click on the “Register” button, or call us directly at (646) 437-9080.

Can I register the day of the event?
We would be happy to assist you with registration at the event. The on-site registration fee is $499.

How many CE hours are offered?
You can choose from 100+ hours of practical, RACE- and NYSED-approved CE and bring home up to 16 hours.

Are there any events and activities planned?
The opening reception and cocktail hour will be held on Thursday, November 7. NYSVMS will also be hosting an after-party to benefit NYSAVES. For more information, visit newyork.vetshow.com/faqs.
THE PLATFORM YOU’VE NEEDED SINCE VETERINARY SCHOOL

SEE IT FOR YOURSELF
plumbsveterinarydrugs.com
Accept no imitations. Learn science-based acupuncture from the Leader of the Pack!

Medical Acupuncture for Veterinarians

Sign up today and save 10%! Join us in October and complete your coursework by the time you attend New York Vet!

CuraCore.org

Coupon Code NYV10 Expires July 31, 2019